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ABSTRACT 
 
Fungal infections caused by opportunistic pathogens tend to be particularly 
severe and systemic in the case of immunocompromised patients. The current treatment 
options fall under classes such as azoles, polyenes, echinocandins and nucleoside 
analogs, to which resistance has been widely reported. Occidiofungin is a novel non-
ribosomal peptide with a base mass of 1,200 Da that has sub-micromolar activity against 
a wide spectrum of fungi. Occidiofungin does not have a similar mechanism of action as 
the other classes of antifungals. Preliminary toxicological analyses suggested that 
occidiofungin was well tolerated in mice at high doses. This dissertation is aimed at 
characterizing the structural, functional and pharmacological aspects of occidiofungin. 
We describe the structural and functional characteristics of occidiofungin without the 
xylose group. Loss of the xylose group affected the secretion of occidiofungin by the 
bacterium but did not affect activity of the purified compound. We analyze a variant that 
is produced when a free standing thioesterase in the biosynthetic pathway is mutated. 
We observed that a distinct diastereomer of occidiofungin cyclized by the mutated 
thioesterase contributed to the activity of occidiofungin. Microscopy assays indicated 
that the wild type compound rapidly triggered apoptosis. Time course analysis showed 
immediate concentration of occidiofungin at the bud tips of S. cerevisiae; after an hour 
of exposure it distributed throughout the parent cells. In S. pombe, localization was seen 
at the poles and division septum. In vivo and in vitro affinity purification assays 
indicated binding of occidiofungin to actin. Pharmacokinetic evaluation of occidiofungin 
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indicated that highest peak plasma concentration could be achieved in a murine model 
via the intravenous route. Lipoformulation of occidiofungin led to a marked increase in 
the peak plasma concentration. Histopathology performed on mice that were exposed to 
long duration treatment indicated that changes in all organ tissues were within normal 
limits. Efficacy of occidiofungin in reducing the fungal load in a murine model of 
systemic candidiasis could not be demonstrated due to the possibility of high levels of 
binding of occidiofungin to serum proteins. Future studies will be aimed at the chemical 
modification of occidiofungin to reduce the binding of serum proteins.  
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1. INTRODUCTION 
 
1.1 Overview 
Fungal pathogens cause diseases in a wide variety of hosts such as plants, 
animals and human beings and lead to the expenditure of several billion dollars annually 
by way of treatment. Fungal infections in plants and livestock lead to extensive loss of 
crop and rapid transmission of infection in animals. In humans, fungal infections may 
manifest as superficial infections, such as thrush and athlete’s foot or as invasive, 
systemic conditions which are more frequently seen in immunocompromised 
individuals.  
Since the 1900s, several antifungals have been developed and clinically 
employed to combat fungal infections in different hosts. These antifungals can be 
classified into groups based on their mechanism of action. Since their use in clinical 
settings, development of resistance to each class of antifungal has been reported. This 
development led to an eventual lull in the antibiotic development arena and progress in 
further identification of bioactive antifungal compounds has been slow. More recently, 
interest in identifying small molecules with novel mechanisms of action has increased 
and several natural products are being investigated for their potential as viable treatment 
alternatives.  
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1.2 Classes of antifungals 
Antifungal agents can be classified into various classes. The most commonly 
used classes of antifungal agents to treat fungal infections are the azole derivatives, 
polyenes, echinocandins and allylamines (Figure 1.1).  
1.2.1 Polyenes 
Polyenes are a class of natural products produced by Streptomyces species. They 
are synthesized by polyketide synthases and typically consist of a cyclic structure with 
multiple carbon-carbon double bonds and hydroxyl groups. The members of this class 
differ from each other based on the number of the double bonds and presence or absence 
of aromatic and aminoglycosidic groups
1
. Polyenes constituted the standard method of 
treatment of systemic fungal infections before the discovery of other classes of 
antifungals such as azoles
2
. It has been observed that a correlation exists between the 
amount of sterols present in the cell wall of an organism to how susceptible it is to 
polyene toxicity
3
. Polyenes interact with the sterols present in the membrane of the 
fungal cell. The predominant sterol found in fungal cell membranes is ergosterol and it 
functions the same way cholesterol does in mammalian cells. Ergosterol plays an 
important role in maintaining structural integrity of the fungal cell membrane
4
.   
Based on the structures of the polyenes and their biological effects, this class of 
antifungals was broadly categorized into two groups by Kotler-Brajtburg et al
5
. Briefly, 
this study analyzed the effect of different concentrations of polyenes on S. cerevisiae and 
mouse erythrocytes. The study concluded that tri-, tetra-, penta- and hexaenes induced 
K
+
 ion leakage and yeast cell death and hemolysis at a range of concentrations tested 
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(approximately 0.5μg/ml to 45 μg/ml) whereas heptaenes (including amphotericin B) 
induced K
+ 
ion leakage at lower concentrations and hemolysis only at higher 
concentrations.  Amphotericin B, a polyene that was discovered in the 1950s, was the 
‘gold standard’ to treat systemic fungal infections3. It is proposed that the antibiotic 
interacts with the hydrophobic leaflet of the membrane and forms a ring like structure 
composed of eight amphotericin B molecules. The ring like structure is formed with the 
hydroxyl residues of amphotericin B facing the cytoplasm of the fungal cell
6,7
. 
Due to poor bioavailability following oral administration of polyenes, amphotericin B is 
administered intravenously. The major limiting factor of the clinical use of amphotericin 
B is the severe nephrotoxicity associated with the use of this compound. The antibiotic 
has been formulated in liposomes and it is believed that targeted delivery of the 
liposomes to the fungal cells can be achieved
8
. Although efficacy against systemic 
fungal infections did not improve with the liposomal preparation, toxicity to the host 
organism was highly reduced
9
. Liposomal amphotericin B does not induce cation efflux 
and cell lysis in mammalian erythrocytes, demonstrating its selectivity at the cellular 
level
10
.  
Development of resistance to amphotericin B is less common than the other 
classes of antifungals and has been suggested to occur through multiple mechanisms. For 
example, alteration of cell wall composition in Aspergillus species
11
, alteration of 
ergosterol content and protection against oxidative damage
12
 have been proposed as 
possible mechanisms by which resistance against amphotericin B occurs. Several studies 
have suggested that presence of sterols other than ergosterol in the cell membrane leads 
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to resistance to polyenes
13,14
. More recently, it has been suggested that in vivo resistance 
to liposomal formulations of amphotericin B possibly occurs due to the administration of 
lower than optimal levels of the drug
15
. 
1.2.2 Azoles 
Azole derivatives are synthetic antifungal compounds that were discovered in the 
1960s. They are reported to be fungistatic, and are the most rapidly expanding group of 
antifungals. They demonstrate broad spectrum activity against yeast and filamentous 
fungi
16
. They are classified into two groups based on the number of nitrogen atoms in 
the azole ring. The imidazoles, such as ketoconazole and miconazole, contain two 
nitrogen atoms in the azole ring, whereas the triazoles, such as itraconazole and 
fluconazole, contain three nitrogen atoms.  
Ergosterols are an important group of sterols in fungal species. They are 
derivatives from squalene and make up the bulk sterol in fungal membranes
17
. 
Membrane integrity requires that sterol C14 demethylation occurs without hindrance. 
Azoles disrupt the demethylation stage thereby causing an accumulation of lanosterols 
and other 14-methylated sterols. Both imidazoles and triazoles act by targeting lanosterol 
demethylase which is a cytochrome P-450 enzyme. The enzyme has a heme moiety in its 
active site
18
. The azoles, which carry an unhindered nitrogen atom in their ring, bind to 
the iron molecule in heme
19
. This prevents activation of oxygen that is necessary for the 
demethylation of lanosterol.  It has also been reported that a second nitrogen atom 
interacts with the apoprotein of the lanosterol demethylase enzyme and the interaction is 
influence by the proximity of the nitrogen atom to the apoprotein
20
. 
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The presence of methylated sterols in the plasma membrane of the fungi disrupts 
the stability of the membrane and cell lysis occurs. It has also been observed that some 
imidazoles have a direct disruptive effect on the cell membrane at higher concentrations 
and are seen to be fungicidal
21
.  
The ergosterols, in addition to providing structural integrity to the fungal cell 
membranes, also carry out a ‘sparking’ function17. At low concentrations, ergosterol 
upon addition to other bulk sterols (such as cholesterol) induces growth of yeast cells. 
Sterol-starved cells undergo G1 arrest and release from such an arrest can be mediated 
by the addition of exogenous ergosterol
22
. Azoles are seen to cause loss of both types of 
ergosterol function
22
. 
Azoles were some of the antifungal agents to have high bioavailability when 
administered orally. The conditions at which maximum availability following oral 
administration is achieved, differs by the type of azole in question. For example, 
itraconazole is best administered following consumption of food whereas voriconazole is 
administered on an empty stomach
23,24
. Fluconazole can be administered via multiple 
routes, including intravenous and oral. Fluconazole and oral itraconazole have relatively 
low in vivo toxicities whereas other members of the triazoles have been reported to 
display severe hepatotoxicity, phototoxicity and cutaneous irritation
25-27
. 
Resistance to azoles has been observed in several isolates and multiple mechanisms of 
resistance have been reported. Initially, mutations in the catalytic site of the target 
enzyme, P450 14α demethylase (ERG11), were reported to confer resistance in S. 
cerevisiae and C. albicans. Further, other non-catalytic site mutations that hindered 
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inhibition were isolated
19
. More recently, independent studies that analyzed clinical 
isolates suggested overexpression of efflux pump genes CDR1 and CDR2 in addition to 
mutations in ERG11 as possible mechanisms of resistance in C. albicans
28
 and 
C.glabrata
29
.  
1.2.3 Echinocandins 
Echinocandins are lipoprotein molecules consisting of cyclic peptides which are 
linked to a long chain fatty acid. They are semi-synthetic compounds derived from 
fermentation products
30-32
. Three types of echinocandins have been approved for clinical 
use by the Food and Drug Administration (caspofungin, micafungin and anidulafungin). 
Though the activity of the three compounds is similar, they vary structurally. The 
activity of the echinocandins is attributed to the hexapeptide nucleus.  Caspofungin 
contains a fatty acid, micafungin a complex aromatic, and anidulafungin an 
alkoxytriphenyl side chain
33
. The most recent addition to the echinocandin family is 
ASP9726, developed by Astellas Pharmaceuticals and currently in preclinical 
development
34
. The structures of caspofungin, micafungin and ASP9726 are depicted in 
Figure 1.1. 
Echinocandins demonstrate antifungal activity by non-competitively inhibiting 
1,3-β-D glucan synthase which is necessary for the synthesis of 1,3-β-D glucan, an 
important cell wall component. The enzyme consists of at least two subunits: Fks1p and 
Rho1p. Rho1p is a regulatory component, controlling the production of 1,3-β-D 
glucan
35
. The echinocandins target FKS1p gene product which constitutes the active site 
of the enzyme, 1,3-β-D glucan synthase36. As a result, 1,3-β-D glucan is not produced 
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and the cell wall loses stability. Eventually, the fungal cell is incapable of resisting the 
osmotic pressure due to loss of membrane integrity leading to lysis of the fungal cells
37
. 
The activity of echinocandins against target fungal species depends on the proportion of 
1,3-β-D glucan in the cell wall. The amount of glucan varies between species and it is 
obvious that the species that have a lower quantity of glucan in their cell wall would not 
be highly susceptible to treatment by echinocandins. It has been reported that exposure 
of yeast cells to sub-inhibitory concentrations of echinocandins leads to a dynamic shift 
in the ratio of chitin to glucan in the cell walls and cell with increased amounts of chitin 
are resistant to echinocandins
38
. Candida species and Aspergillus species are seen to be 
highly susceptible to echinocandins. As an exception, Cryptococcus neoformans whose 
cell wall has a large amount of glucan is not very susceptible to echinocandin treatment, 
indicating that echinocandins may target cells by an alternative mechanism that is, as 
yet, unknown
39
. Echinocandins have also been reported to induce apoptosis in fungal 
cells at lower concentrations, but the intracellular component responsible for the 
induction is still unknown
40
. 
Echinocandins are known to display very low drug-drug interactions. The 
advantage of echinocandin use is also due to the fact that human cells do not have 1,3-β-
D glucan and hence toxicity to host cells can be minimized. Echinocandins are usually 
formulated for administration via the intravenous route and are cleared slowly following 
degradation in the liver
35
. 
Resistance to echinocandins has been widely reported. Mutations in the hotspot 
regions of Fks1 (HS1 and HS2) have been reported as one of the major causes of 
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resistance. Ghannoum et al report multiple studies which suggest other mechanisms of 
resistance. For example, over expression of chitin synthase provides additional 
protection against echinocandins and over expression of Sbe2, a golgi protein involved 
in synthesis of cell wall components has been linked with echinocandin resistance
41
. 
1.2.4 Allylamines 
Allylamine derivatives are a class of chemically derived compounds that have 
antifungal properties. Allylamines were derived by chemically altering the structure of 
naftifine, an antimycotic compound. These compounds inhibit the enzyme squalene 
epoxidase leading to the disruption of ergosterol biosynthesis. It also leads to the buildup 
of squalene within the cell. This results in the cidal activity of the compounds
42
.  
Synthetic modifications of naftifine aimed specifically at making orally bioactive 
compounds led to the development of several allylamines that are used in the treatment 
of infections caused by fungi such as Aspergillus species. Further, allylamines have been 
reported to have remarkable activity against dermatophytes such as Trichophyton spp. 
and Epidermophyton spp. with in vivo efficacy in treating these infections in a porcine 
model
42
. A liposomal formulation of terbinafine has been reported for nasal delivery to 
treat Aspergillosis in order to improve efficacy and bioavailability of the drug
43
. 
Development of resistance to allylamine compounds has been reported and resistant 
clinical isolates have been found. Mechanisms of squalene resistance include over 
expression of and a single amino acid substitution in the squalene epoxidase enzyme
44,45
. 
Efflux pump mediated resistance has also been suspected to occur in Candida albicans
46
. 
 
 9 
 
1.2.5 Nucleoside analog 
5-fluoroctyosine (5-FC) is a synthetic compound that was developed in the late 
1950s and adapted for use as an antimycotic agent by 1968
47
. 5-FC is converted to 5-
fluorouracil (5-FU) following uptake by fungal cells. 5-fluorouracil is then converted to 
metabolites which inhibit nucleotide and protein synthesis leading to fungal cell death. 
The conversion of 5-FC to 5-FU involves deamidation by cysteine deamidase and the 
lack of this enzyme in the fungal cell leads to absence of activity against that type of 
fungus
47
. 5-FC is currently used in combination with amphotericin and azoles in the 
treatment of systemic fungal infections
47
. 
Resistance to 5-FC has been widely reported and has been attributed to 
mechanisms such as mutations leading to reduced uptake of 5-FC, increased synthesis of 
pyrimidines and defective uridine monophosphate pyrophosphorylase
47
. Due to the 
extensive prevalence of resistance to 5-FC, it is not used as an antifungal agent by itself.   
1.3 Novel antifungals that target unique cellular components 
In addition to the previously mentioned classes, several compounds with novel 
cellular targets are currently in clinical trials (Figure 1.2). Denning and Bromley (2015) 
highlight these antifungals currently being developed and point out the promise of novel 
antifungals in the fight against resistance
48
. Antifungals in pre-clinical development 
include [N′-(3-bromo-4-hydroxybenzylidene)-2-methylbenzohydrazide (BHBM) and its 
derivative, 3-bromo-N′-(3-bromo-4-hydroxybenzylidene) benzohydrazide, which were 
discovered in a screen that probed synthetic drugs that could target the synthesis of a 
sphingolipid (glucosylceramide) found in fungi. Glucosylceramide is a possible 
 10 
 
virulence factor that is necessary for fungal cell proliferation in neutral and alkaline 
conditions. The compounds mentioned above inhibit transport of vesicles that carry 
ceramide that is essential in the synthesis of fungal glucosylceramide, thereby halting 
progress through the cell cycle and inhibiting cytokinesis
49
. Sampangine, an alkaloid 
compound derived from plants, is another novel antifungal that possesses broad 
spectrum activity against fungi, protozoans and cancer cell lines. It is believed to inhibit 
heme biosynthesis by hyperactivating uroporphyrinogen III synthase which is encoded 
by the gene HEM4. Due to the fact that the target is conserved in humans, this class of 
compounds possesses antiproliferative properties in human cancer cell lines as well
50
. 
Ilicicolin H is a non-ribosomal tetracyclic peptide which is cytotoxic to HeLa cells and 
also possesses antifungal activity against several fungal species. It causes cell death by 
inhibiting mitochondrial respiration by binding to the Qn site of the cytochrome bc(1) 
complex
51,52
. One of the antifungal compounds currently in Phase I clinical trials is 
biafungin that is currently being developed by Cidara Therapeutics
53
. Biafungin is active 
against Aspergillus species and several resistant strains of Candida. It is also active 
against caspofungin-resistant fungi and has efficacy against an fks mutant of Candida 
albicans in a murine model. Another antifungal in Phase I trials is VT-1129 developed 
by Viamet Inc. VT-1129 belongs to a new class of lanosterol 14-α-demethylase 
inhibitors that contain a tetrazole moiety that binds heme. It has been reported to be 
more effective against fungal enzymes compared to their human counterparts
54
. F901318 
is an orotomide, a novel class of antifungals, which is being developed by F2G Limited 
and is currently in phase I trials. It has been reported that F901318 has in vivo efficacy 
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against Aspergillus species. Antifungals currently in Phase II trials include Nikkomycin 
Z, which is a nucleoside-peptide natural product developed by Valley Fever Solutions 
that targets chitin synthetase. Specifically, Nikkomycin acts as a competitive inhibitor of 
chitin synthetase and eventually leads to osmotic lysis of the cell
55,56
. Additionally, 
VT1161 (developed by Viamet Inc.) is also in Phase II and is related to the tetrazole 
class described above
57
. SCY078 (SCYNEXIS), also in Phase II trials, was developed as 
an orally available glucan synthase inhibitor that has been shown to reduce fungal load 
in a murine disseminated candidiasis model
58
. The development of these antifungals is 
encouraging since they target cellular components that are different from the common 
classes of antifungals. 
1.4 NRPS antifungal agents 
Non-ribosomal peptides are unique bioactive molecules that garner extensive 
interest. NRPs show a broad spectrum of biological activities and pharmaceutical 
applications. They can harbor antimicrobial, immunomodulator, or antitumor activities. 
Non-ribosomal synthesis of peptides occurs independently of messenger RNA. This 
method requires enzymes known as non-ribosomal peptide synthetases (NRPS). NRPS 
may work in conjunction with polyketide synthases (PKS). A unique property of this 
mechanism is that it can catalyze the production of peptides containing proteinogenic 
and non-proteinogenic amino acids. Some common examples of NRPs of high 
therapeutic importance are cyclosporine, an immunosuppressant drug, daptomycin, used 
in the treatment of certain infections caused by Gram-positive bacteria, aminoadipyl-
cysteinyl-valine (ACV)-tripeptide, which is the precursor of cephalosporin and 
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penicillin
59
 and of bleomycin
60
, which is used in the treatment of several cancers. 
Echinocandins are one of the most popular families of non-ribosomal antifungal peptides 
due to their prevalence and wide use. Gramicidin, a non-ribosomally synthesized 
antimicrobial compound has been shown to have activity against Candida species
61
. 
More recently, Cawoy et al reported the production of lipopeptide compounds in 
Bacillus subtilis that possessed bioactivity against fungal pathogens
62
. Pelgipeptin, a 
recently characterized antibacterial and antifungal compound produce by Paenibacillus 
elgii, is another non-ribosomal peptide with nine amino acids and a β-hydroxy fatty 
acid
63
. In addition to these, several antimicrobial, anti-tumor and immunosuppressive 
compounds that are non-ribosomally synthesized have been characterized and some, 
such as cyclosporine and daptomycin, are currently in clinical use. 
The NRPS-PKS process holds immense promise for the production of bioactive 
compounds with novel residues that are capable of targeting new regions of the fungal 
cell, potentially creating new classes of antifungal compounds. One such NRP with 
antifungal properties that appears to target a novel cellular component as compared to 
the existing classes of antifungals is occidiofungin, a glycolipopeptide produced by the 
soil bacterium, Burkholderia contaminans MS14
64
. 
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1.5 Occidiofungin 
Occidiofungin possesses antifungal properties against a host of fungal species 
which have been reported to have acquired resistance to antifungals such as azoles and 
echinocandins, making it an exciting alternative to currently available treatment options.  
Structure and biosynthesis of occidiofungin: 
The covalent structure of occidiofungin consists of eight amino acid residues. 
Occidiofungin is a cyclic compound having a base mass of 1,200 Da and composed of 
an asparagine in the first position, followed by a novel amino acid, a serine, a β-hydroxy 
tyrosine, a diaminobutyric acid (DABA), a glycine, another asparagine and ending with 
a serine. Several variants of the base compound occur naturally and the variations occur 
on the first residue (presence or absence of a hydroxyl group on the asparagine) and the 
fourth residue (presence or absence of a chlorine group on the β-hydroxy tyrosine). 
Further, the novel amino acid has a lipid chain that has a xylose attached to it.  A model 
biosynthesis pathway for the production of occidiofungin has been suggested and the 
enzymes involved in the production of the antifungal have been outlined.  
The gene cluster which was predicted to be responsible for the production of 
occidiofungin, the ocf cluster, was characterized and of the 16 ORFs that are present in 
the cluster, five (ORF5, 6, 7, 9 and 11) were predicted to be NRPS or NRPS-PKS. ORFs 
4, 12, 13, 14 and 15 are involved in the modification of occidiofungin. AmbR1 and 
AmbR2 regulate the production of occidiofungin
65
.     
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1.5.1 Mechanism of action and toxicity profile of occidiofungin 
Occidiofungin has a broad spectrum of activity against fungi. The activity of 
occidiofungin against several plant and animal pathogens was tested. Filamentous fungi 
such as Rhizoctonia solani, Aspergillus fumigatus and Aspergillus niger, were highly 
susceptible to occidiofungin
64
. The activity of occidiofungin against several yeast-like 
fungi was also tested. MICs done on these were according to CLSI standards. The wide 
range of activity of occidiofungin against several fungi suggests that the target of the 
antifungal is highly conserved. 
In order to determine its mode of action, occidiofungin was tested against several 
species of fungi. The inhibition of the enzyme 1,3-β-glucan synthase is the main 
pathway by which echinocandins target yeast cells and cause lysis. Fks1p/Fks2p are 
catalytic subunits of 1,3-β-glucan synthase. Fks1 mutants show reduced sensitivity to 
echinocandins. On treating Fks1 mutants of S. cerevisiae with occidiofungin, no 
reduction in sensitivity was observed. This indicates that occidiofungin does not have a 
similar mode of action as echinocandins. Further, addition of ergosterol to the growth 
medium is seen to reduce the sensitivity of yeast cells to amphotericin B. When DOPC 
vesicles containing 20% ergosterol were introduced in the treatment of C. glabrata with 
amphotericin B, there was a marked decrease in sensitivity. This was not observed when 
the same procedure was carried out during treatment of the cells with occidiofungin, 
indicating that occidiofungin may not act by binding to ergosterol. Therefore 
occidiofungin follows an entirely different mechanism of action from the other classes of 
antifungals
66
.  
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Previous studies done on cells of Rhizoctonia solani and Geotrichum candidum 
treated with sub lethal concentrations of occidiofungin display loss in cell wall thickness. 
Candida cells that were treated with a sub lethal dose of occidiofungin displayed a 
visible loss of mannoproteins. TEM images also showed the presence of visible 
inclusion bodies in these cells. Visualization of S. cerevisiae cells under the microscope 
showed intact cells, though they were reduced in size, indicating that occidiofungin does 
not lyse the target cell. This phenotype was indicative of the induction of apoptosis. 
Apoptotic assays, such as the TUNEL assay, detection of ROS production and 
phosphatidylserine externalization, done on S. cerevisiae and C. albicans cells following 
exposure to multiple concentrations of occidiofungin indicated the occurrence of 
apoptosis in the fungal cells
66
. 
In vitro toxicity studies of occidiofungin have been done using rat hepatoma 
(H4IIE) cell line and it was seen that greater than 90% cell viability was observed in all 
variables until a 5 μM concentration of occidiofungin was attained. Body weight 
analyses have been performed in female BALB/C mice and loss of less than 15% body 
weight was observed in mice treated with 5 mg/kg of occidiofungin in methylcellulose
67
. 
The loss observed was transient and rapidly recovered when drug challenge was 
removed. Further histopathology analyses have been performed on tissues from different 
organs following intravenous administration of occidiofungin at doses of 5mg/kg. 
Tubular necrosis was seen in kidney tissue and was seen to be repaired when the 
treatment was stopped. All other tissues were seen to be normal
68
. 
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The toxicity profile of occidiofungin along with its broad spectrum activity 
against several different kinds of fungi and a potentially unique molecular target makes 
it a promising drug to investigate and develop for treatment against pathogenic fungi that 
are resistant to other classes of antifungals. 
1.6 Conclusion 
This section provides a background for the necessity of developing novel 
antifungal agents and concludes with an introduction to occidiofungin. The sections that 
follow will discuss the merits of and challenges facing the development of occidiofungin 
as a viable treatment option for fungal infection. The following section will introduce 
and characterize one of the naturally synthesized variants of occidiofungin in an effort to 
understand the biosynthesis of the compound. 
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Figure 1.1. Structures of clinically used antifungal classes: a) Polyenes: Amphotericin 
B; b) Azoles: Imidazoles (left to right): Miconazole, Ketoconazole; Triazoles (left to 
right): Fluconazole, Itraconazole; c) Echinocandins (left to right): Caspofungin, 
Micafungin, ASP9726; d) Allylamines: Naftitine, Terbinafine; e) Nucleoside analog: 5-
Flucytosine 
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Figure 1.2: Antifungals in clinical development: BHBM, Sampagnine and Ilicicolin H 
are in pre-clinical development, Biafungin and VT-1129 are in Phase I trials, 
Nikkomycin Z, SCY078 and VT-1161 are in Phase II trials 
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2. THE OCFC GENE ENCODES A XYLOSYLTRANSFERASE FOR THE 
ANTIFUNGAL OCCIDIOFUNGIN PRODUCTION BY BURKHOLDERIA 
CONTAMINANS MS14
*
 
 
2.1 Overview 
Burkholderia contaminans strain MS14 produces the antifungal compound 
occidiofungin, which is responsible for significant antifungal activities against a broad 
range of plant and animal fungal pathogens. Occidiofungin is a cyclic glycolipopeptide 
made up of eight amino acids and one xylose. A 56-kb ocf gene cluster was determined 
to be essential for occidiofungin production. In this study the ocfC gene, which is located 
downstream of ocfD and upstream of ocfB gene in the ocf gene cluster, was examined. 
Antifungal activity of the ocfC gene mutant MS14KC1 was reduced against the indicator 
fungus Geotrichum candidum compared with the wild-type strain. Furthermore, the 
analysis of the protein sequence suggests that the ocfC gene encodes a 
glycosyltransferase. Biochemical analyses using NMR and Mass spectroscopy revealed 
that the ocfC mutant produced the occidiofungin without the xylose. Purified ocfC 
mutant MS14KC1 product had similar level of bioactivity as compared to the wild-type 
product. The revertant MS14KC1-R of the ocfC mutant produced the same antifungal 
activity level on plate assays and the same antifungal compound based on HPLC and 
                                                 
*
 Reprinted with permission from The Burkholderia contaminans MS14 ocfC Gene Encodes a 
Xylosyltransferase for Production of the Antifungal Occidiofungin by Akshaya Ravichandran, Kuan-Chih 
Chen, Adam Guerrero, Peng Deng, Sonya M. Baird, Leif Smith and Shi-En Lu. Applied and 
Environmental Microbiology 79:9. Copyright [2013] American Society for Microbiology. DOI: 
10.1128/AEM.00263-13 
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mass spectroscopy analysis as the wild type strain MS14. Collectively, the study 
demonstrates the ocfC gene encodes a glycosyltransferase responsible to add a xylose to 
the occidiofungin molecule and that the presence of the xylose is not important for 
antifungal activity against Candida species.  The finding provides a novel variant for 
future studies aimed at evaluating its use for inhibiting clinical and agricultural fungi and 
the finding could also simplify the chemical synthesis of occidiofungin variants. 
2.2 Introduction 
Members of the bacteria Burkholderia exist naturally in environments such as 
water, soil, and the rhizosphere of crop plants
69
. Some Burkholderia strains show 
striking efficacy in controlling fungal diseases of crops as biological control agents for 
plant disease management
70
. However, the use of Burkholderia strains is prohibited 
because of difficulty differentiating taxonomically these beneficial strains from the 
strains that are opportunistic pathogens associated with the human disease cystic 
fibrosis
71
. Understanding the molecular mechanisms of antifungal activities of the 
Burkholderia strains will provide important clues for the development of biologically 
based fungicides while eliminating potential health risks. 
Burkholderia contaminans strain MS14 showed a broad range of antifungal 
activity to plant and human fungal pathogens
64
. A glycopeptide, named occidiofungin, 
produced by strain MS14 is responsible for its antifungal activity
64,72
. It is a cyclic 
glycopeptide made up of eight amino acids and one xylose
65
.  Four variants, named as 
occidiofungin A, B, C and D have been identified from the MS14 strain culture
65
. 
Occidiofungin inhibits the growth of a broad range of fungal pathogens and it was 
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shown to inhibit the production of cell wall of Geotrichum candidum 
65
. The compounds 
have shown great potential for pharmaceutical and agricultural applications
67,73
. 
Genetic analysis revealed that a 56-kb ocf gene cluster is required for production of 
antifungal activity by Burkholderia contaminans strain MS14. Sixteen genes have been 
predicted in the ocf gene cluster, including the genes encoding nonribosomal peptide 
synthetases (ocfD, ocfE, ocfF, ocfH, and ocfJ), the bacterial LuxR regulatory proteins 
(ambR1 and ambR2), and an ATP-binding cassette (ocfA)
65
. Mutagenesis and sequence 
analysis revealed that these genes are associated with occidiofungin production by strain 
MS14. Functions of a few genes in the ocf gene cluster, such as ocfC, remain to be 
investigated.  Preliminary analysis showed the deduced protein of the ocfC gene shares a 
significant similarity to galactosyltransferases. We hypothesized that the ocfC gene 
codes for an enzyme to catalyze addition of xylose to the backbone peptide of 
occidiofungin. In this study, the ocfC gene was disrupted with an insertional mutation 
and effects of the mutation on occidiofungin production were evaluated.  Possible 
functions of the ocfC gene are discussed.  
2.3 Materials and methods 
2.3.1 Bacterial strains, plasmids and media  
Bacterial strains and plasmids used in this study are listed in Table 2.1. 
Escherichia coli JM109 (Promega, Madison, WI) was used for cloning and was cultured 
at 37°C on Luria-Bertani (LB) agar. Nutrient broth-yeast extract (NBY) agar media
74
 
were used to culture Burkholderia contaminans strain MS14 at 28°C. Potato dextrose 
agar (PDA) (Difco, Detroit, MI) was used for antifungal activity assays. Antibiotics 
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(Sigma Chemical Co., St. Louis, MO) were added to media at the following 
concentrations: ampicillin (100 µg/mL), kanamycin (100 µg/mL for Escherichia coli and 
300 µg/mL for the MS14 mutants) and trimethoprim (50 µg/mL). 
DNA isolation, manipulation and sequence analysis: The cetyl trimethyl 
ammonium bromide protocol
75
 (10) or Wizard
®
 Genomic DNA Purification kit 
(Promega Corporation, Madison, WI) was used for extraction of bacterial genomic 
DNA. Primers were synthesized by Integrated DNA Technologies Inc. (Coralville, IA) 
and Eurofins MWG Operon (Huntsville, AL). Plasmid extraction was done using the 
QIAprep
®
 Spin Miniprep kit (QIAGEN Inc., Valencia, CA). Wizard
®
 SV Gel and PCR 
Clean-Up System kit (Promega) was used to recover DNA fragments for cloning. 
Sequencing was sent to Eurofins MWG Operon. The evolutionary history of the putative 
OcfC was inferred using the Minimum Evolution method
76
. The evolutionary distances 
were computed using the Poisson correction method
77
. Phylogenetic analyses were 
conducted in MEGA4
78
.  
2.3.2 Mutagenesis of the ocfC gene  
Primers 6471R1649 (5’- GCCTACCTGCG CGTCTATCA) and 6471F137 (5’- 
CCATGGCGGCGATTTGCTTTGA) were designed in order to amplify the ocfC gene 
by polymerase chain reaction (PCR). The final concentrations of PCR reagents in the 50 
μL reaction were: MgCl2, 2 mM; dNTPs, 0.4mM; primers, 0.6mM each; Taq DNA 
polymerase, 0.75 units. The PCR cycling conditions were 4 min at 95°C, then 50 s at 
95°C, 50 s at 56°C and 2 min at 72°C for 30 cycles, followed by 8 min at 72°C. The 
PCR amplicon containing the ocfC gene with the flanking regions was cloned into the 
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vector pGEM-T Easy (Promega) to generate the plasmid pKC1. Plasmid pBSL15
79
 was 
partially digested with EcoRI and then self-ligated to remove the restriction 
endonuclease EcoRI digestion site as described previously
80
. A 1.3-kb PstI fragment of 
the plasmid pBSL15 lacking EcoRI site and carrying the terminatorless kanamycin 
cassette (the nptII gene fragment) was cloned into the ocfC gene of the plasmid pKC1 
using a PstI partial digestion strategy.  The resulting plasmid pGEM-T Easy-ocfC::nptII  
was named pKC2. The ocfC::nptII DNA fragment was introduced to the EcoRI site of 
the suicide vector pBR325
81
 for Burkholderia spp.
82
 to generate plasmid pKC3. Plasmid 
pKC3 was electroporated into competent cells of the wild type MS14, which was 
prepared using the 10% glycerol-washing protocol
83
, for marker exchange mutagenesis 
(C=25µF, 200Ω, v=1.8KV, and cuvette 1mm).  NBY media containing kanamycin 
(300µg/mL) were used for selection of the mutants. PCR amplification and sequencing 
were used for confirmation of double crossover mutagenesis. Plate bioassays were used 
to evaluate the production and biological activity of occidiofungin as described 
previously
84
. 
The intact ocfC gene was obtained by PCR for the complementary assays.  
Primers ocfC-compF (5’- CGGAA- TTCCATGTCAATTCGTTTCTG) and ocfC-compR 
(5’- TTAAGCTTCGCTTCGAGGTCAACGGT) were designed for PCR amplification 
of the functional ocfC gene. The purpose of these two primers is to add EcoRI and 
HindIII sites at the both end of PCR product. The 0.8 kb PCR product was inserted into 
the Burkholderia gene expression vector pMLS7 digested with EcoRI and HindIII, to 
generate pKC4. Plasmid pKC4 were electroporated into cells of the mutant MS14KC1. 
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NBY plates with trimethoprim were used to screen the colony with pMLS7
85
 which were 
confirmed by sequencing. Complementation experiments were done by the plate assay to 
examine the antifungal activity against G. candidum. 
2.3.3 Reversion of the ocfC mutant into its wild genotype  
To revert the ocfC mutant into its wild genotype, plasmid pDP12 was generated 
for marker exchanger gene replacement.  The 1.5 Kb EcoRI fragment of pKC1 was 
cloned into the EcoRI site of the suicide vector pBR325.  To obtain the revertants of the 
ocfC mutant MS14KC1, plasmid pDP12 was electroplated into MS14KC1 cells for 
marker exchange.  Transformed cells were cultured in NBY broth with shaking for 4 
hours. Bacterial colonies that grew on NBY supplemented with 25 µg/mL of tetracycline 
were used for further analysis. The colonies that were able to grow on the NBY plates 
supplemented with 100 µg/mL kanamycin but not 300 µg/mL were selected as 
candidates of the revertants.  The revertants were confirmed by PCR analysis as 
compared with the mutant MS14KC1 and the wild type strain MS14. Verified revertant 
MS14KC1-R was used for further analyses of occidiofungin production.     
Isolation of antifungal compound of the mutant MS14KC1 and MS14KC1-R: 
Isolation and purification of the occidiofungin variant produced by the ocfC mutant and 
its revertant were conducted as described previously
84
. In brief, the bacterial strains were 
incubated at 28
o
C for 7 days without shaking.  The cell free culture extract was 
precipitated using ammonium sulfate (AS) (50% w/v) on ice for 2 hours. The pellet was 
resuspended in 1 ml of 35% acetonitrile (ACN):water (v/v) and placed in a 1.5 ml 
microcentrifuge tube.  RP-HPLC was done using a 4.6 × 250 mm C18 column (Grace-
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Vydac, catalog 201TP54) on a Bio-Rad BioLogic F10 Duo Flow with Quad Tec UV-Vis 
Detector system.  
2.3.4 In vitro susceptibility testing  
Microdilution broth susceptibility testing was performed in triplicate according to 
the CLSI M27-A3 method (21) in RPMI 1640 [buffered to a pH of 7.0 with MOPS 
(morpholinepropanesulfonic acid)] growth medium.  100X stock solutions of 
occidiofungin were prepared in dimethyl sulfoxide (DMSO).  Minimum inhibitory 
concentration (MIC) endpoints for occidiofungin were determined by visual inspection 
and were based on the wells that had no visible growth (an optically clear well) after 24 
hours of incubation.  DMSO containing no antifungal agent was used as a negative 
control.  
2.3.5 NMR spectroscopy  
The same procedure for NMR analysis was used as described previously
65
. 
Occidiofungin was dissolved in deuterated dimethyl sulfoxide (DMSO-d6) and the NMR 
data were collected on a Bruker Avance DRX spectrometer with a CryoProbe, operating 
at a proton frequency of 600 MHz. The 
1
H resonances were assigned according to 
standard methods
86
 using COSY, TOCSY NOESY and 
13
C-HSQC experiments.  NMR 
experiments were collected at 25°C. The TOCSY experiment was acquired with a 60 ms 
mixing time using the Bruker DIPSI-2 spinlock sequence. The NOESY experiment was 
acquired with 400 ms mixing times. Phase sensitive indirect detection for NOESY, 
TOCSY, and COSY experiments was achieved using the standard Bruker pulse 
sequences. Peaks were assigned using NMRView
87
.  
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Molecular weight of the occidiofungin variant produced by MS14KC1 was 
measured as described previously
64,84
. Matrix-Assisted Laser Desorption/Ionization 
Mass Spectrometry — Time of Flight (MALDI-TOF, Shimadzu/Kratos) was used to 
determine the mass of peaks. The antifungal HPLC fraction was evaporated to dryness 
and was dissolved in 100 µL of 35% acetonitrile containing 0.1% trifluoroacetic acid. 
From these resuspended fractions, 0.5 µL was mixed with 0.5 µL of α-cyano-4-
hydroxycinnamic acid matrix (6 mg/ml in 50% acetonitrile containing 0.1% 
trifluoroacetic acid) and dried on the target plate.  
2.4 Results 
2.4.1 Sequence analysis of the ocfC gene  
The ocfC gene is located downstream of the ocfD gene and upstream of the ocfB 
gene in the ocf gene cluster (GenBank accession number: EU938698)
65
.  No significant 
promoter region or terminator was identified from the 5’ and 3’ termini of the ocfC gene, 
suggesting the ocfC gene may be organized as a transcriptional operon with the 
downstream and upstream genes.  The 657 base-paired ocfC gene was predicted to code 
for a 218-amino acid putative protein which was predicted to be the glycosyltransferase 
that catalyzes the transfer of a xylose to the C-7 site of occidiofungin
65
. Sequence 
analysis showed this putative protein encoded by the ocfC gene shared 94.0 % identity 
with the putative glycosyltransferase (Bamb_6471) of Burkholderia ambifaria AMMD 
(GenBank accession number: NC_008392). BLAST search showed there is one 
conserved domain from amino acid 13 to 89 on the OcfC protein, which is the signature 
of the Glycosyltransferase family 25
88
. According to the phylogenetic analysis, the OcfC 
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putative protein of Burkholderia contaminans MS14 is clustered with Bamb_6471 of 
Burkholderia ambifaria AMMD with a bootstrap value of 100 and both were predicted 
to be members of the glycosyltransferase family 25. The Xcc-b100_0220 protein for 
Xanthomonas campestris pv. campestris B100
89
 and the PXO_04234 protein of 
Xanthomonas oryzae pv. oryzae PXO99A
90
 shared 55% of similarity to OcfC. 
2.4.2 Site-directed mutagenesis of the ocfC gene  
A 1.5-kb PCR product was amplified using the primers 6471R1649 and 
6471F137 and confirmed by sequencing to be the ocfC gene with its flanking regions. 
Sequencing further confirmed the plasmid pKC1 identity, which is the vector pGEM-T 
Easy carrying the ocfC gene. An insertional mutation was obtained by insertion of an 
nptII cassette, resulting in plasmid pKC2. The plasmid pKC3 was obtained by cloning 
the nptII- disrupted ocfC gene into pBR325. Introduction of pKC3 into cells of strain 
MS14 resulted in generations of the ocfC mutants MS14KC1, which was confirmed by 
PCR and sequencing. 
2.4.3 Effect of mutation in ocfC on antifungal activity  
Mutant MS14KC1 with an insertion in the nptII gene cassette was evaluated for 
occidiofungin production by inhibitory activities against the indicator fungus G. 
candidum (Figure 2.1). The ability of MS14KC1 to inhibit the growth of the indicator 
fungus G. candidum remained with a reduced inhibitory zone (0.82 ± 0.02 cm). In 
contrast, the antifungal activity for wild-type strain MS14 was 1.42 ± 0.06 cm in radius. 
The disruption of ocfC gene caused a 42% decrease in the antifungal activity against G. 
candidum (Figure 2.1). Based on the Fisher’s least significant difference (LSD) test, this 
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was a significant difference (α < 0.05). As expected, the revertant strain MS14KC1-R 
produced the wild-type level of antifungal activity against G. candidum. As a negative 
control, the mutant MS14MT18, in which the biosynthetase gene ocfE is knocked out by 
transposon
65,84
, did not produce measurable antifungal activity.  These results revealed 
the importance of ocfC gene for the production of the antifungal activity of strain MS14. 
Interestingly, no significant restoration of antifungal activity was observed when the 
mutant MS14KC1 harboring the intact ocf gene under the control of promoter plac in the 
broad-host range vector pMSL7.  A significant reduction of occidiofungin production by 
the ocfC mutant was observed compared to the wild type strain. The average yield per 
liter of the wild-type and ocfC mutant product was approximately 350 µg/L (average 
taken from 9 liters) and 47 µg/L (average taken from 10.5 liters), respectively. The seven 
fold reduction in yield indicates that the attachment of the xylose might be important for 
biosynthesis or transport.   
NMR analysis reveals a loss of the xylose from the wild-type product in the ocfC 
mutant (Figure 2.2A and 2.2B). Comparison of the TOCSY spectrum of the product 
from the ocfC mutant to the wild-type product reveals the loss of the proton chemical 
shifts for the xylose sugar. MALDI-TOF analysis also reveals the loss of the xylose 
sugar. The product of the ocfC mutant has a base mass of 1068.73 Da (Figure 2.2C), 
which correlates to the loss of a pentose sugar (149 Da) plus the addition of a hydroxyl 
group remaining on the antifungal compound. The NMR spectrum of occidiofungin has 
multiple spin systems for each amino acid due to different conformers on the NMR time 
scale. Interestingly, the spectrum is complex for a peptide that is only eight amino acids 
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(Figure 2.3A).  The ocfC mutant product has a far less complex spectrum than the wild 
type (Figure 2.3B and Table 2.2). This is due to the loss of the bulky xylose sugar which 
presumably allows the compound to interchange between conformations more freely. 
This is reflected in the loss of conformational families in the NMR spectra for Asn1, 
BHY4 Gly6 and Asn7 (Figure 2.3C). The conformational families that are missing in the 
ocfC mutant have been highlighted green in the overlays of the wild-type and mutant 
spectrum. Cyclization of the peptide is carried out by two cyclase thioesterases that form 
two distinct conformational families of occidiofungin. These conformational families are 
visible in the ocfC mutant spectrum, and are easily observed by the presence of two 
different amide proton frequencies for Asn1 and NAA2. Therefore, the loss of the xylose 
sugar does not affect the formation of these two conformational groups of the antifungal 
compound.  
2.4.4 Effects of the ocfC mutation on production and antifungal activity of occidiofungin 
Occidiofungin products of the wild-type and the ocfC mutant MS14KC1 were 
purified by RP-HPLC. The ocfC mutant product eluted with a lower percentage of water 
(46%) than the wild-type product (49%) (Figure 2.4).  Additionally, the ocfC mutant 
product did not elute as a doublet peak as observed in the wild-type fraction.  
Presumably, the observed doublet peak in the wild-type fraction is attributed to the 
presence of the xylose and that its presence contributes to conformational variants that 
have slightly different retention times. NMR analyses also revealed the loss of 
conformers (Figure 2.3).  As expected, product isolated from ocfC revertant strain 
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(MS14 KC1-R) has the same RP-HPLC retention time and mass as the wild-type product 
(Figure 2.5).  
MIC assay was conducted according to the CLSI M27-A3 method to determine 
whether the loss in activity in the G. candidum overlay assay was attributed to the loss of 
the xylose or a reduction in production. Comparing the purified wild-type and the ocfC 
mutant product on several strains of the genus Candida, G. candidum and 
Saccharomyces cerevisiae provided a quantitative assessment of the bioactivity of the 
mutant product. The results are listed in Table 2.2. The ocfC mutant product essentially 
had the same antifungal activity as the wild-type product in the in vitro assay. 
Presumably, the addition of the xylose may help promote solubility under normal 
environmental conditions. The RP-HPLC chromatograms do reveal that the ocfC mutant 
product had a longer retention time with an increased percentage of the organic solvent 
acetonitrile (Figure 2.4).  
2.5 Discussion 
2.5.1 The ocfC gene encodes a member of the GT25 family of glycosyltransferases   
Glycosyltransferases are identified from various organisms and classified based 
on amino acid sequence similarity
91
. The GT25 family includes the known members of 
beta- 1,4-galactosyltransferase and lipopolysaccharide biosynthesis protein
92
. For 
Haemophilus influenza, glycosyltransferase LpsA is responsible for the addition of a 
hexose which can be either glucose or galactose
93
. Previous GC-MS analysis has showed 
that a xylose sugar is attached to the antifungal compound occidiofungin
65
. In this study, 
we hypothesized that the ocfC gene codes for glycosyltransferase, which was predicted 
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to add xylose to the oligopeptide backbone to form occidiofungin.  This is proved by the 
sequence analysis showing that this putative protein encoded by the ocfC gene shared 
94.0 % identity to glycosyltransferase of B. ambifaria AMMD in the phylogenetic tree 
generated. The known activities of the GT25 family include beta-1, 4- 
galactosyltransferase, beta-1, 3- glucosyltransferase, beta-1, 2 – glucosyltransferase and 
beta-1, 2- galactosyltransferase
94
. This study is the first evidence that xylosyltransferase 
is found in GT25 family. This novel glycosyltransferase has expanded the function 
categories of this family. Based on the evidence of this study, glycosyltransferase 
encoded by the ocfC gene should be named xylosyltransferase. 
2.5.2 The ocfC gene is important for the production of occidiofungin 
  The ocfC mutant strain MS14KC1 has approximately 42% less inhibitory activity 
to G. candidum than the wild-type strain and the occidiofungin yield of the mutant was 
decreased significantly compared with the wild-type strain.  The revertant strain 
MS14KC1-R, in which the ocfC::nptII DNA fragment was replaced with the wild-type 
ocfC gene, restored the wild-type level of antifungal activity.  More  importantly, the 
function of the ocfC gene to add xylose to the occidiofungin molecule was further 
verified by RP-HPLC and MALDI-TOF analyses. The results further confirmed the role 
of ocfC gene in occidiofungin biosynthesis. The broad-host range vector pMLS7 was 
successfully used to complement the phenotype of the mutant MS14GG44 to that of the 
wild type strain B. contaminans MS14
80
. Surprisingly, like other studies
95
, a functional 
ocfC gene did not fully restore occidiofungin production of the mutant MS14KC1. The 
downstream genes of ocfC include the ABC transporter gene (ocfB), the hypothetical 
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gene (ocfA) and the regulator gene (ambR2), which have the same transcriptional 
orientation
65
. However, the mutation was made by a insertion of a terminatorless nptII 
gene
79
, which should not have any polar impacts on the expression of the downstream 
genes
96
. The phenotype of the mutant MS14KC1 was resulted from the disruption of the 
targeted gene ocfC. It is speculated that the accurate balance of gene expression based on 
the correct genomic position and gene dosage of ocfC may be critical for its function.  
The derivative of occidiofungin produced by the ocfC mutant MS14KC1 lacks 
xylose, which is confirmed by both NMR and MALDI-MS analysis. As noted in the 
TOCSY fingerprint analyses, the xylose-free occidiofungin has a far less complex 
spectrum than the wild type occidiofungin, which may be due to the loss of the sugar 
which allows the compound to interchange between conformations more freely. The two 
distinct conformational families of occidiofungin
65
 carried by two cyclase thioesterases 
have been observed in the xylose-free occidiofungin, which suggests that the xylose 
sugar is not an important component for the cyclization step in occidiofungin production.       
The mechanism by which the sugar xylose affects the production of 
occidiofungin remains to be investigated. In this study, a mutation of the ocfC gene 
results in significant reduction of occidiofungin production based on the standard plate 
bioassays and the yield of the xylose-free occidiofungin was decreased in the ocfC 
mutant. However, the purified xylose-free occidiofungin, which is produced by the 
mutant MS14KC1, showed similar antifungal activity as the wild-type occidiofungin 
product. Yethon et al. found that mutation of the waaG gene, a glycosyltransferase gene 
for liposaccharide (LPS), destabilized the outer membrane of Escherichia coli
97
. It was 
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shown that this glycosyltransferase gene, waaG, played an important role in stabilization 
of the lipopolysaccharide core protein of the outer cell membrane. We hypothesize that 
xylose in occidiofungin may be associated with efficient secretion or for the 
biosynthesis.  However, sonication of the bacterial pellet did not improve the yield of the 
occidiofungin, which indicates the produced occidiofungin may not be significantly 
accumulated in bacterial cells. It is possible that the lower yield is attributed to the 
insertion of a terminatorless nptII gene, lowering the production of the downstream gene 
products. This is not likely given the number of reports that have shown that the cassette 
is non polar. Collectively, there is no significant impact of xylose on the peptide 
backbone and no significant effect of xylose on antifungal activity of purified 
occidiofungin. More investigations are needed to understand the effect of xylose on 
occidiofungin production.  
2.6 Conclusion 
In conclusion, this study demonstrated that the ocfC gene encoding 
glycosyltransferase is responsible for the addition of xylose to the occidiofungin 
molecule. This discovery has provided important genetic and enzymatic clues for 
engineering new chemical variants of occidiofungin that may have applications in 
treating or preventing fungal infections in plants and animals.  
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Table 2.1: Bacterial strains and plasmids 
 
Strains or 
plasmids Relevant Characteristics* 
Sources or 
reference 
Strains   
  E. coli JM109 recA1, endA1, gyrA96, thi,hsdR17,  
supE44, relA1, Δ(lac-proAB)/F'[traD26,  
rpoAB+, laclq, lacZΔM15] 
Promega 
  B. contaminans   
     MS14 Wild type strain (19) 
     MS14KC1 ocfC::nptII derivative of MS14; km
r
 This study 
     MS14MT18 ocfE::Tn5 derivative of MS14; km
r
 (6) 
     MS14KC1-R Revertant strain of the ocfC::nptII mutant This study 
Plasmids   
     pBR325 Cloning vector; Cm
r
, Tc
r
, Ap
r
 (16) 
     pMLS7 Expression vector of Burkholderia; Tp
r
 (20) 
     pGEM-T 
Easy Cloning vector; Ap
r
 Promega 
     pBSL15 Kanamycin resistance gene cassette; Km
r
 (14) 
     pKC1 pGEM-T Easy carrying 1.5-kb PCR 
product containing the intact ocfC gene; 
Ap
r
 
This study 
     pKC2 pGEM-T Easy containing 2.8-kb ocfC 
and nptII; Km
r
 
This study 
     pKC3 pBR325 carrying 2.8-kb EcoRI fragment 
containing the intact ocfC gene; Km
r
, Tc
r
, 
Ap
r
 
This study 
     pKC4 pMLS7 carrying 1.5-kb 1.5-kb PCR 
product containing the intact ocfC gene; 
Cm
r
, Tp
r
 
This study 
     pDP12 pBR325 carrying 1.5-kb EcoRI fragment 
of pKC1  containing the intact ocfC gene; 
Km
r
, Tc
r
, Ap
r
 
This study 
*Km
r
, kanamycin resistance; Ap
r
, ampicillin resistance; Tp
r
, trimethoprim 
resistance; Cm
r
, chloramphenicol resistance 
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Table 2.2: Chemical shift values for the ocfC mutant product 
 
Amino 
acid 
H
N 
H
α 
H
β 
Other proton 
Asn1 
8.13
a
 4.53 [52.91] 2.58, 2.36 
[40.09] 
γ-NH2: 7.23, 6.84 
BHN1 
7.95 4.62 [58.79] 4.03 [74.94] γ-NH2: 7.20, 6.77, β-
OH: 5.71  
NAA2 
7.49 
 
7.35 
 
 
 C2:CH2- 2.38 [39.98], 
C3:CH- 4.14 [47.49], 
C4:CH2- 1.77 [41.32] 
C2:CH2- 2.32 [43.78], 
C3:CH- 4.19 [47.49], 
C4:CH2- 1.39 [41.32] 
Ser3 
8.13 
8.18 
4.21 [58.90] 
4.18 [58.81] 
 β-OH: 5.08 
β-OH:5.08 
BHY4 8.02 
 
 
4.18 [63.07] 5.08 [73.89] β-OH: 5.70 
 
DABA5 
7.71 4.39 [53.86] 
 
2.11, 1.91 
[32.78] 
 
γ-H: 2.92 [32.78] NH2: 
7.74 
Gly6 
7.93 
7.85 
3.81, 3.64 
[45.11] 
3.87, 3.65 
[45.11] 
  
Asn7 
8.36 
8.30 
4.58 [58.71] 
4.56 [52.91] 
2.63, 2.41 
[40.09] 
2.63, 2.40 
[40.09] 
γ-NH2: 7.38, 6.92 
γ-NH2: 7.38, 6.92 
Ser 8 7.81 4.20 [58.70] 3.62 [63.07] β-OH: 5.69 
a
Proton chemical shift values are from a TOCSY and NOESY experiments. 
Chemical shifts in brackets are 
13
C values from the HSQC experiment. 
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Table 2.3: Antifungal activities of the ocfC mutant product 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain 
Antifungal (μg/ml) 
Wild-type ocfC mutant 
C. tropicalis 66029 0.5 0.5 
C. glabrata 66032 0.5 0.5 
C. albicans 66027 1.0 1.0 
C. albicans LL 0.5 0.5 
C. albicans  TE 0.5 0.5 
C. parapsilosis 90018 1.0 1.0 
C. glabrata TE 0.5 0.25 
G. candidum 0.5 0.5 
S. cerevisiae BY4741 0.06 0.06 
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Figure 2.1: Plates of bioassays for antifungal activities of Burkholderia contaminans 
strains (A: The wild type strain MS14; B: MS14KC1, ocfC::nptII; C: MS14KC1-R, a 
revertant of the ocfC mutant; and D: MS14MT18, ocfE::Tn5) against indicator fungus 
Geotrichum candidum. Potato dextrose agar plates were inoculated with each strain (5 µl 
containing ~10
6
 cells) and the inoculated plates were incubated at 28
o
C for 4 days. The 
plates were oversprayed with spore suspensions of the indicator fungus G. candidum Km 
and further incubated at 28
o
C overnight. 
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Figure 2.2: Absence of Xylose in the ocfC mutant product.  A. Region of the TOCSY 
spectrum showing the proton chemical shifts of the xylose in the wild-type sample.  B.  
Region of the TOCSY spectrum showing the absence of the xylose in the ocfC mutant 
product sample. C. MALDI-TOF spectrum of the ocfC mutant product showing a base 
mass of 1068 Da, which is a loss of 132 Da compared to the wild-type product mass. 
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Figure 2.3: TOCSY fingerprint region (NH correlations). A. NH correlations in the 
wild-type sample.  B. NH correlations in the ocfC mutant sample. C. Overlay of the NH 
correlations found in the wild-type and mutant samples. NH correlations that are not 
present in the ocfC mutant sample are colored green. 
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Figure 2.4: Overlaid RP-HPLC chromatogram obtained from the extracts of both the 
wild-type strain MS14 (black) and the ocfC mutant (grey). 
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Figure 2.5: Product analysis of the ocfC mutant revertant MS14 KC1-R. A. Overlaid 
RP-HPLC chromatogram obtained from the extracts of the wild-type strain MS14 (grey 
dashed line), the ocfC mutant (grey) MS14 KC1, and ocfC revertant (black) MS14 KC1-
R.  B. MALDI-TOF spectrum of the ocfC revertant MS14 KC1-R product showing a 
base mass of 1200 Da and the absence of the ocfC mutant MS14 RC1 base mass of 1068 
Da. 
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3. THE PRESENCE OF TWO CYCLASE THIOESTERASES EXPANDS THE 
CONFORMATIONAL FREEDOM OF THE CYCLIC PEPTIDE 
OCCIDIOFUNGIN
*
 
 
3.1 Overview 
Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with 
submicromolar activity produced by Gram-negative bacterium Burkholderia 
contaminans. The biosynthetic gene cluster was confirmed to contain two cyclase 
thioesterases. NMR analysis revealed that the presence of both thioesterases is used to 
increase the conformational repertoire of the cyclic peptide. The loss of the OcfN cyclic 
thioesterase by mutagenesis results in a reduction of conformational variants and an 
appreciable decrease in bioactivity against Candida species. Presumably, the presence of 
both asparagine and β-hydroxyasparagine variants coordinate the enzymatic function of 
both of the cyclase thioesterases. OcfN has presumably evolved to be part of the 
biosynthetic gene cluster due to its ability to produce structural variants that enhance 
antifungal activity against some fungi. The enhancement of the antifungal activity from 
the incorporation of an additional cyclase thioesterase into the biosynthetic gene cluster 
of occidiofungin supports the need to explore new conformational variants of other 
therapeutic or potentially therapeutic cyclic peptides. 
                                                 
*
 Reprinted with permission from The Presence of Two Cyclase Thioesterases Expands the 
Conformational Freedom of the Cyclic Peptide Occidiofungin by Akshaya Ravichandran, Ganyu Gu, 
Jerome Escano, Shi-En Lu, and Leif Smith. Journal of Natural Products 76:2. Copyright [2013] American 
Chemical Society. DOI: 10.1021/np3005503 
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3.2 Introduction 
Nonribosomal peptide synthetases (NRPSs) produce a wide array of small and 
structurally complex peptides that have therapeutic potential. The system enables the 
incorporation of nonproteinogenic amino acids into the polypeptide. Polyketide 
synthetases (PKSs) are a family of enzymes or enzyme complexes that produce 
polyketides. Integration of PKSs into the NRPSs system further increases the variety of 
polypeptides that can be produced by these systems. Recent studies are aimed at 
exploiting nonribosomal peptide synthetases (NRPSs) for producing peptide libraries 
that can be screened for therapeutic applications.
98-105
  
Unlike linear peptides, cyclic peptides are restrained to fewer conformations that 
facilitate their interaction with their molecular target.
106-114
 These structural constraints 
provide resistance to proteases, extreme pH, and temperature.
106,115
 These attributes 
make them one of the most promising scaffolds for pharmacophores.  Classical total 
synthesis of peptides by solid phase or solution phase peptide synthesis followed by 
subsequent cyclization reactions requires the addition and removal of protecting groups 
at the right stages to drive the cyclization among the correct residues.
105
 Even with these 
considerations, proper cyclization is hindered by intermolecular interactions and 
entropically disfavored pre-cyclization conformations resulting in a vast mixture of 
compounds or low yields. Microorganisms ensure the formation of a functional cyclic 
peptide conformation by enzymatically catalyzing the cyclization and release of the 
peptide with regioselectivity using a cyclase thioesterase.
98,104
 The cyclase thioesterase is 
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often located at the C-terminal end of the last NRPS involved in the synthesis of the 
peptide and is referred to as the TE domain.  
The TE domain can hydrolyze the bound peptide as a linear peptide or it can 
catalyze an intramolecular reaction resulting in the formation of a cyclic peptide. At 
present, little is known about the cyclization mechanism of peptides. The crystal 
structure of the surfactin peptide cyclase provided the first basic understanding of its 
mechanism of action.
116,117
 The peptidyl chain bound to 4-phosphopantetheine cofactor 
(ppan) that is attached to the thiolation (T)-domain is transferred to a serine, which is 
part of a catalytic triad in the adjacent TE domain. Once the peptide is transferred to the 
TE domain, the cyclase binding pocket enables proper orientation and cyclization of the 
peptide substrate. The enzyme was found to share structural homology to the α,β-
hydrolase family. The lack of water in the binding cleft of the cyclase, which prevents 
hydrolysis, is the significant alteration from the hydrolase family that gives the cyclase 
thioesterase its ability to form cyclic peptides.   
Occidiofungin is a broad spectrum nonribosomally synthesized cyclic antifungal 
peptide that has submicro/nanomolar activity and low toxicity.
64,115,118-121
 ESI-MS and 
NMR data revealed the existence of four structural variants of the antifungal peptide 
occidiofungin produced by the soil bacterium Burkholderia contaminans MS14, having 
a mass [M + 1] of 1,200.39, 1216.41, 1234.17, and 1250.41 Da.
118
 The mass differences 
correspond to the addition of oxygen to Asparagine (Asn1) forming β-
hydroxyasparagine (BHN1) and/or addition of chlorine to β-hydroxytyrosine (BHY4) 
forming chlor-BHY4.
118
 NMR data sets and amino acid analysis revealed that 
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occidiofungin is produced via a hybrid PK-NRPS system and that the antifungal 
compound is composed of eight amino acids (Figure 3.1). Using NRPS-PKS web-based 
software and interProScan software in EMBL-EBI, predicted epimerase domains were 
identified in the NRPS modules for BHY4, 2,4-diaminobutyric acid (DABA5), and 
Ser8.
118
 The peptide is predicted to have L-Asn1(BHN1), L-Ser3, D-BHT4, D-DABA5, 
L-Asn7, and D-Ser8. An interesting feature in the biosynthetic pathway of occidiofungin 
is the presence of two putative thioesterases. One is present as an independently 
expressed thioesterase, OcfN, and the other is a C-terminal TE domain of OcfD.  We set 
out to gain a better understanding of the role of the two putative thioesterases in the 
biosynthetic gene cluster of occidiofungin.  
We have focused our study on the last step in the formation of the cyclic NRP 
occidiofungin.
118
 Here we conclusively show that the biosynthesis utilizes two distinct 
cyclase thioesterases to expand the formation of conformers and that the evolutionary 
integration of an additional cyclase thioesterase improves its bioactivity against Candida 
species. Restrictions in the conformational freedom of a peptide may facilitate the 
interaction of the compound with its molecular target, but there is also an inherent 
evolutionary constraint using an enzymatic cyclization approach. Our results suggest that 
when the molecular target is associated with a broad spectrum of microorganisms, the 
constrained conformers of a cyclic peptide may not always provide the best activity 
against all organisms. Our study supports the need to investigate new stereoisomers of 
antimicrobial cyclic peptides in an effort to identify the most effective therapeutic 
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compound. In addition, our study provides further understanding of the function of 
cyclase thioesterases. 
3.3 Materials and methods 
3.3.1 Materials   
Occidiofungin produced by both the wild type strain MS14 and the ocfN mutant 
MS14GG88 were purified as previously described for the wild-type sample.
119
  
Chemicals were purchased from Sigma-Aldrich (St. Louis, MO) and were the highest 
grade, unless otherwise stated. Media were purchased from Fisher Scientific, enzymes 
were purchased from New England BioLabs (Ipswich, MA), and primers were 
purchased from Integrated DNA Technologies (Coralville, IA) unless otherwise stated. 
Candida strains used were purchased from the ATCC biological resource center and 
were a gift from Thomas Edlind (Drexel University College of Medicine). 
3.3.2 Site directed mutagenesis   
A nonpolar mutation was constructed in the open reading frame of wild-type 
ocfN by the insertion of a kanamycin resistance gene, nptII.
79
  To mutate ocfN, a 1-kb 
fragment containing ocfN was obtained by PCR using primers MocfNF (5'-
CGCCACCCGTTACGAGGATTC) and MocfNR (5'-ACGCGTCCCCTCTTCCTACG). 
The 1-kb PCR product was cloned into the pGEM-T Easy Vector System I (Promega 
Corporation, Madison, WI) resulting in plasmid pGG30.  The nptII gene was inserted 
into the cloned ocfN at SmaI, generating plasmid pGG31.  The ~2-kb EcoRI fragment of 
pGG31 harboring the ocfN gene disrupted by insertion of nptII was cloned into 
pBR325
81
 at the EcoRI site to generate pGG32.  Mutagenesis of the ocfN gene was 
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conducted via a marker exchange procedure as described previously,
122
 to generate the 
mutant MS14GG88.  PCR analysis and sequencing were used to verify the double 
crossover mutants.  Production and purification of the antifungal were done as 
previously described.
119
   
3.3.3 NMR spectroscopy   
A 2 mM sample of ocfN thioesterase mutant fraction of occidiofungin was 
prepared in DMSO-d6 (Cambridge Isotopes) and data were collected as previously 
described for the wild-type fraction.
118
 The NMR data were collected on a Bruker 
Advance DRX spectrometer, equipped with a CryoProbe, operating at 600 MHz. The 
1
H 
NMR resonances were assigned according to standard methods
123
 using COSY, TOCSY, 
NOESY and HSQC experiments.  NMR data were collected at 25°C. The carrier 
frequency was centered on the residual water resonance (3.33 ppm), which were 
suppressed minimally using standard presaturation methods. A 2.0 s relaxation delay 
was used between scans. The TOCSY experiment was acquired with a 60 ms mixing 
time using the Bruker DIPSI-2 spinlock sequence. The NOESY experiment was 
acquired with 400 ms mixing time. The parameters for collecting the HSQC spectrum 
were optimized to observe aliphatic and aromatic CH groups. The sweep width for the 
TOCSY and NOESY experiments was 11.35 ppm in both dimensions. The sweep widths 
for the HSQC experiments were 11.35 ppm in the proton dimensions and 0 and 85 ppm 
for the carbon dimension. 2D data were collected with 2048 complex points in the 
acquisition dimension and 256 complex points for the indirect dimensions, except for the 
HSQC which was collected with 2048 and 128 complex points in the direct and indirect 
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dimension, respectively. Phase sensitive indirect detection for NOESY, TOCSY, and 
COSY experiments was achieved using the standard Bruker pulse sequences. 
1
H NMR 
chemical shifts were referenced to the residual water peak (3.33 ppm). Data were 
processed with nmrPipe
124
 by first removing the residual water signal by deconvolution, 
multiplying the data in both dimensions by a squared sinebell function with 45 or 60 
degree shifts (for the 
1
H NMR dimension of HSQC), zerofilling once, Fourier 
transformation, and baseline correction. Data were analyzed with the interactive 
computer program NMRView.
125
 1D NMR temperature titrations were collected on the 
wild type and mutant peptides, using a Bruker AVANCE III HD 600 MHz spectrometer 
equipped with a cryoprobe.  Eight scans were collected in each 1D experiment, using 
32K points, at 298 K.  The experiments were repeated using higher temperatures for 
both samples in 5 degrees K increments, up to a temperature of 323 K.  2D TOCSY 
spectra were collected at 323 K, using a mixing time of 60 milliseconds.  Eight scans 
and 256 indirect points were used for both the wild type and mutant peptides. The 2D 
spectra were processed using NMRPipe, with 45 degree sinebell squared shifts in both 
dimensions. 
3.3.4 Mass spectrometry  
The wild-type occidiofungin and the ocfN mutant sample (10 µg) were 
evaporated to dryness in a Speed Vac Concentrator (ThermoScientific, San Jose, CA) 
and the residue was taken up in 50 µL MeOH and analyzed by direct infusion at 3 
µL/minutes into an LCQ DecaXP (ThermoScientific, San Jose, CA).   Data were 
acquired over a mass range of m/z 200 to 2000.   
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Microdilution broth susceptibility testing was performed in triplicate according to 
the CLSI M27-A3 method in RPMI 1640 [buffered to a pH of 7.0 with MOPS 
(morpholinepropanesulfonic acid)] growth medium.  100X stock solutions of 
occidiofungin were prepared in DMSO.  MIC endpoints for occidiofungin were 
determined by visual inspection and were based on the wells that had no visible growth 
(an optically clear well) after 24 hours of incubation.  DMSO containing no antifungal 
agent was used as a negative control. Colony forming units (CFUs) were determined in 
triplicate by plating 100 µL from the MIC wells onto a Yeast Peptone Dextrose (YPD) 
plate as well as plating 100 µL from 10-fold serial dilutions of the cell suspension in 
Yeast Peptone Dextrose (YPD) Broth. Colony counts were performed and reported as 
CFUs/mL. Time-kill experiments were performed as previously reported.
115
 C. glabrata 
(ATCC 66032) colonies on 24-h-old YPD plates were suspended in 9 mL of sterile H2O. 
The density was adjusted to a 0.5 McFarland standard and was diluted 10-fold with 
RPMI 1640 medium to a final volume of 10 mL containing a final concentration of 2, 1, 
0.5 and 0 µg/mL of occidiofungin from wild type strain MS14 and the ocfN mutant 
MS14GG88. The cultures were incubated at 35°C with agitation. Samples were drawn, 
serially diluted, and plated on YPD medium for colony counts. 
3.4 Results 
3.4.1 Proportion of occidiofungin variants in the sample  
The C-terminal TE domain of OcfD and the OcfN cyclase thioesterase in the 
occidiofungin biosynthetic gene cluster are both predicted to be involved in the 
termination of synthesis and formation of the cyclic peptide. Given that the N-terminal 
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of the linear peptide is an Asn or a BHN, we hypothesized that each thioesterase was 
required for cyclization of the Asn1 and BHN1 variants. The Asn1 and BHN1 variants 
of occidiofungin are not separable by RP-HPLC, thus, both variants are present in the 
purified fraction (Figure 3.2). The final RP-HPLC step in the purification process reveals 
the presence of three peaks. Occidiofungin samples elute as a double peak before the 
third peak. Occidiofungin derived from the wild type strain MS14 and the ocfN mutant 
MS14GG88 have the same chromatographic profile as observed in the last purification 
step. Occidiofungin peaks were confirmed by MALDI-TOF and bioassays. It is 
important to note that the presence of the doublet peak is not associated with the 
presence of Asn1 or BHN1. Each peak of the double peak contains both the Asn1 and 
BHN1 variants.  
The relative proportion of the Asn1 and BHN1 variants could not be directly 
compared, because direct measurement of the Asn1 peak intensities could not be done 
due to the peaks overlapping with Asn7. The relative proportion of the Asn1 and BHN1 
variants in the wild-type fraction was determined by measuring the 
13
C NMR HSQC Ha-
Ca cross peak intensities of each BHY4 peak in the data set,
126,127
 given that each of the 
BHY4 peaks could be attributed to either the Asn1 or BHN1 variant. Based on the Ha-
Ca cross peak intensities for BHY4 in the HSQC spectrum, the Asn1 and BHN1 variants 
were determined to be approximately 36 and 64% of the total amount of occidiofungin, 
respectively (Figure 3.3). The peaks in red and green represent the BHY4 peaks 
associated with BHN1 and Asn1 variants, respectively. A similar ratio was also observed 
in the relative abundance of each peak in the ESI-MS spectrum (Figure 3.4A). 
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Furthermore, the HSQC Ha-Ca cross peak intensities for the BHN1 peaks were 
determined to be 90.50 and 38.65, which support the intensities measured for BHY4 
peaks corresponding to the BHN1conformational variants. 
Mutagenesis of the ocfN gene was conducted via a marker exchange procedure as 
described previously,
118
 to generate the mutant MS14GG88. The percentage of Asn1 to 
BHN1 variants in the ocfN mutant MS14GG88 fraction could be determined by 
measuring the proportion of each BHN1 variant using the HSQC data set and by the 
integration of the HN of Asn1 and BHN1 in the 
1
H NMR spectra. Asn1 and BHN1 
variants are approximately 20 and 80% of the total amount of occidiofungin, 
respectively. The ESI-MS spectrum also shows a lower relative abundance for the Asn1 
variant (1200.39 Da) compared to the BHN1 variant (1216.41 Da) (Figure 3.4B). 
3.4.2 Comparison of wild-type and ocfN mutant NMR spectra  
Occidiofungin has a complex spectrum for a peptide of only eight amino acids 
(Figure 3.5A, Table 3.1). The NMR spectrum represents an average of the conformers 
on the NMR time scale. Conformers in slow exchange on the NMR time scale may 
result in multiple spin systems for each amino acid. In some situations, multiple 
conformers are known to arise for cyclic peptides due to slow interconverting 
conformational families.
128,129
 Despite the conformational restrictions brought about by 
the cyclization, occidiofungin still has a significant amount of conformational freedom. 
Both Asn1 and BHN1 variants are visibly present in the wild-type fraction, which are 
colored red in Figure 3.5A. The TOCSY fingerprint region (NH correlations) is not as 
complex for the ocfN thioesterase MS14GG88 mutant spectra (Figure 3.5B). A 
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significant number of spin systems found in the wild-type spectra are absent in the ocfN 
thioesterase mutant spectra. Our experiments show that the TE domain on the C-terminal 
region of OcfD is able to perform the peptide macrocyclization of both the Asn1 and 
BHN1 variants, although there is only one amide spin system for Asn1 produced by 
OcfD. The loss of OcfN results in the disappearance of the other three Asn1 amide spin 
systems.  
An overlay of the wild-type and ocfN mutant NMR spectra shows the amino acid 
spin systems in green that are absent in the mutant spectra (Figure 3.5C). These spin 
systems are for Asn7, Ser8, Asn1, Novel Amino Acid 2 (NAA2), Ser3, BHY4, and 
Gly6. The loss of these spin systems suggests that the complex spin system observed for 
the wild-type occidiofungin fraction is not only due to interconverting conformational 
families, but is the result of distinct diastereomers formed by the regiospecific activity of 
the OcfN cyclase and OcfD TE domain. Dramatic chemical shifts observed, such as the 
2 ppm shift for HN of the NAA2, supports the formation of a structurally unique 
conformer of occidiofungin. A unique conformer is further supported by the subsequent 
loss of an NAA2 spin system in the NMR spectra of the ocfN mutant. Furthermore, the 
presence of both Asn1 and BHN1 spin systems in the mutant spectra along with the 
absence of the amide spin systems shown in green indicate that the additional spin 
systems are not due to the presence of the β-hydroxy group on Asn1.  The additional 
spin systems are due to the formation of a unique diastereomer produced by OcfN 
cyclase thioesterase. To further test for the formation of a configurational isomer versus 
an interchangeable conformer, 1D NMR temperature titrations were performed.  Amide 
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and aromatic regions revealed little change in the complexity of peaks present with the 
occidiofungin derived from ocfN mutant MS14GG88 or wild-type strain MS14 (Figure 
3.6). Given that NAA2 spin systems are a good indicator for the presence of both 
diastereomers in the wild-type spectrum, we collected TOCSY spectra for occidiofungin 
derived from ocfN mutant MS14GG88 or wild-type strain at 50°C (Figure 3.7). There 
was no loss or addition of a spin system for NAA2 in the mutant spectrum.  
Furthermore, both spin systems for NAA2 remained in the wild-type spectrum. This data 
supports that the stereoisomers are non-interchangeable isomers, supporting their 
classification as diastereomers rather than conformers.   
3.4.3 Model for the coordinated function of two cyclase thioesterases  
There was no loss of an amide spin system for a BHN1 in the ocfN mutant NMR 
spectra. This suggests that OcfN thioesterase has a substrate requirement for the peptide 
containing Asn1, since there is no concomitant loss of a BHN1 spin system with the 
observed loss of the Asn1 spin systems.  The C-terminal TE domain of OcfD has a 
preference for the peptide containing the BHN1, but is capable, albeit at a lower 
efficiency of cyclizing the Asn1 variant. This provides an interesting scenario for the 
activity of the two thioesterases (Figure 3.8). Both thioesterases contain the GXSXG 
motif, which is important for the catalytic transfer of the peptide from the T domain to 
the cyclase.
130
 This suggests that substrate recognition occurs prior to the catalytic 
transfer of the peptide to the cyclase. Presumably, OcfN cyclase has a higher affinity or 
better access for the Asn1 peptide product given that the proportion of the Asn1 cyclic 
peptide produced by OcfD compared to the BHN1 product is reduced in the wild-type 
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fraction. Therefore the biosynthesis of occidiofungin utilizes the structural differences 
between Asn and BHN to increase the conformational biodiversity of occidiofungin. The 
increase in conformational diversity is accomplished by the regiospecific activity of each 
cyclase, presumably by differences in their binding clefts that helps orientate the peptide 
before cyclization.  
3.4.4 Comparison of the bioactivity of the wild-type and ocfN mutant product 
To determine whether the increase in conformational diversity is important for 
bioactivity, minimum inhibitory concentrations were determined against medically 
relevant Candida species (Figure 3.9A). There was a 2-fold decrease in the MIC with the 
purified ocfN mutant product with respect to the wild-type product against Candida 
albicans LL, C. albicans TE, C. glabrata ATCC66032, C. parapsilosis ATCC90018, 
and C. tropicalis ATCC66029. There was no difference in the MIC for C. albicans 
ATCC66027. Colony forming units (CFUs/mL) were determined for the MIC wells of 
wild-type product for each Candida species and compared to the corresponding well 
containing the same concentration of the ocfN mutant product (Figure 3.9B). Following 
exposure to the same concentration of wild-type and ocfN mutant products, these results 
show a 5 to 7-log decrease in cell density of the Candida species treated with wild-type 
product. The differences in activity are also visualized by the rate of cell death.  Time-
kill experiments were performed against C. glabrata  ATCC66032. There was a 10-fold 
difference in yeast present at 4 and 8 hours when cells were treated with 0.5 µg/mL of 
occidiofungin derived from ocfN mutant MS14GG88 or wild-type strain (Figure 3.7). 
Furthermore, a slower rate of cell death was also observed for yeast treated with 
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occidiofungin derived from ocfN mutant MS14GG88 at 1.0 and 2.0 µg/mL. Given that 
the cyclic occidiofungin variants produced by OcfN constitute less than half of the total 
structural variants, a 2-fold loss in activity suggests that the diastereomers synthesized 
by OcfN are 4-fold more active than the isomer produced by OcfD against five of the 
Candida species tested. Another possible explanation for the observed differences in 
activity could be attributed to possible synergism between the diastereomers produced 
by each cyclase thioesterase. Furthermore, the antifungal activity of the ocfN mutant 
(MS14GG88: 8.79 ± 0.38 mm) was also significantly reduced (P < 0.05) compared to 
wild-type activity (inhibitory zone radius ± SEM: 13.00 ± 0.58 mm) in an overlay assay 
against Geotrichum candidum (Figure 3.10). 
3.5 Discussion 
The findings from this study include experiments showing the following: the 
relative proportion of the Asn1 and BHN1 variants in the purified fraction; distinct 
differences in spin systems for the wild-type and ocfN mutant products; a proposed 
model for the coordinated function of two cyclase thioesterases; and demonstrated 
differences in biological activity of wild-type and ocfN mutant products against 
therapeutically relevant Candida species.  Expanding the conformational repertoire of 
cyclic peptide natural products can be beneficial to microorganisms. These data suggest 
that the bacterium Burkholderia contaminans MS14 is benefited by maintaining two 
distinct cyclase thioesterases that improves the spectrum of activity of occidiofungin.  
Our data support the observation that cyclase thioesterase substrate recognition 
occurs prior to the catalytic transfer of the peptide. The presence or absence of a hydroxy 
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group on the β-carbon of the N-terminal amino acid (Asn1) appears to be important for 
the substrate recognition by the two cyclase thioesterases.  It has also been shown that 
the N-terminal amino acid is important for substrate recognition for other 
thioesterases.
101,105
 It is possible that the presence of the hydroxy group promotes a
hydrogen bond with the ocfD cyclase thioesterase domain or more likely promotes an 
interaction within the T domain of the NRPS. Different bound orientations of the peptide 
to the T domain would establish a basis for the coordinated function of two cyclase 
thioesterases. 
The presence of the hydroxy group on the β-carbon and the bound orientation of 
the peptide to the T domain may prevent the interaction of the OcfN cyclase, while 
enabling the continued substrate recognition by the OcfD TE domain. Conformational 
diversity of the T domain has been shown to be important for the directed movement of 
the peptide substrate bound to the ppan cofactor and its interaction with externally acting 
enzymes.
100
 More specifically, the active site serine of the cyclase thioesterase needs to
attack the linear peptide attached by a thioester linkage to the ppan forming an acyl-O-
TE intermediate. The position of the peptide bound to the ppan in the T domain will be 
important for bringing the peptide substrate in proximity of the appropriate cyclase 
thioesterase. 
Furthermore, some cyclase thioesterases are capable of transacylation of the 
peptide to the active site serine, when the peptide is bound to a biomimetic prosthetic 
group.
101,112
 However, there are several cyclase thioesterases that will not function when
the product is bound to a biomimetic group. These data suggest that the interaction of the 
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peptide with the T domain is important for the enzymatic activity of some thioesterases 
and this interaction cannot be mimicked using a prosthetic group. It is conceivable that 
the coordinated function of the two cyclase thioesterases, involved in the synthesis of 
occidiofungin, utilize differences in the interaction of the ppan bound peptide within the 
T domain. 
Presumably, ocfN was integrated into the occidiofungin biosynthetic gene cluster 
to improve its spectrum of activity against fungi. Given the broad spectrum of antifungal 
activity associated with occidiofungin, the molecular target is likely to be highly 
conserved. However, there must be some variation among fungal species to account for 
the differences in biological activity. Increasing the conformational repertoire must be a 
selective advantage to the bacterium for it to maintain the two functional cyclase 
thioesterases. The microbial environment is considerably different than how we intend to 
apply the natural products produced by microorganisms. For instance, the bacterium 
Streptomyces roseosporus is a soil saprotroph responsible for the production of 
daptomycin.
131,132
  The microbial community that this bacterium encounters is far more
diverse than the group of bacteria that cause human infection. Thus, evolutionary 
pressures that selected for the current conformers of daptomycin may not necessarily be 
the best conformers for treating a Staphylococcus aureus infection. It is very likely that 
the therapeutic application of daptomycin or other cyclic peptide drugs could be 
improved by engineering novel conformational or configurational isomers. 
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3.6 Conclusion 
Creating novel diastereomers of other cyclic peptide drugs using new or 
engineered cyclase thioesterases may lead to improvements in their therapeutic activity 
against clinically relevant pathogens. This is true for occidiofungin produced by the 
bacterium Burkholderia contaminans MS14, which accomplishes this goal by the 
evolutionary integration of an additional cyclase thioesterase into the occidiofungin 
biosynthetic gene cluster. These sections conclude our analysis of naturally occurring 
variants of occidiofungin. In addition to better understanding the biosynthetic machinery 
involved in the production of occidiofungin, these studies expanded our understanding 
of the variants themselves. The information obtained will be utilized in future endeavors 
involving clinical development of occidiofungin. 
Following this, we will focus on reporting the studies performed on determining 
the mechanism by which occidiofungin causes death in fungal cells and analyzing the 
specific molecular target to which occidiofungin binds, in order to achieve cell death. 
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Table 3.1: Chemical Shift Values for Occidiofungin Derived from the ocfN Mutant 
MS14GG88
a 
 
 
Unit 
 
No. 
 
δC 
 
δH (JHNHα  in 
Hz) 
 
Asn1 
2 
2-NH 
3 
4 
4-NH2 
52.71, CH 
 
39.91, CH2 
- 
4.59 
7.75 (12.1) 
2.62, 2.41 
 
7.39, 6.93 
 
BHN1 
2 
2-NH 
3 
3-OH 
4 
4-NH2 
58.47, CH 
 
75.01, C 
 
- 
4.66, 4.61 
7.81, 7.9 
(8.1, 12.1) 
3.98, 4.02 
4.66 
 
7.24 
 
NAA2 
2 
3 
3-NH 
4 
5 
6 
7 
8 
9-17 
18 
43.88, CH2 
47.25, CH 
 
41.57, CH2 
66.36, CH 
76.07, CH 
79.61, CH 
33.19, CH2 
25.14-28.02, CH2 
16.94, CH3 
2.34, 2.36 
4.23 
7.31, 7.34 
(8.4, 11.4) 
1.39, 1.76 
3.50 
3.08 
3.72 
1.54 
1.27 
0.86 
 
Ser3 
2 
2-NH 
3 
3-OH 
58.59, CH 
 
70.23, 64.29 
4.07, 4.15 
8.11, 8.14 
(11.2, 8.0) 
3.49, 3.45 
4.95 
 
BHY4 
2 
2-NH 
3 
3-OH 
4 
5,6 
8,9 
58.71,CH 
 
73.75,CH 
 
- 
- 
- 
4.06, 4.15 
7.83, 7.94 
(8.7, 11.7) 
4.98, 5.08 
5.66, 5.73 
 
7.15 
6.67 
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Table 3.1(continued): Chemical Shift Values for Occidiofungin Derived from the 
ocfN Mutant MS14GG88
a 
 
 
Unit 
 
No. 
 
δC 
 
δH (JHNHα  in 
Hz) 
 
DABA5 
2 
2-NH2 
3 
4 
4, NH 
53.49, CH 
 
32.68, CH2 
39.17, CH2 
4.43 
7.66 (8.5) 
1.88, 2.11 
2.92 
7.71 
 
Gly6 
2 
2-NH 
44.76, CH2 3.87, 3.58, 
3.84, 3.70 
7.68, 7.85 
 
Asn7 
2 
2-NH 
3 
4 
4-NH2 
53.25, CH 
 
40.03, CH2 
- 
4.51, 4.58 
8.35, 8.41 
(9.3, 8.7) 
2.61, 2.38 
 
7.39, 6.93 
 
Ser8 
2 
2-NH 
3 
3-OH 
58.11, CH 
 
64.59 
 
4.33, 4.32 
7.76, 7.78 
(8.2, 12.00) 
3.61, 3.62 
4.79 
 
a 
Proton chemical shift values are from a TOCSY and NOESY experiments. 
13
C values 
are from the HSQC experiment. 
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Figure 3.1: Covalent structure of occidiofungin.  (R1 = H or OH; R2 = H or Cl) 
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Figure 3.2: RP-HPLC Chromatograms. A.  Chromatogram of the final purification step 
of the wild-type occidiofungin fraction at 220 nm using a 4.6 x 250 mm C18 column. B. 
Chromatogram of the final purification step of ocfN mutant occidiofungin fraction at 220 
nm using a 4.6 x 250 mm C18 column.  C. Overlay of the wild-type (black) and the 
mutant (grey) fractions of occidiofungin. 
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Figure 3.3:  TOCSY (left panel) and HSQC (right panel) spectra of BHY4 in the wild-
type sample.  The proportions of Asn1 and BHN1 variants were determined by the 
measurement of the Ha-Ca cross peak intensities of BHY4 in the HSQC spectra.  These 
values are listed next to their corresponding peaks in the right panel.  The peaks in red 
and green represent the BHY4 peaks associated with BHN1 and Asn1 variants, 
respectively.  Based on the calculation of their relative proportions, i.e. (34.81 + 87.97 
for the BHY4 peaks found in the BHN1 conformational variants) and (32.79 + 37.61 for 
the BHY4 peaks found in the Asn1 conformational variants), the approximate proportion 
of the Asn1 variants could be calculated as (32.79 + 37.61)/(34.81 + 87.97) + (32.79 + 
37.61). 
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Figure 3.4:  ESI mass spectrometry.  A. ESI-MS data of purified wild-type 
occidiofungin fraction.  B. ESI-MS data of purified ocfN mutant occidiofungin fraction. 
 
 
 
Figure 3.5: TOCSY fingerprint region (NH correlations).  A. NH correlations in the 
wild-type sample. The two BHN1 and four Asn1 spin systems present in the wild-type 
sample are colored red.  B. NH correlations in the ocfN mutant sample.  C. Overlay of 
the NH correlations found in the wild-type and ocfN mutant samples.  NH correlations 
that are not present in the ocfN mutant sample are colored green. 
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Figure 3.6: One-dimensional NMR temperature titration curves for occidiofungin 
derived from ocfN mutant MS14GG88 and wild-type strain MS14. 
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Figure 3.7: Time-kill experiments performed against Candida glabrata ATCC66032. 
Solid black lines and dashed grey lines correspond to samples treated with occidiofungin 
derived from wild-type strain MS14 and ocfN mutant MS14GG88, respectively.  
Circles, squares, and triangles represent samples treated with 0.5, 1.0, and 2.0 µg/mL of 
occidiofungin, respectively. The diamonds represent the sample treated with the blank 
control.   
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Figure 3.8:  Schematic of occidiofungin ring closure.  The completely synthesized eight 
amino acid linear peptide is bound by a 4-phosphopantetheine cofactor (ppan) linker to 
the thiolation (T) domain. The peptide varies by the presence or absence of a hydroxy 
group on the β-carbon of Asn1. The TE domain of OcfD is capable of forming the cyclic 
peptide of both variants in the absence of a functional OcfN cyclase thioesterase. 
However, it is not as efficient at producing the Asn1 cyclic peptide variant as OcfN. In 
the presence of a functional OcfN cyclase thioesterase, novel diastereomers of 
occidiofungin are formed by the selective ring closure of the Asn1 cyclic peptide. R1 and 
R2 are BHN1 and Asn1, respectively. 
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Figure 3.9: Comparison of the bioactivity from the wild-type and ocfN mutant 
occidiofungin fractions. A. MICs of wild-type and ocfN mutant fraction determined by 
CLSI M27-A3 method in RPMI 1640.  B. Comparison of the CFUs in the MIC wells of 
wild-type fraction to the corresponding well having the same concentration of the ocfN 
mutant occidiofungin fraction. Asterisks represent no detectable colonies in the MIC 
wells of the wild-type occidiofungin fraction. Black and grey bars are ocfN mutant and 
wild-type fractions, respectively. Standard deviations for the CFU measurements are 
presented. 
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Figure 3.10: Potato dextrose agar plates were inoculated with each of the strains and 
incubated for 3 days at 28°C. The plates were oversprayed with the indicator fungus 
Geotrichum candidum and incubated overnight.  A: The wild-type strain MS14; B: 
Negative control MS14GG78 (ocfJ::nptII); C: MS14GG88 (ocfN::nptII). 
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4. THE ANTIFUNGAL OCCIDIOFUNGIN TRIGGERS AN APOPTOTIC 
MECHANISM OF CELL DEATH IN YEAST
*
 
 
4.1 Overview 
Occidiofungin is a non-ribosomally synthesized cyclic peptide having a base 
mass of 1200 Da. It is naturally produced by the soil bacterium Burkholderia 
contaminans MS14 and possesses potent broad-spectrum antifungal properties. The 
mechanism of action of occidiofungin is unknown. Viability, terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL), reactive oxygen species (ROS) detection, 
membrane and cell wall stability, and membrane mimetic assays were used to 
characterize the effect of occidiofungin on yeast cells. Confocal and electron microscopy 
experiments were used to visualize morphological changes within treated cells. TUNEL 
and ROS detection assays revealed an increase in fluorescence with increasing 
concentrations of the antifungal. Yeast cells appeared to shrink in size and showed the 
presence of ‘dancing bodies’ at low drug concentrations (1μg/ml). A screen carried out 
on Saccharomyces cerevisiae gene deletion mutants in the apoptotic and autophagy 
pathways identified the apoptotic gene for YCA1, as having an important role in 
occidiofungin response as cells deleted for this gene exhibit a 2-fold increase in 
resistance. Autophagy mutants had no difference in sensitivity compared to the wild-
                                                 
*
Reproduced with permission from ‘The antifungal occidiofungin triggers an apoptotic mechanism of cell 
death in yeast’ by Akshaya Ravichandran, Dayna Emrick, Jivendra Gosai, Shi-En Lu, Donna Gordon, Leif 
Smith. Journal of Natural Products 76, 829-838. Copyright (2013) American Chemical Society. DOI: 
10.1021/np300678e 
 71 
 
type control. Results from our experiments demonstrate that the mechanism of action for 
occidiofungin in yeast is different from that of the common classes of antifungals used in 
the clinic, such as azoles, polyenes, and echinocandins. Our study also indicates that 
occidiofungin causes cell death in yeast through an apoptotic mechanism of action. 
4.2 Introduction 
Discovery and implementation of novel antifungal agents are needed for more 
effective treatment of serious fungal infections.
133
 Antifungals currently used in the 
clinic do not meet the growing needs of an increasing population of immuno-
compromised patients due to limitations in their spectra of activity and toxicities. Some 
current antifungal treatments lead to abnormal liver function test and are primarily 
fungistatic. Discovery of novel antifungals with a broader spectrum of activity and lower 
toxicity are needed. There is a significant demand for new antifungals given the 
prevalence of resistant fungal pathogens to conventional therapies.
134,135
 Furthermore, 
identifying novel antifungals with a different mechanism of action from the current class 
of therapeutically used antifungals may aid in the development of new and more 
effective treatments. 
There are three major therapeutic groups of antifungal agents used for the 
treatment of serious fungal infections: polyenes, azoles, and the echinocandins. The first 
two groups primarily target ergosterol biosynthesis or bind to ergosterol, disrupting the 
fungal membrane.
136-138
 Ergosterol, much like cholesterol found in mammalian cells, is 
important for maintaining proper cell permeability and fluidity. These antifungals lead to 
an osmotic disruption of the cell membrane, leading to an efflux of essential cellular 
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contents resulting in cell death. Echinocandins, the third group, are the newest fungal 
treatment option that has fairly recently (in 2003) entered the clinic. The echinocandins 
are synthetically modified lipopeptides that originate from natural compounds produced 
by fungi and function to selectively inhibit -1,3-glucan biosynthesis.139,140 In fungi, 
covalently cross-linked polysaccharides such as -1,3-glucan, -1,6-glucan, and chitin 
form the primary scaffold that is responsible for the structural integrity and shape of the 
cell.
141-143
 As non-competitive inhibitors of -1,3-glucan synthase, echinocandins reduce 
-1,3-glucan levels leading to loss of fungal cell wall integrity and osmotic disruption of 
the fungal cells.
144-148
 Echinocandins are primarily used to treat Aspergillus spp. and 
Candida spp. infections. They are fungistatic against Aspergillus spp. and only 
moderately fungicidal against Candida spp.
139,149-152
 Infections are often refractory to 
treatment with echinocandins due to their mechanism of action resulting in their use 
against a limited spectrum of fungi.
153,154
   
Induction of apoptosis in fungal cells is an area that holds an immense 
opportunity for the development of new antifungals, because factors that are involved in 
the induction of apoptosis in yeast are different from those found in mammalian 
cells.
155,156
 These differences afford an opportunity to selectively target fungal cells, 
while minimizing the toxicological impact the antifungal has on a patient. Cellular 
changes typical of mammalian cell apoptosis, such as accumulation of reactive oxygen 
species (ROS), fragmentation and degradation of DNA, and externalization of 
phosphatidylserine, occur in fungal cells.
157
 Reports have shown that amphotericin B, a 
polyene antifungal drug, is capable of inducing apoptosis in fungal cells.
158-160
  This 
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apoptotic response appears to occur within a narrow concentration of amphotericin B,
159
 
while a large portion of the fungal cells die from an expected necrotic mechanism 
attributed to its binding to ergosterol. Papiliocin, an antifungal first identified from a 
swallowtail butterfly, is also reported to induce apoptosis in fungal cells.
161
 Papiliocin is 
believed to function in the same manner as other cationic amphipathic peptides, causing 
membrane disruption and leakage of cytoplasmic constituents. The peptide also has 
antibacterial activities associated with its broad-spectrum membrane disruptive function. 
Presumably, amphotericin B also contributes to a nonspecific disruption of membrane 
function, which triggers an apoptotic mechanism of cell death in a subset of cells.
162
  
  Occidiofungin is a cyclic glyco-lipopeptide and its complete chemical 
composition has been determined.
64,118
 Its base molecular weight is 1200 Da (Figure 
3.1). Occidiofungin has been demonstrated to have a broad spectrum of antifungal 
activity.
64,115
 Minimum inhibitory concentrations (MICs) of occidiofungin against 
Candida species are between 0.5 and 2.0 µg/mL, which is similar in activity to 
echinocandins and amphotericin B.
115
 Pharmacodynamic experiments revealed that 
occidiofungin's fungicidal activity against Candida albicans is more rapid than the 
fungicidal activity reported for the echinocandin caspofungin. Occidiofungin exhibited 
potent antifungal activity when Candida albicans was exposed to the antifungal for as 
little as one hour, suggesting that occidiofungin has a strong interaction with a cellular 
target.
115
 A mouse toxicity study showed that doses higher than those commonly used to 
treat fungal infections did not result in mortality.
163
 A dose as high as 20 mg/kg, resulted 
in no negative gross or microscopic findings in the liver or kidneys. Hematology and 
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serum biochemistry tests also revealed that occidiofungin does not significantly alter 
organ function. 
Considering that the mechanism action of occidiofungin is unknown, the aim of 
this study was to determine the cause of fungal death following exposure to 
occidiofungin. We found that exposure to sublethal doses of occidiofungin leads to 
morphological anomalies and that exposure to lethal concentrations results in an increase 
in ROS, cell shrinkage, and DNA fragmentation. Overall, our study supports an 
apoptotic mechanism of cell death for yeast exposed to occidiofungin, which might be 
triggered by membrane perturbation. 
4.3 Materials and methods 
4.3.1 Antifungal preparation  
Isolation of the antifungal compound was accomplished as previously 
reported.
119
  In brief, Burkholderia contaminans MS14 was incubated at 28
o
C for 7 days 
without shaking.  The cell free culture extract was precipitated using ammonium sulfate 
(50% w/v) on ice for 2 hours. The pellet was resuspended in 1 ml of 35% acetonitrile 
(ACN):water (v/v) and placed in a 1.5 mL microcentrifuge tube.  RP-HPLC was done 
using a 4.6 × 250 mm C18 column (Grace-Vydac, catalog 201TP54) on a Bio-Rad 
BioLogic F10 Duo Flow with Quad Tec UV-Vis Detector system with a 30 minute 
gradient from 10 to 90% (ACN):water (v/v). Purifed occidiofungin elutes as a doublet 
peak around 45% (Figure 4.1). 
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4.3.2 Strains, media, and plasmids  
C. albicans (ATCC 66027), C. glabrata (ATCC 66032), and S. cerevisiae 
(BY4741) strains were used for all experiments described. All strains were maintained 
on Sabouraud dextrose (SD), yeast peptone dextrose (YPD), or synthetic selective media 
(-leucine) with 2% agar added for solid media. Candida spp. were also grown in RPMI-
1640 with MOPS media where indicated.  To express the human Bcl2 gene in yeast, 
primers were designed to amplify the Bcl2 coding sequence by PCR using pDNR-Dual-
Bcl2 plasmid as the template (PMID 16512675)
164
. Standard molecular techniques were 
used to clone the resulting DNA fragment into the LEU2-marked pRS415 plasmid 
downstream of the constitutive GAPDH promoter and in frame with a C-terminal HA3 
(three haemagglutinin) epitope tag. All constructs were confirmed by sequencing before 
use. 
4.3.3 In vitro susceptibility testing  
Minimal Inhibitory Concentrations (MICs) were determined using Clinical 
Laboratory Standards Institute (CLSI) method M27-A3. Prior to susceptibility testing, 
yeasts were subcultured and grown for 24 hours on fresh SD, YPD, or -leucine media. 
MIC endpoints were reported based on consistency in sensitivity differences from wild-
type S. cerevisiae BY4741 after 24 and 48 hours of incubation. Susceptibility testing was 
done in experimental triplicate of technical duplicates. Dimethyl sulfoxide (DMSO) was 
used as a negative control. The strains on which the MICs were performed included 
haploid mutants of wild type S. cerevisiae BY4741 obtained from the yeast deletion 
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collection in which the entire open reading frame of each gene was deleted (Thermo 
Scientific).  
Colony forming units (CFUs) were determined in duplicate by plating 100 µL 
from the MIC wells following the 48 hour exposure to occidiofungin onto a YPD plate. 
In addition, 100 µL from two-fold serial dilutions of the cell suspension in YPD broth 
were plated to aid in determining the CFUs. Deletion mutants (apg7, aif1, 
csg2, hos3, nde1, nma1, nuc1, rny1, rpd3, vtc2, vtc3, and yca1) that had more than a 10-
fold increase or decrease in CFUs were tested by a yeast drop assay. For the drop assay, 
yeasts were taken from a 24 hour YPD plate and resuspended in 5 mL of YPD to an 
OD530 of 0.095 (density of a 0.5 McFarland standard).  The suspension was divided into 
two samples of 0.8 mL each and occidiofungin was added to one sample at 0.5µg/mL, 
which is equivalent to 0.5X MIC for this cell density. After 4hrs at 30 ˚C, 200 µL 
aliquots were placed onto a 96-well microtiter plate and the cells were five-fold serially 
diluted seven times using YPD as the diluent. Then, 2 µL from each well was spotted to 
YPD plates in duplicate. Photos were taken after a72 hour incubation at 30 ˚C. Drop 
assays were carried out in duplicate.  
  In the sorbitol protection assay, MIC values were determined using Candida 
glabrata 66032 using the in vitro susceptibility assay described above except that 0.8M 
sorbitol was included in the suspension media. Assays were performed in duplicate and 
MICs were read 24 hours following incubation at 35 °C. 
MIC measurements in the presence of ergosterol were performed using C. glabrata 
66032. 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) was purchased from Avanti 
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Polar Lipids (Alabaster, AL) and ergosterol was purchased from Sigma-Aldrich (St. 
Louis, MO). Vesicles were prepared using a standard sonication procedure provided by 
Avanti Polar Lipids in which 20 mg of DOPC with and without 2 mg of ergosterol was 
dissolved in 1mL of chloroform. The lipid-chloroform solution was placed in a 250 mL 
flask attached to a vacuum line at room temperature and dried to remove the chloroform. 
The dry lipid film was hydrated in 1.0 mL of RPMI 1640 media. The suspension was 
added to the microtiter wells yielding a final concentration of ~80 μg/mL of ergosterol. 
Each microtiter well contained a series of occidiofungin concentrations as described 
above for the in vitro susceptibility assay. Amphotericin B was used as a positive 
control, while DOPC vesicles containing no ergosterol were used as a negative control.  
The MICs were determined after 24 hours of incubation at 35˚C. 
4.3.4 Monitoring cell-cycle progression  
Samples of Candida spp. were treated with 0, 0.5, 1, and 2 µg/ml occidiofungin 
over a 2.5 hour period with aliquots removed at 30 minute intervals for analysis.  All 
cells were fixed with the addition of formaldehyde to 3.7% final and stored at 4 ˚C until 
analyzed.  Cells were viewed by phase contrast microscopy (100X objective) and 
multiple random images were captured using a Retiga EXi Black and White CCD 
Camera and Image Q software.  A minimum of 250 cells per time point per treatment 
were scored for cell cycle distribution using bud size as a marker for position within the 
cell cycle.  
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4.3.5 Protein extracts and Western blot analysis  
C. albicans (ATCC 66027) and C. glabrata (ATCC 66032) strains were grown in 
YPD at 35 ˚C until reaching an OD600 of 0.5.  The cultures were split and occidiofungin 
added to achieve a 2-fold series of concentrations ranging from 4 to 0.062 µg/mL.  
Samples were returned to 35 ˚C with shaking for 10 or 20 minutes.  For each sample, an 
equivalent number of cells were isolated by centrifugation, and the resulting cell pellets 
stored at -20 ˚C.  Total cellular protein was isolated by alkaline lysis,165 separated by 
SDS polyacrylamide gel electrophoresis (PAGE), and transferred to nitrocellulose for 
Western blot analysis. Activation of the cell wall integrity pathway was determined 
using phospho-specific antibodies against p44/42 MAP kinase (Cell Signaling 
Technology) shown to cross react with the doubly phosphorylated form of Mkc1p from 
Candida spp.
166,167
  Weak cross recognition of the phosphorylated form of Cek1p was 
also detected under some experimental conditions.  Total Mkc1p was detected using 
anti-p44/42 antibodies (Cell Signaling Technology).  A monoclonal antibody to 3-
phosphoglycerate kinase (Pgk1p) was used as a loading control (Molecular Probes).  
Activation of Hog1p was achieved by growing cells in the presence of 1M NaCl for the 
time periods indicated and monitored using phospho-specific antibodies against p38 
MAP kinase (Cell Signaling Technology). Autoradiographs were scanned and images 
analyzed using NIH Image J software.  The ratio of phosphorylated Mkc1p to total 
Mkc1p was calculated using the intensity of each protein band taken from the same 
autoradiograph with the value of untreated or DMSO treated samples normalized to one.   
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For S. cerevisiae expressing plasmid-borne human Bcl2, cells were grown in -leucine 
synthetic media at 30 ˚C until an OD600 of 0.5.  An equivalent number of cells were 
isolated by centrifugation, and the resulting cell pellets stored at -20 ˚C.  Total cellular 
protein was isolated by alkaline lysis,
165
 separated by SDS PAGE, and transferred to 
nitrocellulose for Western blot analysis. HA3 tagged Bcl2 protein was detected using 
anti-HA antibodies (Covance); an anti-3-phosphoglycerate kinase (Pgk1p) antibody was 
used as a loading control (Molecular Probes). 
4.3.6 Electron microscopy  
For transmission electron microscopy (TEM), samples were fixed in 2.5% 
glutaraldehyde pH 7.2 for 2 hours at 4 ˚C. Specimens were rinsed in 0.1 M phosphate 
buffer, pH 7.2, post-fixed in 2% OsO4 in 0.1 M phosphate buffer for 2 hours then rinsed 
in distilled water and dehydrated in a graded ethanol series. Specimens were infiltrated 
and embedded in Spurr’s resin and polymerized at 70 ˚C for 15 hours. Thin sections (60-
100 nm) were collected and mounted on 50 mesh grids.  Samples were stained with 
uranyl acetate and lead citrate and were examined and photographed with a JEOL 100 
CX II TEM (JEOL USA, Peabody, Massachusetts) at 80 kV.  
For scanning electron microscopy (SEM), C. albicans was grown in RPMI to an 
OD600 of 1.0 at which time occidiofungin was added to 2 µg/mL final concentration.  
After 30 minute exposure, cells were isolated by centrifugation and fixed in 2.5% 
glutaraldehyde in 0.1M sodium cacodylate pH 7.2. Samples were rinsed and post-fixed 
in osmium tetraoxide in 0.1M sodium cacodylate pH 7.2. Samples were rinsed, 
dehydrated through a graded ethanol series and then critical point dried with a Polaron 
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critical point dryer (Quorum Technologies, Newhaven, UK).  Dried samples were 
mounted on aluminum stubs using carbon tape, coated with gold/palladium using a 
Polaron E5100 sputter coater, and viewed on a JEOL JSM-6500 FE Scanning Electron 
Microscope (JEOL USA, Peabody, MA) 
4.3.7 Fluorescent microscopy  
C. glabrata 66032 cells were grown at a sub-inhibitory concentration of 
occidiofungin (0.25 µg/mL) for 24 hours at 35 ˚C using the CLSI method described 
above.  Cells were fixed with the addition of 3.7% formaldehyde to the media and stored 
at 4 ˚C until staining with Calcofluor White (Sigma; 18909) as described by the 
manufacturer. To visualize mannoproteins, cells were fixed for 30 minutes in 3.7% 
formaldehyde, washed in PBS, incubated with 0.1mg/ml Concanavalin A-FITC (Sigma; 
C7642) for 10 minutes at room temperature, and washed again with PBS before 
visualization. Stained cells were visualized using a 100X objective on a Nikon 50i 
fluorescent microscope.  Random images were captured using a Retiga EXi Black and 
White CCD Camera and Image Q software. 
Cell culture for fluorescent microscopy studies was prepared as follows. S. 
cerevisiae BY4741 and C. albicans (ATCC 66027) were grown overnight in YPD at 30 
˚C. The cell suspension was then diluted to 0.1 OD600 with YPD and incubated at 30 ˚C 
until the culture reached an OD600 between 0.6 to 0.8. The minimum inhibitory 
concentration of occidiofungin against S. cerevisiae C. albicans with this cell density in 
YPD medium is 2 µg/mL.  Images were acquired using Olympus confocal microscope 
with a 40x/0.90 dry objective.  
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Viability assay using FUN-1 dye (Invitrogen) was carried out by adding 15μM of 
dye to the untreated cells and cells treated with 2μg/ml of occidiofungin and incubating 
at 30 ˚C for 30 minutes. The cells were mounted on a glass slide and observed using an 
Olympus confocal microscope. The excitation wavelength of FUN-1 is 480 nm and the 
emission wavelengths are 510-560 nm (green) and 560-610 nm (red). Negative control 
in this assay was 1.6% DMSO. 
ROS detection was performed using dihydrorhodamine 123 (DHR123) 
(Invitrogen) which has an excitation and emission maxima of 505 nm and 534 nm, 
respectively.
168,169
 The dye (25μg/ml) was added to cells treated with 1, 2 and 4 μg/ml of 
occidiofungin for 3 hours. Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) assay was carried out using the APO-BrdU TUNEL assay kit 
(Invitrogen).
168,169
  The assay was performed on cells treated with 1, 4, and 8 μg/ml of 
occidiofungin for 3 hours. Protoplasts of the treated cells were obtained by treatment of 
cells with 24 μg/ml of zymolyase in 1.2 M sorbitol. Staining was then carried out 
according to the protocol outlined by APO-BrdU TUNEL assay kit (Invitrogen). The dye 
used in the TUNEL assay is Alexa Fluor 488 which has an excitation and emission 
maxima of 495 nm and 519 nm, respectively. Negative and positive controls included 
1.6% DMSO and 5 mM H2O2, respectively. FITC-labeled annexin-V staining was done 
using Annexin-V-FLUOS kit (Roche Applied Science).
168,169
  Cells were treated with 1 
and 4 μg/ml of occidiofungin for 3 hours and washed with PBS. The cell pellet was 
incubated in 100 μL of Annexin-V-FLUOS labeling solution for 10-15 minutes at room 
temperatures, as specified by the manufacturer. The cells were mounted on a slide and 
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observed. Excitation and emission maxima for fluorescein are 488nm and 518nm 
respectively and for propidium iodide are 488nm and 617nm respectively. 
4.4 Results 
4.4.1 Membrane and cell wall stability  
Candida albicans ATCC 66027 was used to determine whether occidiofungin 
activated cell wall stress following a 10 minute and 20 minute exposure to occidiofungin 
(Figure 4.2).  The MIC value of occidiofungin in these assays was 4 µg/mL.  
Phosphorylation of Mkc1p indicates the presence of oxidative stress, changes in osmotic 
pressure, or cell wall damage. For C. albicans, an increase in the phosphorylation status 
of this MAP kinase was observable at a dose of 250 ng/mL, which is one sixteenth less 
than the inhibitory concentration. A dose-dependent increase in Mkc1p phosphorylation 
at 10 minutes was also seen for C. glabrata (Figure 4.3). Mkc1p phosphorylation 
occurred at 125 ng/ml occidiofungin, one half of the concentration seen for C. albicans. 
Both C. albicans and C. glabrata had a maximum increase in Mkc1p phosphorylation at 
1 µg/ml. The decreased levels of Mkc1p phosphorylation at 2 µg/ml and the absence of 
Mkc1p phosphorylation at 4 µg/ml is likely due to the increased cell death occurring at 
these concentrations. Similarly, an increase in the level of phospho- Cek1-p indicates 
that occidiofungin induces cell wall stress at subinhibitory concentrations. At the higher 
concentrations of occidiofungin, phosphorylation of Hog1p, a MAP kinase in the 
osmotic stress response pathway, was also detected. Although Hog1p phosphorylation 
was induced by occidiofungin, the extent of activation was significantly lower than that 
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seen for conditions known to induce the osmotic stress response pathway (e.g. 1M 
NaCl).   
To further analyze the impact that occidiofungin may have on cell wall integrity, 
MICs were determined in media supplemented with 0.8M sorbitol. Sorbitol functions as 
an osmotic stabilizer and would decrease the activity of occidiofungin if the antifungal 
targets cells by disrupting membrane stability.
170
 MICs for C. albicans (ATCC 66027) in 
the presence and absence of sorbitol in RPMI 1640 media at 24 hours were determined 
to be 0.5 µg/mL (Table 4.1). This observation suggests that osmotic disruption, which 
would be predicted for a cell wall biosynthesis inhibitor or a membrane disruptive 
compound, is not likely involved in the cidal activity of occidiofungin.  
Echinocandins inhibit -1,3-glucan synthase, a multi-enzyme complex composed 
of catalytic subunits Fks1p/Fks2p. Mutations in FKS1 exhibit decreased sensitivity to 
echinocandins.
144,145
 To determine whether occidiofungin’s mode of action is similar to 
that of echinocandins, we compared the sensitivity of a S. cerevisiae Δfks1 mutant to the 
wild type strain. MIC values were similar (Table 4.2), suggesting that the mechanism of 
action of occidiofungin differs from that of echinocandins.   
Lipoformulation of ergosterol has been used in media as a competitive inhibitor 
of amphotericin B.
171
 We made 1,2-dioleoylphosphatidylcholine (DOPC) vesicles 
containing 20% ergosterol and added them to microtiter wells yielding a final 
concentration of ~80 μg/mL of ergosterol. As controls we also used DOPC vesicles with 
no ergosterol and vesicle free media. In these experiments we observed a 16-fold 
decrease in activity of amphotericin B against C. glabrata in the presence of DOPC 
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vesicles containing 20% ergosterol and a 2-fold decrease in activity in the presence of 
DOPC vesicles with no ergosterol (Table 4.1). There was no change in the sensitivity of 
C. glabrata treated with occidiofungin in the presence of DOPC vesicles containing 20% 
ergosterol or DOPC vesicles with no ergosterol as compared to the vesicle free control. 
These data suggest that binding of ergosterol is not an important component to the 
activity of occidiofungin.  
4.4.2 Morphological changes following subinhibitory dosing of occidiofungin  
Cell density of C. albicans cells exposed to a sublethal concentration of 
occidiofungin (0.25 µg/mL) was notably lower than that of untreated cells. To determine 
whether occidiofungin inhibited cell cycle progression, bud morphology of 
occidiofungin treated and untreated cell populations were scored. In budding yeast there 
is a correlation between cell growth and division such that cell cycle progression can be 
determined visually by simply measuring the bud size. We found that even at 
concentrations of occidiofungin shown to decrease cell viability; there was no difference 
in cell cycle distribution between the two groups (Table 4.3).    
SEM and TEM were used to determine whether occidiofungin caused aberrant 
morphological features in Candida cells treated with a subinhibitory concentration of 
occidiofungin.  Comparison of untreated cells and cells grown in subinhibitory 
concentrations of occidiofungin did not reveal any morphological differences by SEM 
(Figure 4.4). However, TEM showed a number of mild cell morphological defects in the 
cells grown in the presence of subinhibitory concentrations of occidiofungin. The most 
dramatic defect was with the organization of the coat (manno) proteins (Figure 4.5). The 
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coat proteins appear to be reduced (Figure 4.5B, demarcated by black arrows) compared 
to untreated samples. TEM results also showed the presence of intracellular inclusions 
(Figure 4.5B, demarcated by white arrow). Cell wall thickness was the same for treated 
and untreated sample supporting our Fks1 results, and suggesting that inhibition of cell 
wall synthesis is not involved in the mechanism of action of occidiofungin against yeast 
cells. Prior TEM microscopy studies with the non-yeast fungus Geotrichum candidum 
showed loss of cell wall thickness and the accumulation of intracellular inclusions.
64
 The 
accumulation of intracellular inclusions appears to be the common factor between these 
two groups of fungi.  In addition, microscopy studies using concanavalin A-FITC 
fluorescence against yeast cells showed no major disruption in -1,3-glucan distribution 
(Figure 4.6).  However, microscopy studies using calcofluor white, which binds to 
chitin, did reveal some other interesting morphological differences. Calcofluor staining 
of C. glabrata showed an enhanced distribution of chitin in daughter cells following 
exposure to a subinhibitory concentration of occidiofungin. Enhanced chitin localization 
was observed primarily at the emerging bud tips (Figure 4.7).  
4.4.3 Cell death experiments  
Microscopy studies were carried out on S. cerevisiae using FUN-1 dye as a cell 
viability indicator. The MIC for S. cerevisiae in these experiments was determined to be 
1 µg/mL. FUN-1 is a membrane permeable dye with red and green emission properties. 
The dye accumulates within the cytosol of cells (live or dead) with an intact plasma 
membrane to generate a green fluorescence. In metabolically active yeast, FUN-1 is 
transported from the cytosol into a vacuole where it forms cylindrical intravacuolar 
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structures (CIVS) that fluoresce red.
172
 The viability assay indicated that the untreated 
cells possessed well defined vacuoles and the presence of CIVS. However, cells exposed 
to 2 µg/ml of occidiofungin for 30 minutes did not possess these cylindrical structures 
and appeared to have lost volume (Figure 4.8). This reduction in cell size is not typical 
of a cell wall active antifungal which would be expected to result in swelling or lysis of 
the cell. These results suggest that occidiofungin does not function through a lytic 
pathway in S. cerevisiae and these results indicate the need for additional studies in non-
lytic pathways of cell death.  
Microscopy assays were carried out to determine whether occidiofungin-induced 
cell death through an apoptotic or autophagic pathway. TUNEL and ROS assays were 
performed to determine whether occidiofungin induced an increase in ROS and double 
stranded DNA breaks. In the TUNEL and ROS assays, C. albicans and S. cerevisiae 
cells were treated for 3 hours at 30 °C.  Both assays were performed with 5mM H2O2 as 
positive control and a solvent blank as a negative control. In the TUNEL assay, an 
increase in fluorescence was observed for cells exposed to H2O2 but not for cells treated 
with the solvent blank (Figure 4.9A and Figure 4.10A). For occidiofungin treated cells, 
fluorescence of increasing intensity was observed with increasing concentration of 
occidiofungin. ROS was detected using DHR123 which is oxidized to rhodamine 123 in 
the presence of ROS to generate a red fluorescent signal. This experiment showed results 
similar to the TUNEL assay; fluorescence increased with increasing concentrations of 
occidiofungin (Figure 4.9B and Figure 4.10B). To determine the importance of ROS 
accumulation to occidiofungin mediated cell death, MIC measurements were carried out 
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anaerobically, conditions known to reduce ROS production.
173
 A reduction in sensitivity 
to occidiofungin was observed when wild type S. cerevisiae BY4741 and S. cerevisiae 
BY4741 rho
0
 were grown under anaerobic conditions (Table 4.2).   
We noticed a large population of S. cerevisiae cells, when exposed to 
occidiofungin at 1 µg/mL, showed the presence of “dancing bodies” in the vacuole. 
These are presumably polyphosphate granules and have been shown to form prior to 
apoptotic cell death.
174
 Dancing bodies are indicated by an arrow in the DIC image of 
cells processed for ROS detection (Figure 4.10B).  As further evidence for activation of 
apoptosis, an increased binding of Annexin-V-Fluos to externalized phosphatidylserine 
was detected with increasing concentrations of occidiofungin without membrane 
disruption as would be observed with propidium iodide staining (Figure 4.11 and Figure 
4.12).  
MIC measurements of S. cerevisiae deletion mutants in the apoptotic and 
autophagic pathway were done to determine whether mutants defective in these 
pathways were resistant to occidiofungin (Table 4.2). Thirteen mutants involved directly 
or indirectly with the apoptotic pathway and seventeen autophagy mutants were 
evaluated. Among the apoptotic mutants, Δnde1, which is a mutant of the gene encoding 
the cytosolic NADH for the mitochondrial respiratory chain, was two-fold more 
sensitive compared to wild-type. Deletion of yca1, which is the gene responsible for 
synthesis of a cysteine protease similar to caspase, was two-fold more resistant 
compared to wild type. Sensitivity of S. cerevisiae expressing plasmid-borne human 
Bcl2 was tested and there was no difference in the MICs for the plasmid-borne human 
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Bcl2 and empty vector, thus, Bcl2 did not have a protective role in preventing cell death. 
This inability to rescue occidiofungin mediated cell death was not due to lack of Bcl2 
protein expression (Figure 4.13). All of the autophagy mutants tested (Δizh2, Δizh3, 
Δstm1, Δmre11, Δapg12, Δapg5, Δaut7, Δapg7, Δapg10, Δapg3, Δvtc1, Δvtc2, Δvtc3, 
Δvtc4, Δmms22, Δatg14, and Δvps30) had the same sensitivity profile as the wild type 
strain suggesting that autophagic cell death was not a central mechanism of 
occidiofungin action. Cell viability was tested for all the mutants by determining the 
colony forming units following a 48-hour incubation at the minimum inhibitory 
concentration. Deletion mutants (nde1, yca1, rny1, rpd3, nma1, vtc2, vtc3, csg2, apg7, 
nuc1, hos3, and aif1) that showed at least a ten-fold higher or lower viability than wild-
type after a 48 hour exposure to the MIC of occidiofungin were further analyzed by a 
drop assay (Figure 4.14). Deletion mutants nde1 and yca1, were used as a control for an 
increase or decrease in sensitivity in this assay, respectively. Deletion mutants (rpd3, 
nma1,  apg7, nuc1, hos3, and aif1) that showed a difference in viability from wild-type, 
showed no difference in sensitivity in the drop assay. Deletion mutants (rny1, csg2, vtc2, 
vtc3) demonstrated resistance to occidiofungin. Gene rny1 codes for a vacuolar RNase 
that promotes apoptosis under oxidative stress conditions.
175,176
 Gene csg2 codes for 
calcium regulatory protein that is involved in sphingolipid metabolism.
177
 Genes vtc2 
and vtc3 code for vacuolar transport chaperone proteins that are involved in 
polyphosphate accumulation and autophagic and non-autophagic vacuolar fusion.
178,179
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4.5 Discussion 
  The experimental findings from this study show that: 1) the mechanism of action 
for occidiofungin differs from current antifungal agents used in the clinic, 2) there are 
morphological changes in yeast cells exposed to sub-lethal concentrations of 
occidiofungin, 3) microscopy studies demonstrate that occidiofungin is rapidly 
fungicidal against yeast, and 4) there is a dramatic increase in ROS, double stranded 
DNA breakage, and externalization of phosphatidylserine, all documented indicators of 
apoptosis. 
The yeast cell wall is composed of chitin, -1,3-glucan, -1,6-glucan, and 
mannoproteins, the organization of which is critical for cell survival under altering 
environmental conditions.  Disruption of cell wall composition is sensed by an 
intracellular signaling pathway mediated by a cascade of MAP kinases. Activation of 
this pathway leads to the upregulation of genes whose protein products are involved in 
cell wall synthesis including Chs3p, the catalytic subunit of chitin synthase III (CSIII).  
Phosphorylation of both Mkc1p and Cek1p within a short period of time after 
occidiofungin addition is indicative of cell wall damage.
166,167,180
 Further evidence for 
the activation of the cell wall integrity pathway comes from the microscopy studies of 
chitin staining using calcofluor white.  Calcofluor staining of C. glabrata showed an 
enhanced distribution of chitin in daughter cells following exposure to a subinhibitory 
concentration of occidiofungin (Figure 4.7).  Localization of chitin deposits is strictly 
cell cycle dependent.  Fks1p localizes at the site of active cell wall growth and no cell 
wall material is deposited in the mother cell during bud growth.
181
 Chs3p is primarily 
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responsible for the production of the chitin found in the septal ring and the majority of 
the cell wall.  The increased chitin deposition at the site of bud growth should be the 
result in an upregulation of chitin synthase activity and this increase is known to occur in 
response to mutations resulting in cell wall weakening mutations
182
 or hypo-osmotic 
stress.
183
 Activation of the cell wall integrity pathway is not unique to occidiofungin as 
the echinocandin, capsofungin, has also been shown to induce both CHS expression and 
Mkc1p phosphorylation.
184,185
 
These results suggest that occidiofungin does perturb the membrane integrity of 
yeast; however activity assays using the osmotic stabilizer sorbitol or the Fks1 mutant 
resulted in no change in sensitivity compared to controls. Presumably, activation of the 
cell wall stress pathway compensates for the effect of occidiofungin at the 
concentrations resulting in cell death in our study. Upregulation of Hog1p, which is an 
osmotic disruption indicator, was significantly lower than that seen for conditions known 
to induce the osmotic stress response pathway (e.g. 1M NaCl).  This may be attributed to 
a rapidly cidal function induced by apoptosis compared to osmotic stress induced by 
exposure.  Activation of both the Mkc1p and Hog1p MAPK pathways have been 
detected in cells treated with the cell wall disruption agent zymolyase and the oxidative 
stress inducer hydrogen peroxide suggesting that a level of coordinated regulation exists 
between these two signaling pathways.
186,187
 
There were no differences in activity of occidiofungin in the ergosterol 
competition assay or the Fks1 deletion mutant, which are known to confer resistance to 
polyenes (amphotericin B) and echinocandins (caspofungin), respectively. Based on the 
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results of the microscopy assays and the MIC values of the selected mutants, it can be 
concluded that occidiofungin triggers an apoptotic pathway in the fungal cell. The 
apoptotic mechanism reported for amphotericin B resulted in an accumulation of cells at 
the G2/M phase of the cell cycle.
159
 However, the apoptotic mechanism for 
occidiofungin resulted in no differences in cell cycle distribution, supporting distinct 
differences in the apoptotic mechanism of action for occidiofungin compared to 
amphotericin B. The antifungal protein osmotin also induces an apoptotic mechanism of 
cell death in yeast and does not arrest cell cycle progression.
188
 Studies have shown that 
both apoptotic and autophagic pathways can be induced simultaneously,
189,190
 supporting 
a common upstream signal in their respective pathways. VPS30 is essential for the 
transport of cytoplasmic material, such as large proteins and organelle material, to the 
lysosome under starvation conditions. Autophagy is known to be absent in null vsp30 
mutants.
191
 Since there was no decrease in sensitivity to occidiofungin in the S. 
cerevisiae Δvsp30 mutant, the non-lytic autophagy pathway is not likely a major 
component in the killing mechanism of occidiofungin. The fact that most mutants 
deleted for components of the autophagic pathway, except for vtc2 and vtc3, did not 
confer any increase or decrease in sensitivity to occidiofungin suggests that autophagy is 
not a key pathway activated by occidiofungin and that the apoptotic pathway triggered 
by occidiofungin is distinctly separate from the autophagy pathway. It is likely that the 
non-autophagic vacuolar fusion activity of vtc2 and vtc3 is involved in the observed 
resistance of these mutants in the drop assay.   
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We propose that induction of apoptosis is likely the causative mechanism of cell 
death for cells exposed to occidiofungin. Deletion of the caspase like enzyme, Yca1p, 
resulted in an increase in resistance to occidiofungin, while there was a decrease in 
resistance with the deletion of NADH dehydrogenase (Nde1). Yca1p caspase like 
activity is known to contribute to the degradation of proteins under oxidative conditions 
and this activity contributes to apoptotic cell death.
192
 Nde1p is known to provide 
cytosolic NADH to the mitochondrial respiratory chain and the decrease in respiratory 
chain activity should contribute to a reduction in the production of ROS that should 
contribute to resistance against occidiofungin. The MIC activity results for these mutants 
support an apoptotic mechanism of cell death. Confocal microscopy studies clearly 
reveal an increase in ROS and double stranded DNA breakage following a short 
exposure to occidiofungin. Together, the studies presented in the manuscript suggest that 
occidiofungin mediated cell death is primarily through apoptosis.   
4.6 Conclusion 
Studies aimed at understanding the apoptotic mechanism of cell death induced by 
occidiofungin are warranted. The specific target of occidiofungin is still unknown and 
the identification of the molecular target in yeast may provide an avenue for the 
development of antifungal agents that have reduced toxicity in mammalian cells. 
Occidiofungin is resistant to gastric proteases
115
 and may provide an alternative to 
azoles, which are the only orally available class of antifungals. An understanding of 
occidiofungin’s function may provide novel opportunities towards the development of 
other new antifungal compounds for the treatment of serious fungal disease. 
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Table 4.1: Bioactivity of Occidiofungin 
 
Isolate                                                                    
   
Experiment                    MIC/MLC*               
                                                           (µg/mL)          
 
Bioactivity Compared 
to Control 
Occidiofungin  
C. glabrata 66032 CLSI                                               0.5/N.D. - 
C. glabrata 66032 0.8 M sorbitol                                 0.5/N.D.                       No Change 
C. glabrata 66032 DOPC vesicles                                0.5/N.D.                       No Change 
C. glabrata 66032 DOPC vesicles:ergosterol               N.D./0.5                       No Change 
Amphotericin B  
C. glabrata 66032 CLSI                                               0.5/N.D. - 
C. glabrata 66032 DOPC vesicles                               1.0/N.D.              2-Fold Decrease 
C. glabrata 66032 DOPC vesicles:ergosterol              N.D./ > 8.0          >16-Fold Decrease 
* Only the MLC is reported, given the turbidity of the ergosterol DOPC suspension. 
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Table 4.2: Occidiofungin MICs 
 
Isolate                                            MIC (µg/ml) 
S. cerevisiae  BY4741 0.1250 
S. cerevisiae  BY4741 Rho
0
 0.1250* 
S. cerevisiae  BY4741 0.2500
¥
 
S. cerevisiae  BY4741 Rho
0
 0.2500*
¥
 
Membrane and Cell Wall Mutants 
S. cerevisiae Δsur1 0.1250 
S. cerevisiae Δipt1 0.1250 
S. cerevisiae Δcsg2 0.1250 
S. cerevisiae Δfks1p 0.1250       
Apoptotic Mutants 
S. cerevisiae Δyca1 0.2500 
S. cerevisiae Δnde1 0.0625* 
S. cerevisiae Δaif1 0.1250 
S. cerevisiae Δhos3 0.1250 
S. cerevisiae Δuth1 0.1250 
S. cerevisiae Δnma1 0.1250 
S. cerevisiae Δhda1 0.1250 
S. cerevisiae Δste20 0.1250 
S. cerevisiae Δrny1 0.1250 
S. cerevisiae Δrpd3 0.1250 
S. cerevisiae Δsir2 0.1250 
S. cerevisiae Δnuc1 0.1250 
S. cerevisiae Δybh3 0.1250 
Autophagy Mutants 
S. cerevisiae Δizh2 0.1250 
S. cerevisiae Δizh3 0.1250 
S. cerevisiae Δstm1 0.1250 
S. cerevisiae Δmre11 0.1250 
S. cerevisiae Δapg12 0.1250 
S. cerevisiae Δapg5 0.1250 
S. cerevisiae Δaut7 0.1250 
S. cerevisiae Δapg7 0.1250 
S. cerevisiae Δapg10 0.1250 
S. cerevisiae Δapg3 0.1250 
S. cerevisiae Δvtc1 0.1250 
S. cerevisiae Δvtc2 0.1250 
S. cerevisiae Δvtc3 0.1250 
S. cerevisiae Δvtc4 0.1250 
S. cerevisiae Δmms22 0.1250 
S. cerevisiaeΔatg14 0.1250 
S. cerevisiaeΔvps30 0.1250 
*MIC recorded at 48 hours  
¥
Cells were grown anaerobically 
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Figure 4.1:  RP-HPLC chromatogram of 50 µg of purified occidiofungin.  
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Figure 4.2:  Western blot detection of MAPK activation. Candida albicans cells were 
treated with increasing concentrations of occidiofungin (0-4 µg/mL) for 10 or 20 
minutes.  Cell extracts were analyzed by immunoblotting with antibodies against 
phospho-Mkc1p, total Mkc1p, and phospho-Hog1p. Detection of phosphoglycerate 
kinase (Pgk1p) was used to verify equal protein loading.  Cells grown in the presence of 
1M NaCl were used as a positive control for Hog1p activation.  The relative ratios of 
phosphorylated Mkc1p to total Mkc1p are indicated for each set of immunoblots with 
the ratio of DMSO treated cells normalized to one. 
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Figure 4.3: Western blot detection of MAPK activation in Candida glabrata. Cells were 
treated with increasing concentrations of occidiofungin (0-4 µg/mL) for 20 minutes. Cell 
extracts were analyzed by immunoblotting with antibodies against phospho-Mkc1p, total 
Mkc1p, and phospho-Hog1p. Detection of phosphoglycerate kinase (Pgk1p) was used to 
verify equal protein loading. The relative ratios of phosphorylated Mkc1p to total Mkc1p 
are indicated with the ratio obtained for untreated cells set to one. 
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Figure 4.4: Scanning electron microscopy (SEM) images of Candida albicans: 
untreated (a) and occidiofungin treated (b) cells.  C. albicans cells were propagated at 
35˚C in RPMI until reaching an OD600 of 1.0.  Occidiofungin (2 µg/mL), or an 
equivalent volume of DMSO, was added and cells returned to 35˚C for 30 minutes.  
Cells were isolated by centrifugation and processed for SEM as described in Materials 
and Methods. 4000X magnification is shown. 
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Figure 4.5:   TEM Micrographs.  (A) Candida albicans cells treated with the solvent 
blank, DMSO. (B) Candida albicans cells grown in a sub-lethal concentration of 
occidiofungin.  The arrows revealed a loss of coat proteins on the surface of the cell wall 
as well as vesicle-like inclusions inside the cell. Side panels show an expanded region of 
cells having the morphological defect. 
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Figure 4.6: Cell wall mannoprotein distribution in Candida glabrata treated with 
occidiofungin remains unchanged.  C. glabrata cells were grown for 24hr in the absence 
(A) or presence (B) of a sublethal concentration of occidiofungin. 1,3-b-glucan was 
visualized with concanavalinA-FITC staining by fluorescence microscopy. A montage 
of cells is shown for each treatment. 
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Figure 4.7:  Chitin staining in Candida glabrata.  Chitin staining was visualized with 
calcofluor white staining in live cells by fluorescence microscopy using a 100X 
objective and a DAPI filter set.  (A) Chitin localization in cells treated with a sublethal 
concentration of occidiofungin.  (B) Chitin localization in untreated cells. A montage of 
cells is shown for each. 
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Figure 4.8:  FUN-1 Assay. DIC and fluorescence images of yeast cells stained with 
FUN-1. Panels “a-d” are untreated yeast cells. CIVS stained red with FUN-1(shown by 
arrows). Panels “e-h” are occidiofungin treated cells (2μg/ml). CIVS not present in cells. 
Panels “a” and “e" are DIC images. Panels “b” and “f” are the green emission, while “c” 
and “g” are the red emission channels. Panels “d” and “h” are overlays of “a-c” and “e-
g”, respectively. 
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Figure 4.9: Fluorescent Microscopy Studies on Candida albicans. (A) TUNEL Assay. 
Rows “1” and “2” are DIC and fluorescence images, respectively.  Column “a” shows 
cells treated with the solvent blank (DMSO with no occidiofungin), “b” shows cells 
treated with 5mM H2O2 and “c-e” correspond to cells treated with 1 μg/ml, 4 μg/ml and 
8 μg/ml of occidiofungin, respectively. (B) ROS Detection Assay.  Rows “1” and “2” are 
DIC and fluorescence images, respectively. Column “a” corresponds to treatment with 
solvent blank, “b” corresponds to cells treated with 5mM H2O2, and “c-e” show cells 
treated with 1μg/ml, 2 μg/ml and 4 μg/ml of occidiofungin, respectively. 
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Figure 4.10: Fluorescent Microscopy Studies on S. cerevisiae. (A) TUNEL Assay. 
Rows “1” and “2” are DIC and fluorescence images, respectively.  Column “a” shows 
cells treated with the solvent blank, “b” shows cells treated with 5mM H2O2 and “c-e” 
correspond to cells treated with 1 μg/ml, 4 μg/ml and 8 μg/ml of occidiofungin, 
respectively. (B) ROS Detection Assay.  Rows “1” and “2” are DIC and fluorescence 
images, respectively. Column “a” corresponds to treatment with solvent blank, “b” 
corresponds to cells treated with 5mM H2O2, and “c-e” show cells treated with 1μg/ml, 2 
μg/ml and 4 μg/ml of occidiofungin, respectively. 
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Figure 4.11:  Phosphatidylserine Detection Assay on Candida albicans.  Rows A-D are 
negative control (treatment with DMSO with no occidiofungin), positive control (5mM 
H2O2), cells treated with 1 μg/ml, 4 μg/ml of occidiofungin, respectively. Columns “a-d” 
correspond to DIC image, annexin fluorescence image, propidium iodide fluorescence 
image, and overlay of annexin and propidium iodide fluorescence images, respectively. 
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Figure 4.12:  Phosphatidylserine Detection Assay on S. cerevisiae.  Rows A-D are 
negative control (treatment with DMSO with no occidiofungin), positive control (5mM 
H2O2), cells treated with 1 μg/ml, 4 μg/ml of occidiofungin, respectively. Columns “a-d” 
correspond to DIC image, annexin fluorescence image, propidium iodide fluorescence 
image, and overlay of annexin and propidium iodide fluorescence images, respectively. 
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Figure 4.13: Western blot analysis. Constitutive expression of HA3 tagged Bcl2 protein 
was observed. Anti-HA antibodies were used to detect HA3 tagged Bcl2 protein and 
anti-3-phosphoglycerate kinase (Pgk1p) antibody was used as a loading control.  
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Figure 4.14: Drop assay.  Growth sensitivity of S. cerevisiae deletion mutants exposed 
to 0.5µg/mL occidiofungin for 4 hours was analyzed by spotting five-fold serially 
diluted cells to a YPD plate.  The growth profile for untreated (-) or occidiofungin 
treated (+) cells are shown after 72 hours at 30 ˚C. An untreated and treated wild-type 
strain was included on all plates to control for experimental variations. 
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5. IDENTIFICATION OF THE CELLULAR TARGET FOR THE NOVEL 
ANTIFUNGAL OCCIDIOFUNGIN 
 
5.1 Overview 
Since the 1950s, the antifungal compounds that have been developed for clinical 
use fall under three broad families: azoles, polyenes and echinocandins.
193,194
 These 
compounds target fungal cells by inhibiting ergosterol production, binding of ergosterol, 
or by disrupting cell wall biosynthesis.
195-197
 Widespread resistance to these mechanisms 
of action has been reported
19,28,29,198,199
 and this has created an urgent need to identify 
antifungal compounds that have new fungal cell targets.
48
 Here, we show that a novel 
antifungal named occidiofungin targets actin. An alkyne functionalized variant of 
occidiofungin (alkyne-OF) was synthesized enabling affinity purification and confocal 
microscopy studies. Affinity purification assays of yeast exposed to alkyne-OF showed a 
high proportion of actin and actin associated proteins. Furthermore, occidiofungin was 
shown to bind to rabbit muscle G-actin and F-actin. Localization studies and time course 
experiments indicated the binding of occidiofungin to bud tips in Saccharomyces 
cerevisiae and eventual internalization into the mature cell. Similar studies in 
Schizosaccharomyces pombe demonstrated localization of occidiofungin near the poles 
of the cells and along the division septum, which are well-documented regions for actin 
patches.
200
 These observations support the binding of occidiofungin to actin causing cell 
cycle arrest, starvation and death. 
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5.2 Background  
Occidiofungin is a cyclic glycolipopeptide produced by a soil bacterium called 
Burkholderia contaminans MS14 and has been reported to have a wide spectrum of 
activity against several fungal species.
64
 Preliminary toxicological analyses of 
occidiofungin using a murine model indicated that it was well tolerated at concentrations 
of 10 to 20 mg/kg.
67
 Blood chemistry analyses and histopathology performed on 
multiple organs showed a transient non-specific stress response with no damage to organ 
tissues.
67
 Taken together, the data suggest that occidiofungin is a promising candidate 
for development as a clinically useful antifungal agent. This study is directed towards 
identifying the molecular target of occidiofungin within the fungal cell to better 
understand how it causes fungal cell death. 
5.3 Materials and methods 
5.3.1 Spectrum of activity of occidiofungin 
Minimum inhibitory concentration (MIC) susceptibility testing was performed 
according to the CLSI M27-A3 and M38-A2 standards for the susceptibility testing of 
yeasts and filamentous fungi, respectively.
 
Incubation temperature was 35° C and the 
inoculum size was 0.5 – 2.5 x 103 colony-forming units (CFU)/mL and 0.4 - 5 x 104 
conidia/mL for yeasts and filamentous fungi, respectively. Inoculum concentration for 
dermatophytes was 1-3x10
3 
conidia/mL. RPMI was used throughout as the growth 
medium and Cryptococcus strains were tested in YNB. Occidiofungin MICs were 
recorded at 50% and 100% growth inhibition after 24 and 48 hours of incubation, with 
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the exception of dermatophytes which were incubated for 96 hours. Fluconazole MICs 
against Candida strains were recorded at 50% inhibition after 24 hours and against 
Cryptococcus strains after 72 hours. Voriconazole MICs were recorded at 100% 
inhibition after 24 hours for zygomycetes and after 48 hours for Fusarium and 
Aspergillus strains. Voriconazole MICs were recorded at 80% inhibition after 96 hours 
of incubation for dermatophytes.  
5.3.2 Derivatization of occidiofungin 
Occidiofungin was purified from a liquid culture of Burkholderia contaminans 
MS14 as previously described.
84
 Pure occidiofungin was aliquoted into 100 μg fractions 
and stored dry at 4°C until use. Addition of an alkyne reactive group to the primary 
amine on occidiofungin was performed initially at the Texas A&M Natural Products 
LINCHPIN Laboratory at Texas A&M University and subsequently at the CPRIT 
Synthesis and Drug-Lead Discovery Laboratory at Baylor University. The reaction is 
depicted in Supplementary Figure 1a and the synthetic procedure employed is described 
below along with 
1
H and 
13
C NMR line listing.   Spectral data (
1
H and 
13
C NMR , X 
MHz and Y MHz, respectively) are depicted in Figure 1b. The derivatized occidiofungin 
was purified by Reversed-Phase High Performance Liquid Chromatography (RP-HPLC) 
using a 4.6- by 250-mm C18 column (Grace-Vydac; catalog no. 201TP54) on a Bio-Rad 
BioLogic F10 Duo Flow with Quad Tec UV-Vis detector system. The solvents used 
were 99.9% water (with 0.1% trifluoroacetic acid) and 99.9% acetonitrile (with 0.1% 
TFA). Alkyne occidiofungin (Alkyne-OF) eluted at 48% water and was collected 
separately and dried down. Matrix-assisted laser desorption/ionization–time of flight 
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mass spectrometry (MALDI-TOF MS; Shimadzu/Kratos) was used to confirm mass of 
the isolated peak. The fraction collected from the HPLC was evaporated to dryness and 
was dissolved in 100 μL of 35% acetonitrile containing 0.1% TFA. From these 
resuspended fractions, 0.5 μL was mixed with 0.5 μL of α-cyano-4-hydroxycinnamic 
acid matrix (6 mg/mL in 50% acetonitrile containing 0.1% TFA) and dried on the target 
plate. 
5.3.3 Confirmation of activity of alkyne-OF 
The activity of the purified alkyne-OF was compared to the native compound 
using the CLSI M27-A3 method of determination of the minimum inhibitory 
concentration (MIC) against yeast such as Saccharomyces cerevisiae BY4741 and 
Schizosaccharomyces pombe 972h (wild type), which was obtained from Dr. Susan 
Forsburg (Department of Biological Sciences, University of Southern California). 
Additionally, activity of the alkyne derivatized occidiofungin was also checked against a 
higher density (OD600=0.6 to 0.8) of cells of both the afore-mentioned types of yeast. In 
order to confirm that the alkyne-OF triggered the same response in yeast as native 
occidiofungin, the apoptosis assays such as the TUNEL assay (APO™-BrdU TUNEL 
Assay Kit, LifeTechnologies), phosphatidylserine externalization assay (Annexin-V-
Fluos staining kit, Roche) and ROS detection assay (Dihydrorhodamine 123, Sigma) 
were repeated as previously described
(16)
. 
5.3.4 Affinity purification of proteins with alkyne-OF 
An overnight culture of S. pombe was grown to OD600 of 0.6 to 0.8. 1 mL of cells 
was incubated with 8 μg/mL of alkyne-OF for 30 minutes at 30°C. The cells were spun 
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down and washed in PBS. The cells were then sonicated with a probe tip sonicator for 30 
seconds and placed on ice for 30 seconds alternatingly to avoid overheating. The sample 
was then spun down at 16000x g for 10 minutes and the supernatant was removed. The 
Click-it protein reaction kit (Life Technologies) was used and the alkyne-OF was reacted 
with azide-biotin, as per the instructions on the kit. The reaction was allowed to proceed 
for 90 minutes at 37°C while shaking. The reacted mixture was passed through a 10 kDa 
cutoff filter and the proteins retained at the top of the filter were solubilized in 100 μL of 
100 mM Tris HCl (pH=7.5). Streptavidin agarose beads (ThermoFisher Scientific) 
obtained from a 100 μL of a 50% slurry were added and the mixture was incubated at 
37°C for 90 minutes. The beads were washed with 10 mL of 100 mM Tris HCl (pH=7.5) 
and the proteins extracted by boiling in 50 µl of 1X SDS sample loading buffer for 15 
minutes. This sample was run on a 12% SDS gel until the band runs just out of the 
stacking phase to create a single band. The band was then cut out and used for analysis. 
Trypsin digestion on the band was done in the Protein Chemistry Laboratory (Texas 
A&M University) and subsequent LC-MS/MS analysis was performed by the Mass 
Spectrometry Laboratory at the University of Texas Health Science Center (San 
Antonio). The results were analyzed using the Scaffold software. Cells treated with 
DMSO and native occidiofungin were used as controls. An additional sample using cells 
that were lysed prior to alkyne-OF treatment was used for comparison.  
5.3.5 Localization of alkyne-OF over a time course of exposure 
An overnight culture (S. pombe or S. cerevisiae) was grown using colonies from 
a freshly streaked plate to an OD600 of 0.6 to 0.8. 1 mL of cells was incubated with MIC 
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quantities of alkyne-OF for 60 minutes at 30°C while removing 200 μL of the cell 
suspension at 10 minutes, 30 minutes and 60 minutes post incubation. The cells were 
spun down, washed in phosphate buffered saline (PBS) and fixed for 15 minutes in 3.7% 
formaldehyde (in PBS) at room temperature. Permeabilization of cells was done using 
0.5% Triton-X (in PBS) at room temperature for 20 minutes. The cells were then washed 
twice using 1 mL of PBS per wash. Click reaction with azide derivatized Alexa-488 was 
done according to the manufacturer’s protocol (Click-iT EdU Imaging kit, ThermoFisher 
Scientific).  The cells were washed with PBS and added to the microscope slide for 
visualization. A competition assay was carried out by pre-treating cells with an MIC 
amount (0.5 μg/mL) of the native occidiofungin followed by treatment with alkyne-OF. 
Cells were observed using Olympus FV1000 confocal microscope with a 100x/1.4 oil 
immersion objective and 40x/0.9 dry objective.  
5.3.6 Estimation of endocytosis following occidiofungin treatment 
Three 1 mL aliquots of S. pombe, at a density of OD600 0.6 to 0.8, were treated 
with 1 μL DMSO, 0.5 μg/mL (0.5x MIC) or 1 μg/mL (1x MIC) of native occidiofungin 
for 30 minutes at 30°C. Cells were isolated by centrifugation at 21000x g for 2 minutes, 
washed thrice with PBS and resuspended in YPD containing 8 mM FM-464 
(ThermoFisher Scientific). The cells were incubated in the presence of the dye for 60 
minutes at 30°C, followed by two washes with PBS and then added to a microscope 
slide for visualization. Images were obtained using an Olympus FV1000 confocal 
microscope with a 40x/0.9 dry objective. 
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5.3.7 Affinity purification of actin 
Purified rabbit skeletal muscle filamentous actin (Catalog no.: AKF99) and G-
actin (Catalog no.: AKL95) was purchased from Cytoskeleton Inc. According to the 
supplier’s instructions, the protein was reconstituted in Milli-Q water to achieve a stock 
concentration of 0.4 mg/mL. This resulted in the filaments being stored in a buffer that 
consisted of 5 mM Tris-HCl (pH 8.0), 0.2 mM CaCl2, 0.2 mM ATP, 2 mM MgCl2 and 
5% (w/v) sucrose. The solution was aliquoted into 50 μL quantities and stored at -80°C 
until use. Immediately before use, each aliquot was thawed by placing the tube in a 37°C 
water bath for 5 minutes followed by room temperature. 24 μg of F- or G-actin was then 
reacted with 8 μg alkyne-OF. Click chemistry was performed on this mixture to react the 
alkyne-OF with azide-biotin for 90 minutes as described (Click-iT protein reaction 
buffer kit, ThermoFisher Scientific).  Unreacted reagents were removed by passing the 
mixture through a 10 kDa cutoff filter with 20 minutes of centrifugation at 15000x g. 
Proteins retained in the filter chamber were solubilized in 200 μL of 100 mM Tris-HCl 
(pH=7.5) and reacted with streptavidin beads as described above. The beads were 
washed multiple times using 100 mM Tris HCl (pH=7.5) and bound proteins eluted by 
boiling in 50 µL of SDS sample loading buffer. The sample was electrophoresed through 
a 12% SDS gel and protein bands were visualized by silver staining according to the 
manufacturer’s protocol (Pierce Silver stain kit, ThermoFisher Scientific). F- and G-
Actin treated with DMSO and native occidiofungin were used as controls.  
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5.3.8 Actin polymerization and depolymerization assays 
The effect of unmodified occidiofungin on actin polymerization and 
depolymerization was measured using the Actin Polymerization Biochem Kit 
(fluorescence format): rabbit skeletal muscle actin purchased from Cytoskeleton Inc. 
(Catalog no.: BK003). Occidiofungin was brought up in 1.5% β-cyclodextrin in PBS 
(pH=7.5) at a concentration of 1 µg/µL. 20 µL of this solution was used per well as 
described in the instructions. The same buffer without occidiofungin was used for the 
test buffer controls. G-buffer was made by adding 2 μL of 100 mM ATP stock for every 
1 mL of General Actin buffer prior to the start of the experiment as instructed. G-actin 
and F-actin stock were prepared as described in the kit to achieve stock concentrations of 
0.4 mg/mL and 1 mg/mL respectively. The polymerization and depolymerization assays 
were then carried out as per the manufacturer’s instructions. 
5.3.9 Microscopic analysis of actin treated with occidiofungin 
Purified rabbit skeletal muscle filamentous actin (Catalog no.: AKF99, 
Cytoskeleton Inc.) was treated with alkyne-OF (24 μg of F-actin to 8 μg of alkyne-OF) 
as described above. The mixture was reacted with azide functionalized Alexa Fluor 488 
according to the manufacturer’s instructions (Click-iT EdU Imaging kit, ThermoFisher 
Scientific). Unbound dye was removed by overnight dialysis at 4°C against actin 
polymerization buffer using a 1 kDa cutoff membrane (Catalog no.: BSA02, 
Cytoskeleton Inc.). The actin filaments were removed, added to a slide and analyzed 
using an Olympus FV1000 confocal microscope 40×/0.90 dry objective and a 100x/1.4 
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oil immersion objective. A control was done using 140 nM Acti-stain 670 phalloidin 
(Cytoskeleton Inc.) staining of actin filaments as per instructions provided. 
F-actin filaments were also reacted with different concentrations of the native 
occidiofungin. Approximately, molar ratios of 1:10 (24 μg actin:8 μg native 
occidiofungin) and 1:5 (24 μg actin:4 μg native occidiofungin) were tested. The 
filaments were reacted with occidiofungin for 15 minutes at room temperature. The 
respective mixtures were then stained with 140 nM Acti-stain 670 phalloidin for another 
15 minutes at room temperature. The stained filaments were then added to a glass slide 
and observed on an Olympus FV1000 confocal microscope using a 100x/1.4 oil 
immersion objective. Untreated actin filaments were stained and observed as the control. 
5.4 Results and discussion 
We have previously demonstrated that the mechanism of action of occidiofungin 
differs from the primary mode of action of the three common classes of antifungals.
66
 
Occidiofungin has been observed to rapidly induce apoptosis in yeast cells at the 
minimal inhibitory concentrations.
66
 In addition, occidiofungin was seen to have sub-
micromolar activity against Pythium species which lacks ergosterol in the membrane and 
Cryptococcus neoformans which is resistant to echinocandins.
64
 Several studies have 
reported occurrence of widespread resistance to these mechanisms of action, especially 
in the case of the azoles
19,28,29
 and the echinocandins.
198,199
 Due to its unique mechanism 
of action, occidiofungin has sub-micromolar activity against azole and echinocandin 
resistant strains of fungi. For example, several species of Candida that were resistant to 
fluconazole at high concentrations (32-64 μg/mL) were inhibited at 1-8 μg/mL of 
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occidiofungin. Furthermore, strains of Candida parapsilosis and C. neoformans that 
were resistant to treatment with caspofungin were found to be susceptible to treatment 
with occidiofungin. Occidiofungin was also found to have a broader spectrum of activity 
than clinically available antifungals and was found to be active against Aspergillus, 
Mucor, Fusarium and Rhizopus species. The results, as reported in Table 5.1, indicate 
that occidiofungin has activity against filamentous and non-filamentous fungi at sub-
micromolar concentrations.  
Occidiofungin was chemically modified to have a functional alkyne for Click 
chemistry (Sharpless-Hüisgen cycloaddition) on the free amino group of the 
diaminobutyric acid residue at position 5 (Figure 5.1). The modified occidiofungin, 
alkyne-OF, had an eight-fold reduction in activity with the minimum inhibitory 
concentration of 1 and 0.5 µg/mL against Saccharomyces cerevisiae BY4741 and 
Schizosaccharomyces pombe 972 h-, respectively (Table 5.2). To determine whether 
alkyne-OF still had the same apoptosis inducing bioactivity as the native occidiofungin, 
S. cerevisiae was treated with alkyne-OF and apoptotic assays such as TUNEL, reactive 
oxygen species (ROS) detection and phosphatidylserine externalization assays were 
performed. Double stranded DNA breaks, the generation of ROS, and the externalization 
of phosphatidylserine were observed in the alkyne-OF treated cells, supporting the same 
mechanism of action (Figure 5.2A, 5.2B, 5.2C). Although this alkyne modification 
moderately reduced the inhibitory activity of the compound, the functionalized 
derivative has the same apoptotic bioactivity and was therefore used to identify the 
fungal target. 
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Alkyne-OF was used in a pull-down assay to identify intracellular proteins that 
directly or indirectly interact with the compound (Figure 5.3A). Data from multiple 
analyses using S. pombe 972h- and S. cerevisiae BY4741 were pooled. The resulting list 
of proteins obtained following LC-MS/MS analysis of bands cut from gels was distilled 
as follows. The proteins that were observed in the control samples (i.e. treatment with 
DMSO and native occidiofungin) were removed from consideration resulting in proteins 
that were exclusively found in the test sample (Table 5.3). The culled protein list was 
grouped based on gene ontology including cellular localization or molecular function. 
The resulting distribution is presented in Figure 5.3B. From this analysis, the majority of 
the proteins that were pulled down by alkyne-OF are actin or actin associated proteins, 
e.g. Pil1 and Cap1. In addition to the actin-related proteins, proteins involved in vesicle 
transport and mannosylation were found associated with alkyne-OF. The remaining 
proteins that were pulled down were ribosomal and mitochondrial related proteins. The 
data indicate that occidiofungin may play a role in binding to actin since a majority of 
the proteins either directly interacted with actin (such as Arp2/3 complex and myosin) or 
are in close proximity to actin patches within the cell.  
Pull-down assay and confocal microscopy were used to confirm occidiofungin 
interaction with actin. Biotinylation of alkyne-OF following incubation with F- or G-
actin and streptavidin agarose beads was performed to determine whether occidiofungin 
directly associated with purified actin in vitro. F- or G-actin incubated with the wild type 
occidiofungin and DMSO was used as a control for potential non-specific interaction of 
actin with the agarose beads. As shown in Figure 5.4a, the biotinylation of alkyne-OF 
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was required for the binding of F- or G- actin to the streptavidin beads (Lane 5 and 8). 
Actin was not present in the control lanes (lanes 6,7,9 and 10). The eluant from the 
biotinylated alkyne-OF had a single band at approximately 42 kDa which is the expected 
size for actin. Therefore, the affinity purification assays done with F- or G-actin 
confirmed that occidiofungin binds to actin. To further support this observation, confocal 
microscopy using the fluorophore Acti-stain 670 phalloidin was used to visualize F-actin 
exposed to occidiofungin or alkyne-OF. F-actin exposure to increasing concentrations of 
occidiofungin leads to more aggregation of actin filaments (Figure 5.4b).  Using alkyne-
OF labeled with azide functionalized Alexa Fluor 488 dye, occidiofungin interaction 
with F-actin is directly observed (Figure 5.5).  In this experiment, F-actin also appears to 
aggregate following exposure to occidiofungin. Fluorescence visualization of this 
interaction following treatment with alkyne-OF and native occidiofungin demonstrated a 
high degree of aggregation of the filaments which could not be seen in the untreated 
controls. These results indicate that occidiofungin directly interacts with actin leading to 
the formation of aggregated filaments. However, occidiofungin association with actin 
was found to have no effect on its in vitro polymerization or depolymerization properties 
(Figure 5.6). 
In vivo visualization of the localization of occidiofungin was done in intact yeast 
cells. Cellular localization of F-actin is well characterized in S. pombe and S. cerevisiae. 
Time course analysis of S. pombe following alkyne-OF treatment and derivatization with 
azide Alexa-488 showed a specific pattern of localization of the compound (Figure 
5.7a). Alkyne-OF was seen to have a faint pattern of staining at the polar tips at 10 
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minutes post treatment, which subsequently increased in intensity at 30 minutes post 
treatment. Strong fluorescence was observed at the polar ends of the cell and at the 
septum of dividing cells. A similar assay done using S. cerevisiae showed localization of 
alkyne-OF at the bud tips at the early time points and staining throughout the parent cell 
at later time points (Figure 5.7b). The unique pattern formed was observed to be a 
combination of striated and inclusion-like structures. In both yeast systems, when the 
cells were pre-treated with the native occidiofungin prior to treatment with alkyne-OF, 
the observed cellular localization patterns disappeared (Figure 5.7a & b, panels D, E, and 
F). This indicates that alkyne-OF and occidiofungin compete for the same target. The 
vesicular pattern observed at the later time points of exposure is indicative of endocytic 
vesicles that are coated with actin being circulated through the cell.
201
 Additionally, actin 
patches in the cells of S. pombe were seen at the cell tips in growing cells and at the 
division septum in dividing cells. Actin patches recruited to the division septum interact 
with myosin to form the acto-myosin ring which is instrumental in cell division.
202
 The 
time course analysis in both types of fungal cells indicates localization of occidiofungin 
to the regions with high concentration of actin. Recent studies have shown that the 
dynamic nature of actin is necessary to maintain the cellular functions in which actin is 
involved.
203
 The effect of native occidiofungin on endocytosis in fission yeast was 
evaluated by staining cells with FM-464 following treatment (Figure 5.8). Cells exposed 
to 0.5X MIC and 1X MIC demonstrated a concentration dependent reduction in stained 
endocytic vesicles.  A newly formed bud has several actin patches which co-ordinate the 
retrograde transport of vesicles along the actin cable into the mother cell. Actin 
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nucleation is carried out by the Arp2/3 complex and a host of proteins including Cap1, 
Abp1 and Sac6 which are involved in the actin patch based transport of vesicles.
200
 
Fluorescence time course assays done on the cells of S. cerevisiae and S. pombe support 
this hypothesis. The early time points in S. cerevisiae cells show localization to bud tips 
with the compound eventually forming a vesicular pattern within the parent cell. Bud 
tips in S. cerevisiae are known to be rich in actin patches which are necessary to carry 
out cellular functions such as cell division and endocytosis.
204
 Disruption of the 
dynamics of actin turnover has been reported to trigger apoptosis in yeast and 
mammalian cells. Specifically, clustering of actin filaments has been reported to trigger 
mitochondrial damage which in turn leads to release of reactive oxygen species.
205
 In 
addition, caspase dependent pathways have been theorized to be induced following 
aggregation of actin filaments in animal cells and it is possible that a similar pathway 
takes place involving Yca1, the caspase found in yeast.
206
   
5.5 Conclusion 
One of the challenges facing the development of antifungals is the fact that 
uptake of compounds into yeast cells does not occur as easily as it does in bacteria. 
Yeast cells have a sturdy cell wall made of several glycoproteins that make up almost 
one-third of the dry weight of the cell. The efficiency of antifungals relies heavily upon 
being able to penetrate the cell envelope. Occidiofungin has the advantage of being 
easily taken up by the yeast cell, as evidenced by the low MICs against several different 
types of fungi. Susceptibility to occidiofungin can be seen in pathogenic strains that are 
resistant to treatment with azoles and echinocandins (Table 5.1). Although it is now 
 123 
 
observed that occidiofungin binds to F- and G-actin and causes aggregation of the F-
actin filaments leading to apoptosis, the exact chain of events needs to be determined. 
Future studies aimed at understanding how occidiofungin enters the fungal cell and how 
this leads to the induction of apoptosis needs to be determined. Nevertheless, an actin-
targeting antifungal that has a wide spectrum of activity against clinically pathogenic 
fungi and minimal toxicity in animal models could be the novel drug that is needed in 
the current antifungal arsenal to combat fungal infections. 
In these sections we reported that occidiofungin rapidly induces apoptosis in 
fungal cells by binding to actin filaments and setting off an as yet unknown pathway of 
events that culminate in the apoptotic death of the cell. Knowing the target of 
occidiofungin is vital to the development of the compound as a clinically viable drug. In 
the following section, we will discuss additional findings that are vital to our 
understanding of how occidiofungin behaves in an animal system.   
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Table 5.1: Activity of occidiofungin against filamentous and non-filamentous fungi 
 
 
 
 
Species 
 
Occidiofungin (μg/mL) 
 
Voricona
zole 
 
Flucona
zole 
24 hours 48 hours 72 hours 96 hours MIC 
(μg/mL) 
MIC 
(μg/mL) 
50
% 
100
% 
50
% 
100
% 
50
% 
100
% 
80
% 
100
% 
  
*Trichophy
ton 
mentagrop
hytes 
10207 
      1 2 0.25 >16 
Trichophyt
on 
mentagrop
hytes 
28556 
      1 2 0.06 >16 
Trichophyt
on 
mentagrop
hytes 
28641 
      1 2 0.06 16 
&
Trichophy
ton rubrum 
11199 
      1 2 0.008 0.25 
Trichophyt
on rubrum 
28658 
      1 2 0.03 2 
Trichophyt
on rubrum 
28659 
      1 2 0.03 2 
Rhizopus 
microsporu
s 28506 
4 8 - 8     16  
Rhizopus 
oryzae 
28403 
4 8 - 8     >16  
Rhizopus 
microsporu
s 27785 
2 4 - 8     >16  
Mucor 
circinelloid
es 19445 
 
4 8 4 8     >16  
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Table 5.1 (continued): Activity of occidiofungin against filamentous and non-
filamentous fungi 
 
 
 
 
Species 
 
Occidiofungin (μg/mL) 
 
Voricona
zole 
 
Flucona
zole 
24 hours 48 hours 72 hours 96 hours MIC 
(μg/mL) 
MIC 
(μg/mL) 
50
% 
100
% 
50
% 
100
% 
50
% 
100
% 
80
% 
100
% 
  
Mucor 
racemosus 
27784 
 
2 
 
4 
 
- 
 
4 
     
>16 
 
Mucor 
fragilis 
27782 
2 4 - 4     >16  
Fusarium 
solani 
28386 
2 4 - 4     >16  
Fusarium 
oxysporum 
27718 
2 4 - 4     >16  
Fusarium 
solani 
18749 
2 4 2 4     >16  
Aspergillus 
flavus 
28517 
- 4 - 4     1  
Aspergillus 
flavus 
28455 
2 4 - 4     2  
Aspergillus 
flavus 
28445 
2 4 - 4     2  
Aspergillus 
fumigatus 
28434 
- 4 - 4     1  
Aspergillus 
fumigatus 
28435 
- 2 - 2     1  
Aspergillus 
fumigatus 
28436 
2 4 2 4     1  
#
Candida 
albicans 
23512 
- 1 - 2      32 
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Table 5.1 (continued): Activity of occidiofungin against filamentous and non-
filamentous fungi 
 
 
 
 
Species 
 
Occidiofungin (μg/mL) 
 
Voricona
zole 
 
Flucona
zole 
24 hours 48 hours 72 hours 96 hours MIC 
(μg/mL) 
MIC 
(μg/mL) 
50
% 
100
% 
50
% 
100
% 
50
% 
100
% 
80
% 
100
% 
  
Candida 
albicans 
28200 
4 8 4 8      8 
Candida 
albicans 
28102 
- 2 - 2      0.125 
#
Candida 
glabrata 
27243 
2 4 - 4      64 
Candida 
glabrata 
25742 
- 2 - 2      4 
Candida 
glabrata 
28271 
4 8 4 8      >64 
Candida 
krusei 9541 
2 4 - 4      16 
#
Candida 
krusei 
28415 
4 8 4 8      64 
Candida 
krusei 
28570 
4 8 4 8      16 
+
Candida 
parapsilosi
s 2006 
2 4 - 4      0.125 
Candida 
parapsilosi
s 28364 
4 8 4 8      0.25 
Candida 
parapsilosi
s 28174 
- 4 - 4      0.25 
Candida 
tropicalis 
9624 
 
- 2 - 2      0.25 
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Table 5.1 (continued): Activity of occidiofungin against filamentous and non-
filamentous fungi 
 
 
 
 
Species 
 
Occidiofungin (μg/mL) 
 
Voricona
zole 
 
Flucona
zole 
24 hours 48 hours 72 hours 96 hours MIC 
(μg/mL) 
MIC 
(μg/mL) 
50
% 
100
% 
50
% 
100
% 
50
% 
100
% 
80
% 
100
% 
  
Candida 
tropicalis 
28272 
4 8 4 8      0.125 
Candida 
tropicalis 
28478 
4 8 4 8      0.125 
+
Cryptococ
cus 
neoformans 
19526 
 
    - 2    4 
Cryptococc
us 
neoformans 
27708 
    - 2    2 
Cryptococc
us 
neoformans 
28446 
    - 1               
4 
‘-‘ indicates absence of isolates with 50% inhibition endpoint. 
Shaded regions indicate antifungal resistant strains: ‘*’ indicates itraconazole resistance, 
‘&’ indicates terbinafine resistance, ‘#’ indicates fluconazole resistance and ‘+’ indicates 
caspofungin resistance. 
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Table 5.2: Activity of alkyne-OF compared to native occidiofungin 
 
Strain MIC (µg/mL) 
Native 
occidiofungin  
Alkyne-OF 
Saccharomyces cerevisiae BY4741 0.125 1 
Schizosaccharomyces pombe 972 h 0.0625 0.5 
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Table 5.3: List of proteins pulled down exclusively by alkyne-OF using the affinity 
purification. Proteins in the cells highlighted in green are those that were found in 
the pulldown assays in both S.pombe and S.cerevisiae. Proteins in the cells that are 
not highlighted were found in the S.pombe assays only. 
 
Standard 
Name 
 
Description 
Systematic Name 
S.cerevisiae S.pombe 
Act1  Actin YFL039C SPBC32H8.
12c 
Chc1  clathrin heavy chain (predicted) YGL206C SPAC26A3.
05 
Arc5  ARP2/3 actin-organizing complex 
subunit 
YIL062C SPAC17G8.
04c 
Dpm1  dolichol-phosphate mannosyltransferase 
catalytic subunit 
YPR183W SPAC31G5.
16c 
Mpg1  mannose-1-phosphate guanyltransferase YDL055C SPCC1906.
01 
Rho1  Rho family GTPase YPR165W SPAC1F7.0
4 
Sec24 COPII cargo receptor YIL109C SPAC22F8.
08 
Naa25  NatB N-acetyltransferase complex 
regulatory subunit 
YOL076W SPBC1215.
02c 
Rad25  14-3-3 protein YIL143C SPAC17A2.
13c 
Rad24  14-3-3 protein YER173W SPAC8E11.
02c 
Dis2 serine/threonine protein phosphatase PP1 YER133W SPBC776.0
2c 
Pr65 protein phosphatase 2A 65kD regulatory 
subunit (A subunit) 
YAL016W SPBC146.1
4c 
Cka1  serine/threonine protein kinase YIL035C SPAC23C1
1.11 
Myo1 myosin type I YMR109W SPBC146.1
3c 
Pil1 fungal protein associated with 
endocytosis (predicted) 
YGR086C SPBC146.1
4c 
Cap1  adenylyl cyclase-associated protein YKL007W SPCC306.0
9c 
Sey1  GTP binding protein (predicted) YOR165W SPAC222.1
4c 
Sfb3 vesicle component COPII-coated 
(predicted)  
YHR098C SPBC4.03c 
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Table 5.3 (continued): List of proteins pulled down exclusively by alkyne-OF using 
the affinity purification. Proteins in the cells highlighted in green are those that 
were found in the pulldown assays in both S.pombe and S.cerevisiae. Proteins in the 
cells that are not highlighted were found in the S.pombe assays only. 
 
Standard 
Name 
 
Description 
Systematic Name 
S.cerevisiae S. pombe 
Sar1  ADP-ribosylation factor YPL218W SPBC31F10
.06c 
Sec21  coatomer gamma subunit (predicted) YNL287W SPAC57A7.
10c 
Sec26 coatomer beta subunit (predicted) YDR238C SPBC146.1
4c 
RPS002 40S ribosomal protein S0B YLR048W SPAPJ698.0
2c 
RPL200
2 
60S ribosomal protein L20 YMR242C SPAC26A3.
04 
RPS110
1 
ribosomal protein S11 homolog YDR025W SPAC31G5.
03 
RPP0 60S acidic ribosomal protein P0 YLR340W SPCC18.14
c 
RPL170
1 
60S ribosomal protein L17 YKL180W SPBC2F12.
04 
Cyc1 cytochrome c (predicted) YJR048W SPCC191.0
7 
Tom70 mitochondrial TOM complex subunit 
Tom40 (predicted) 
YNL121C SPAC6B12.
12 
Sif2 mitochondrial conserved protein 
(predicted) 
YBR103W SPCC16C4.
01 
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Figure 5.1: Derivatization and characterization of alkyne-OF. A) Chemical addition of 
alkyne group to occidiofungin; B) Purification of alkyne-OF by RP- HPLC; C) 
Confirmation of the addition of alkyne group to occidiofungin by MALDI-TOF mass 
spectrometry. 
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Figure 5.2: Induction of apoptosis by alkyne-OF. The ‘DMSO’ and ‘H2O2’ columns 
represent the negative and positive controls, respectively. The ‘WT’ column corresponds 
to cells treated with 1x MIC quantity of native occidiofungin and the last two panels 
represent treatment of cells with alkyne-OF at the concentration indicated. A) 
Externalization of phosphatidylserine demonstrated by the fluorescence of Annexin-V-
Fluorescein, B) Release of reactive oxygen species indicated by the formation of 
rhodamine from dihydrorhodamine 123 and C) Double stranded breaks visualized by 
TUNEL assay, following treatment with native and alkyne-OF. 
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Figure 5.3: Determination of in vivo interaction of occidiofungin.  A) Samples obtained 
following affinity purification of whole cell extracts run on 12% SDS gels and stained 
with Coomassie blue (top) and silver staining (bottom). The Coomassie stained gel was 
run only until the proteins entered the separating phase whereas the silver stained gel 
was allowed to run completely. The proteins from the bands in the Coomassie stained 
gel were determined by LC-MS/MS analysis. Broad range (10-250kDa) ladder was used 
on both gels; B) Cellular distribution of the results obtained following trypsin digest of 
the bands and LC-MS/MS analysis. 
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Figure 5.4: In vitro interaction of occidiofungin with F- and G-actin.  a) Affinity 
pulldown of actin using alkyne-OF: Lane 1- Ladder, Lane 2-100 ng pure F-actin, Lane 
3-100 ng pure G-actin, Lane 4-Empty, Lane 5-F-actin treated with alkyne-OF, Lane 6-F-
actin treated with native occidiofungin, Lane 7-F-actin treated with DMSO, Lane 8-G-
actin treated with alkyne-OF, Lane 9-G-actin treated with native occidiofungin, Lane 10-
G-actin treated with DMSO; b) Fluorescence microscopy analysis of the effect of 
occidiofungin treatment on actin filaments: A: untreated actin filaments, B: Actin:native 
occidiofungin (24 μg actin:4 μg native occidiofungin), C: Actin:native occidiofungin (24 
μg actin:8 μg native occidiofungin). Scale bar represents 5µm. 
 135 
 
 
Figure 5.5: Visualization of actin filaments. a) Untreated F-actin filaments stained with 
phalloidin 670 dye; Alkyne-OF treated F-actin filaments stained with azide derivatized 
AlexaFluor488 [(b)- 40x; (c)- 100x]  
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Figure 5.6: Effect of occidiofungin on actin (a) polymerization and (b) 
depolymerization in vitro. Symbols are as follows:     - G-buffer (control),    - G-
buffer and pyrene actin,    , ∆ - Test buffer (1.5% β-cyclodextrin in PBS) and pyrene 
actin (control), X – 20 μL of test buffer containing 20 μg of occidiofungin and pyrene 
actin. 
 
 
 
 137 
 
 
Figure 5.7: Time course analysis (A-C) and competition with native occidiofungin (D-
F) in a) Schizosaccharomyces pombe and b) Saccharomyces cerevisiae. Arrows indicate 
specific localization patterns observed in each cell at 10, 30, and 60 minutes. 
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Figure 5.8: Effect of the native occidiofungin on endocytosis in fission yeast. DIC (top 
row) and fluorescence (bottom row) images of cells stained using FM-464 following 
treatment with sample blank (left column), 0.5x MIC of occidiofungin (middle column), 
and 1x MIC occidiofungin (last column). FM-464 dye uptake by endocytosis decreases 
in cells exposed to occidiofungin a dose dependent fashion. 
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6. PHARMACOLOGICAL DEVELOPMENT OF OCCIDIOFUNGIN: 
LIPOFORMULATION, TOXICOLOGICAL ANALYSIS AND EFFICACY 
STUDIES 
 
6.1 Overview 
Occidiofungin is a non-ribosomally synthesized cyclic glycolipopeptide, 
produced by a soil bacterium, which possesses broad spectrum antifungal properties. It 
has been reported to have anti-tumor properties at sub-micromolar concentrations. It has 
been previously shown to have minimal toxicity when administered intraperitoneally and 
subcutaneously at a high dose. This report explores multiple routes of administration of 
occidiofungin to determine the most efficient method of delivery and analyzes the 
toxicity associated with each route. Encapsulation of occidiofungin in lipid vesicles was 
done. Upon administering the liposomal occidiofungin, the peak plasma concentration 
was seen to increase several fold. Histopathology tests revealed mild toxicity in the 
kidneys, which was reversed as occidiofungin was cleared from the blood. A long 
duration study over 28 days, with liposomal occidiofungin administration every 48 
hours, indicated absence of toxicity in organ tissues. Further, the rate of killing of yeast 
by liposomal occidiofungin was found to be similar to that of free occidiofungin. This 
provides an alternate formulation of occidiofungin with reduced organ toxicity, higher 
peak plasma concentration and similar rate of killing as free occidiofungin. 
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6.2 Introduction 
Toxicity to host organisms is a major limiting factor in the clinical use of 
bioactive compounds. This is an important factor in the development of antifungal 
compounds for use in human beings since the fungal cells being targeted share several 
similar features to the host. Currently existing classes of antifungals are limited in their 
use by the maximum tolerated dose, especially when used against strains that have 
acquired resistance. Amphotericin B formulated as amphotericin deoxycholate has been 
associated with severe renal and hepatotoxic side effects.
207,208
 Lipid formulations of 
amphotericin have been developed in order to reduce the toxicity associated with 
amphotericin deoxycholate. These formulations are reported to have reduced the 
nephrotoxic effects but appear to induce a cytokine response following 
administration.
209,210
 The azole class of antifungals, by comparison, is less toxic than the 
polyenes. The most common side effects of azole treatment include skin sensitivity, 
occurrence of rashes and nausea.
211
 Although less common, hepatotoxicity has been 
reported in cases with voriconazole treatment and less frequently with isoconazole and 
itraconazole treatment.
212
 The risk for in vivo toxicity due to azoles is higher due to the 
occurrence of drug-drug interactions. Azoles have the highest drug-drug interactions of 
the three classes of antifungals and this leads to numerous side-effects.
213
 Echinocandins 
are a well-tolerated class of antifungals with minimal toxicity to the host. Reports of 
mild side effects such as gastro-intestinal distress and elevated aminotransferase levels, 
which indicate liver distress, have been seen.
214
 With the occurrence of low drug-drug 
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interactions, the limiting factor of the echinocandins appears to be the development of 
resistance in fungal strains to this class.
215,216
  
There is an urgent need to identify antifungal compounds with novel mechanisms 
of action and low toxicity to the host organisms to treat infections that are resistant to 
currently available forms of treatment. Occidiofungin is a cyclic, non-ribosomally 
synthesized peptide that can be purified from a liquid culture of the soil bacterium 
Burkholderia contaminans MS14.
64
 The covalent structure of occidiofungin has eight 
constituent amino acids, two of which are non-standard. One of the non-standard amino 
acids, NAA2 has an eighteen carbon lipid chain, to which a xylose sugar is attached.
64
 
The bacterium naturally makes several variants of the base structure of occidiofungin 
(1200Da) which contribute to a more varied conformational repertoire of the wild type 
pool of occidiofungin.
217,218
 Occidiofungin has been reported to possess activity against 
a wide spectrum of fungi that are pathogenic to plants, animals and human beings.
64
 
Occidiofungin has been reported to cause cell death in fungi by triggering apoptosis in 
the cells. Occidiofungin does not target cell compartments that the currently available 
families of antifungals target i.e. cell wall and cell membrane stability.
66
 The fact that 
occidiofungin targets actin, an entirely new cellular component for an antifungal, is 
encouraging, in the face of extensive resistance to the existing treatment options.
199
 In 
order to develop occidiofungin as a clinically viable treatment option, the availability 
and toxicity of occidiofungin in animal models need to be determined. Previous research 
indicates that occidiofungin, when administered intraperitoneally and subcutaneously, 
was well tolerated at a dose of 20 mg/kg in 0.5% methylcellulose (constituted with 0.1% 
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Tween-80 in PBS), with minimal tissue toxicity. Repeated dosing, at 2 mg/kg, 
administered intraperitoneally for 5 days indicated up to 12% loss in body weight, which 
was recovered when treatment was stopped. Blood chemistry and microscopic tissue 
analyses indicated no severe effects on organ function and health.
67
 Even so, questions 
regarding the formulation and other possible routes of administration of occidiofungin 
remain. In this report, we discuss alternate formulations of occidiofungin administered 
via multiple routes in an effort to determine the most efficient method of delivery of 
occidiofungin in an organism while monitoring parameters that indicate toxicity. 
6.3 Materials and methods 
6.3.1 In vitro quantification of occidiofungin in plasma 
6.3.1.1 Evaluation of extraction protocols and establishment of standard curve: 
In order to determine the most optimal solvent for the extraction of occidiofungin 
from plasma, different solvents were used. Purified occidiofungin was dissolved in 
phosphate buffered saline (PBS) containing 1.5% hydroxy propyl-beta-cylcodextrin and 
this formulation was used for all the in vitro and in vivo assays reported in this study. 
Occidiofungin was added to commercial BALB/c mouse plasma in vitro to achieve a 
final concentration of 2 μg/mL and multiple solvents at different concentrations were 
used to extract the occidiofungin out of the serum. Each solvent, at the described 
concentration, was added as shown in Figure 6.1 and the mixture was vortexed 
thoroughly. The samples were then spun down at 13000 rpm for 10 minutes and the 
supernatant was utilized for LC-MS/MS analysis. Azithromycin at a concentration of 
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100 ng/mL was used as the internal standard. Based on the comparison of the solvents, 
50% methanol was found to be the most efficient method to extract the compound.  
Liquid chromatography was done using Acclaim 120 C18 columns (Length: 150mm; 
I.D: 2.1mm; 5µm) to purify the occidiofungin in the sample. Occidiofungin was then 
subjected to MS/MS using the ThermoScientific TSQ Vantage and fragmentation of 
occidiofungin (parent mass 1200 m/z) was carried out. Every compound with a mass of 
1200 m/z which fragmented to yield the fragment of 1068 m/z, which corresponds to 
occidiofungin molecule without the xylose sugar, was used for quantification of 
occidiofungin. 
  A concentration gradient of occidiofungin was set up in commercially available 
plasma from BALB/c mice. An initial concentration of 1000 ng/mL was setup and serial 
dilutions were done in plasma down to a concentration of 12.5 ng/mL. Methanol was 
added to each sample to reach a final concentration of 50% (v/v) and the samples were 
vortexed. The samples were then spun down at 13000rpm for 10 minutes and the 
supernatant was analyzed. Azithromycin at a concentration of 100 ng/mL was used as 
the internal standard.  
6.3.1.2 Lipoformulation of occidiofungin: 
Encapsulation of occidiofungin in vesicles using the lipids 1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC) and 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-
glycerol) (DPPG) was carried out. Two types of lipid formulations were tested: the first 
type of formulation was done by encapsulating occidiofungin in 100% DOPC whereas 
the second type was done by encapsulating occidiofungin in a mixture containing a 9:1 
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ratio of DOPC:DPPG. In each case, the appropriate amount of lipid to achieve a final 
concentration of 20 mg/mL was added to the bottom of an acid washed glass beaker. The 
lipids were vacuum dried to create a lipid cake at the bottom of the beaker. The lipids 
were then rehydrated using 0.5 mg/mL of occidiofungin in 1.5% hydroxy propyl-beta-
cylcodextrin suspended in phosphate buffered saline. The cloudy suspension that was 
formed was transferred into a 1.5 mL Eppendorf tube. Sonication was carried out using a 
probe sonicator at 30 second on-off cycles while placing the tube on ice to minimize 
thermal effects. Sonication was done until the solution became translucent. The quantity 
of occidiofungin in the vesicles was estimated by running the vesicles made using 100 
μg of occidiofungin through a gel filtration column in order to separate the encapsulated 
compound from free occidiofungin. The column was prepared using a bed volume of 15 
mL of Sephadex G-10 beads. The void volume was estimated using Blue dextran 
(Sigma) as the marker. Both types of liposomal preparations containing 100 μg of 
occidiofungin were run on the gel filtration column and the void volume was collected. 
Occidiofungin from the vesicles was extracted using 50% methanol and purified by 
Reversed-Phase High Performance Liquid Chromatography (RP-HPLC) using a 4.6- by 
250-mm C18 column (Grace-Vydac; catalog no. 201TP54) on a Bio-Rad BioLogic F10 
Duo Flow with Quad Tec UV-Vis detector system. The solvents used were 99.9% water 
(with 0.1% trifluoroacetic acid) and 99.9% acetonitrile (with 0.1% TFA). The amount of 
occidiofungin extracted from the vesicles was compared to a standard run of 100 μg of 
occidiofungin and the difference was estimated. 
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6.3.1.3 Comparison of bioactivity of free and liposomal occidiofungin: 
Bioactivity assays were carried out using the CLSI method. The strain used to 
carry out the bioactivity assays was Candida glabrata ATCC 2001. A time course 
analysis of yeast cell death in YPD using free and liposomal occidiofungin was done as 
previously described
(11)
.  
6.3.2 In vivo analysis of occidiofungin in a murine model 
6.3.2.1 Comparison of administration routes: 
Six to eight week old female BALB/c mice were used for all in vivo studies.  In 
order to determine the most efficient route of administration of occidiofungin, different 
routes such as the oral, subcutaneous, intraperitoneal and intravenous routes were 
evaluated. 2.5 mg/kg of occidiofungin in 1.5% hydroxy propyl-beta-cylcodextrin 
suspended in PBS was administered to the mice. Four groups of nine mice were used; 
each group corresponding to a different route of administration. The mice were weighed 
prior to occidiofungin administration and changes in body weight were monitored every 
24 hours. Blood draws were done by nipping the tail vein of the mice at 1, 3, 5, 7, 9, 12, 
18, 24 and 48 hpi (hours post injection). Following the intravenous route of 
administration, blood draws were done from the lateral saphenous vein of the mouse for 
the initial two time points. 50μL of blood was drawn from each mouse at each time point 
and the samples were pooled in groups of three. 0.6% sodium citrate was used as the 
anticoagulant. The samples were then spun down at 13000 rpm for 10 minutes and the 
supernatant was removed and stored at -20°C until methanol extraction and LC-MS/MS 
analysis as described above.  
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6.3.2.2 Evaluation of vesicle encapsulated occidiofungin: 
Vesicle encapsulated occidiofungin was prepared as described above using 
DOPC and DOPC-DPPG (9:1 ratio). 2.5 mg/kg of the liposomal occidiofungin was 
administered to six to eight week old female BALB/c mice intravenously and blood 
draws were done at 1, 3, 5, 7, 9, 12, 18, 24 and 48 hpi. Occidiofungin was extracted and 
concentrations were estimated as described above.   
6.3.2.3 Toxicological evaluation: 
In order to determine the toxicological effects of occidiofungin, analysis of blood 
components and tissue was carried out following treatment with 2.5 mg/kg (free and 
liposomal occidiofungin) and 5 mg/kg of free occidiofungin in a murine system. 
Toxicological analyses were carried out as previously described
68
. Briefly, occidiofungin 
in 1.5% hydroxy propyl-beta-cylcodextrin suspended in PBS was administered via tail 
vein to the mice. The mice were monitored for behavioral changes. The mice were 
anesthetized using isoflurane and blood draws were done from the heart for serum 
biochemistry assays (alkaline phosphatase, alanine aminotransferase, aspartate 
aminotransferase, albumin, and blood urea nitrogen) and hematology (white blood cell 
count and white blood cell differentiation). Body weight was measured immediately 
before treatment and 24 hours later before the mice were fully anesthetized and fixed in 
10% neutral buffered formalin. Histological examination of each organ was done by 
embedding tissue in paraffin and staining with hematoxylin and eosin (H & E).  
Six to eight week old mice received 2 mg/kg liposomal occidiofungin every 48 hours for 
28 days, to study the effects of repeated dosing of occidiofungin. The changes in body 
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weight were recorded and histological analyses on tissues were carried out. A control 
group of three mice received empty vesicles for the same duration.  
6.3.2.4 Determination of efficacy of occidiofungin in a murine model of systemic 
candidiasis: 
A group of eighteen female, six week old BALB/c mice was used to determine 
the efficacy of liposomal occidiofungin. Liposomal occidiofungin was prepared using a 
9:1 ratio of DOPC:DPPG as described above. Neutropenia was induced in the mice by 
administering 150 mg/kg of cyclophosphamide in sterile PBS via the intraperitoneal 
route. After 72 hours, the mice were infected with 5x10
6
 CFUs of Candida glabrata 
ATCC 2001 in 100 μL of sterile PBS intravenously. Drug treatment was carried out 24 
hours following administration of C. glabrata. The first group of seven mice was treated 
with 2.5 mg/kg of liposomal occidiofungin intravenously, the second group of seven 
mice was treated with an equal volume of empty vesicles and the last group of four mice 
was treated with 5 mg/kg of caspofungin in PBS intraperitoneally
219
. The mice were 
returned to the cages and their behavior and body weight changes were monitored. The 
mice were sacrificed at 24 hours post drug treatment and the kidneys were removed, 
weighed, macerated in YPD and plated on YPD plates to determine the fungal load. The 
plates were incubated at 35°C before a CFU count was done on each group.  
6.3.3 Estimation of the activity of occidiofungin in the presence of serum 
A freshly streaked plate of Candida glabrata ATCC 2001 was used to test the 
bioactivity of free and liposomal occidiofungin in the presence of 50% serum and whole 
blood from different animals. A culture of the yeast at an OD600 of 0.13 in sterile water 
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was used. This was then diluted into YPD according to the CLSI M27-A3 protocol. 
Occidiofungin was diluted in 100 % serum or blood to achieve a starting concentration 
of 16 μg/mL. An equal volume of the diluted culture was overlaid and the plates were 
incubated overnight at 35°C. The MIC was read at 24 hours post inoculation. MLCs 
were estimated for the assays done in blood by plating 100μL of each well onto YPD 
plates and incubating at 35°C for 24 hours.  
6.4 Results 
6.4.1 Estimation of peak plasma concentration of non-liposomal occidiofungin by 
different routes of administration 
In order to determine the most efficient method of delivery of occidiofungin, four 
different routes of delivery were compared. Prior to the in vivo aspect of this assay, 
occidiofungin was added to commercial mouse plasma in vitro and an extraction 
protocol was developed. Several different solvents at different concentrations were 
tested and the results are listed in Figure 6.1. The table shows the peaks obtained when 
extraction was carried out with each solvent and detection for the parent mass of 
occidiofungin (1200 Da) with a signature fragment of mass 1068 Da (indicating loss of 
sugar due to fragmentation) was performed. An accompanying peak for the detection of 
the internal standard, azithromycin, is also represented. Of the multiple solvents tested, 
50% methanol was found to be best suited to extract occidiofungin from plasma. All 
further extractions of occidiofungin from plasma were carried out using 50% methanol. 
With this established extraction protocol, a standard curve was constructed using known 
concentrations of occidiofungin added to plasma. The standard curve, as represented in 
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Figure 6.2, was seen to have an R
2
 value of 0.9957. As a result, the reliable limit of 
quantification of occidiofungin by this process was determined to be 50 ng/mL and the 
limit of detection was seen to be 10 ng/mL. The comparison of the different routes of 
administration yielded important information regarding the retention of the parent form 
of occidiofungin (1200 Da) in the bloodstream, following an injection of 2.5 mg/kg of 
occidiofungin in 1.5% hydroxy propyl-beta-cyclodextrin by oral, subcutaneous, 
intraperitoneal and intravenous routes of administration (Figure 6.3). The oral and 
subcutaneous routes of administration yielded peak plasma concentrations below the 
limit of quantification. Furthermore, the intraperitoneal route yielded a peak plasma 
concentration of 200 ng/mL at 9-12 hpi. Occidiofungin appears to be cleared from the 
bloodstream at 48 hpi. Intravenous route of administration appeared to yield the highest 
peak plasma concentration: 390 ng/mL at 1 hpi. The compound was eliminated gradually 
from the bloodstream by 24 hpi with a half-life of approximately 14 hours.  
6.4.2 Determination of peak plasma concentration following liposomal occidiofungin 
administration 
Liposomal formulation of occidiofungin was done to improve the peak plasma 
concentration of occidiofungin, since the above mentioned concentrations are not 
sufficient to effect inhibition of fungal load in a murine model. Administration of 2.5 
mg/kg of DOPC vesicles intravenously resulted in higher peak plasma concentration of 
occidiofungin as can be seen in Figure 6.4A. At 1 hpi, the concentration of occidiofungin 
in plasma was seen to reach 1800 ng/mL following which it gradually reduced and was 
eventually cleared out of the system at 48 hpi. In comparison, plasma concentration of 
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occidiofungin following administration of vesicles made out of 9 parts DOPC and 1 part 
DPPG containing 2.5 mg/kg of occidiofungin was seen to be approximately 7500 ng/mL 
at 1 hpi (Figure 6.4B). The half-life in both cases was seen to be around 14.6 hours.  
6.4.3 Comparison of pharmacodynamics between free and liposomal occidiofungin 
The in vitro analysis to estimate the kill kinetics of purified liposomal 
occidiofungin indicated no significant differences in the rate of killing of yeast by 
purified liposomal occidiofungin compared to free occidiofungin. The comparison of 
different concentrations of free and liposomal occidiofungin can be seen in Figure 6.5.  
Ten-fold changes in CFUs between the free and liposomal occidiofungin was observed 
at 4 to 12 hours post antibiotic administration at 0.5x MIC. Similar differences were also 
observed at 1x MIC. Even though differences in CFUs were seen between free and 
liposomal occidiofungin, the rate of killing between free and liposomal occidiofungin 
were found to be consistent over a 12 hour period of time. 
6.4.4 Toxicology and histopathology analysis 
Hematology and serum biochemistry assays done on the blood from the mice 
used for comparison of different routes of administration of free occidiofungin indicated 
that there were no significant differences between the treated mice and the control mice 
for all parameters except levels of alanine transaminase (ALT). ALT levels in the mice 
that received occidiofungin intraperitoneally and intravenously were significantly higher 
than the controls
68
. Further, histopathology analyses conducted on the organs of these 
mice indicated that no significant differences between the treated and the control mice 
were seen, except in the renal medulla of the mice treated intravenously, and in some 
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cases, intraperitoneally. The renal medullary findings included scattered minimal to 
occasionally mild small foci interpreted as acute tubular necrosis with minimal granular 
casts (Figure 6.6). This effect has been reported to be transient as it is not seen at 48 hpi 
following treatment at a higher dose (5 mg/kg)
68
.  
The changes in body weight of mice that were repeatedly dosed with 2 mg/kg 
liposomal occidiofungin every 48 hours for 28 days indicated that weight lost following 
administration of occidiofungin was recovered when the challenge was removed (Figure 
6.7). Furthermore, the histopathology report on these mice indicated no prolonged 
effects on the organ tissues (Figure 6.8). Sections of lung, thyroid, trachea, small 
intestine, thymus, esophagus, stomach, brain, colon, adrenal gland and heart were 
analyzed microscopically for abnormalities. They were found to be histologically within 
normal limits compared to the controls, suggesting that repeated dosing for a long 
duration did not have lasting effects on the organ tissues. 
6.4.5 Efficacy analysis of liposomal occidiofungin 
Comparison of fungal load in the kidneys of mice treated with 5 mg/kg of 
liposomal occidiofungin with the control indicated that no significant reduction 
occurred. The mice treated with 5 mg/kg of caspofungin demonstrated several fold 
reduction in the number of CFUs compared to the controls, as seen in Figure 6.9.  
6.4.6 Activity of occidiofungin in the presence of serum 
When activity of occidiofungin against C. glabrata ATCC 2001 was determined 
in the presence of 50% serum, the activity of occidiofungin was significantly less when 
compared to its effectiveness in YPD (Table 6.1). MIC of free and liposomal 
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occidiofungin in the presence of mouse, rat and porcine serum was seen to be greater 
than 16 μg/mL. When the mouse serum was heat inactivated and when esterase 
inhibitors were added, the activity of free and liposomal occidiofungin was seen to be 
greater than 16 μg/mL. When the assay was carried out using human serum, the MIC 
was seen to be 8 μg/mL. When purified liposomal occidiofungin was used in the place of 
free occidiofungin in human serum, activity was seen to improve two-fold. The same 
two-fold difference was observed in MLCs when the assay was done using 50% human 
whole blood instead of serum. When the activity of free and purified liposomal 
occidiofungin was tested in hamster and guinea pig blood, the MLCs were seen to be 
greater than 16 μg/mL. Liposomal occidiofungin demonstrated an MLC of 16 μg/mL in 
beagle and rhesus monkey blood whereas the MLC of free occidiofungin was greater 
than 16 μg/mL. Liposomal occidiofungin has increased activity in human blood with an 
MLC of 8 μg/mL whereas free occidiofungin has activity at 16 μg/mL.  
6.5 Discussion 
Occidiofungin has a wide spectrum of activity against several types of fungi that 
are resistant to the commonly used classes of antifungals. In addition to being active 
against resistant strains of fungi, occidiofungin is also active against Pythium species 
and filamentous fungi. Preliminary toxicological evaluations done on occidiofungin 
indicated that a transient allergy response, indicated by an increase in neutrophils, 
occurred following administration
68
. Body weight changes observed were within normal 
limits and tubular necrosis seen in the kidney tissue was found to be transient
68
. This 
study focuses on determining the most effective formulation of occidiofungin to 
 153 
 
minimize toxicity in the animal system while increasing peak plasma concentration of 
occidiofungin in an effort to demonstrate efficacy in reducing fungal load in a murine 
model. 
Following the evaluation of four different routes of administration of 
occidiofungin formulated in 1.5% hydroxy propyl-beta-cylcodextrin, we were able to 
demonstrate that intravenous administration of occidiofungin yielded the greatest peak 
plasma concentration. Even so, peak plasma concentration of approximately 390 ng/mL 
following a 2.5 mg/kg intravenous administration would be insufficient to cause a 
significant reduction in the fungal load in organs. Lipoformulation of occidiofungin was 
attempted using two different combinations of lipids to boost the amount of 
occidiofungin that could be recovered from the blood. Lipoformulation has the 
advantage of not only limiting interaction of the drug with other components of blood 
but also reducing toxicity to organs. Following encapsulation of occidiofungin using 
DOPC and a 9:1 mixture of DOPC:DPPG, a marked increase in the peak plasma 
concentration of occidiofungin via intravenous administration was seen for both 
formulations. Between the two, the combinations of the two lipids yielded a peak plasma 
concentration of about 7000ng/ml on average compared to an average of 1500 ng/mL 
with the pure DOPC formulation. Therefore, the DOPC:DPPG (9:1) lipoformulation of 
occidiofungin was used for further studies.  
Tolerability analysis of the lipoformulation by administration of 2 mg/kg of 
DOPC:DPPG-OF every 48 hours for 28 days showed that fluctuations in body weight 
occurred when each dose was administered but recovery was rapid. No significant 
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behavioral changes could be seen following administration. Histopathology assays done 
on multiple organs at the end of 28 days suggested that no significant toxicity could be 
observed following repeated dosing. In addition to being well-tolerated by the mice, the 
lipoformulation of occidiofungin demonstrated similar pharmacodynamics to free 
occidiofungin. Kill curve assays done on free and liposomal occidiofungin demonstrated 
that the rate of killing between the two formulations was not significantly different. 
Therefore, by encapsulating occidiofungin in lipid vesicles we were able to improve the 
formulation of occidiofungin that resulted in a higher peak plasma concentration. In 
addition, the formulation had a reduction in toxicity, while having a similar activity 
against fungi in vitro. 
Efficacy study done in a murine model of systemic candidiasis using 2.5 mg/kg 
of liposomal occidiofungin in comparison with empty vesicle control indicated that there 
was no significant difference in the fungal load in the kidneys of the treated group. A 
positive control group of mice that received 5 mg/kg caspofungin had greater than a log 
reduction in CFU count compared to the negative control. This indicated that even 
though there was enough occidiofungin in the plasma to cause reduction in fungal load 
following administration, efficacy could not be observed. This suggests that 
occidiofungin is not bioavailable in vivo possibly due to binding to serum proteins. This 
was confirmed by bioactivity assays done using 50% serum and blood from different 
animals that could be used as model systems. Interestingly, activity can be seen in 
human blood and serum with both liposomal and free occidiofungin. Liposomal 
occidiofungin was consistently more active in the presence of different sera and blood 
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compared to free occidiofungin. Chemical modification of the base structure of 
occidiofungin or development of alternative formulation needs to be done in order to 
reverse the binding of occidiofungin to proteins in serum.  
6.6 Conclusion 
One of the common problems associated with treatment with antifungals such as 
amphotericin B or caspofungin is the toxicity associated with the drugs. We have been 
able to demonstrate a formulation of occidiofungin that is taken up by a wide spectrum 
of fungal cells and is well tolerated at doses that are capable of controlling fungal 
infection. This opens avenues for the development of occidiofungin as a treatment 
alternative with lower toxicity and histopathological side effects than the antifungals 
currently in use.
8,220
 Additionally, we have reported sub-micromolar activity of 
occidiofungin against multiple cancer cell lines in the presence of serum. Given that 
occidiofungin binds to actin to cause cell death, it may be possible that occidiofungin has 
greater activity against actively growing cells. Further studies will be aimed at 
understanding the reduction in activity of occidiofungin in blood and development of 
ways to combat the problem to demonstrate efficacy in treating systemic candidiasis.  
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Table 6.1: Activity of free and liposomal occidiofungin in serum and blood 
 
  
  
  
Medium 
Minimum Inhibitory 
Concentration 
(μg/mL) 
Minimum Lethal  
Concentration 
(μg/mL) 
 Free 
occidiofungin 
 Liposomal 
occidiofungin 
 Free 
occidiofungin 
 Liposomal 
occidiofungin 
YPD 0.5 0.5  
Mouse serum >16 >16 
Mouse serum 
(Heat inactivated) 
>16 >16 
Mouse serum (w/ 
esterase 
inhibitors) 
>16 >16 
Rat serum >16 >16 
Human serum 8 4 
Porcine serum >16 16 
Hamster whole 
blood 
 >16 >16 
Guinea pig whole 
blood 
>16 >16 
Beagle whole 
blood 
>16 16 
Rhesus monkey 
whole blood 
>16 16 
Human whole 
blood 
16 8 
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Figure 6.1: Comparison of extraction methods of occidiofungin from plasma  
Solvent Occidiofungin Internal standard 
 
 
80% Methanol 
 
 
 
 
 
 
 
70% Methanol 
 
 
 
 
 
 
 
 
50% Methanol 
 
 
 
 
 
 
 
 
70% Methanol with 
0.1% Acetic acid  
 
 
 
 
 
 
 
 
 
70% Methanol with 
2N HCl 
 
 
 
 
 
 
 
70% Acetonitrile with 
0.1% acetic acid 
 
 
 
 
 
 
 
70% Acetonitrile with 
2N HCl 
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Figure 6.2: Calibration curve. Standard concentrations of occidiofungin in serum. 
r
2
=0.9957; y=-159.8398x+3152.4367 
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Figure 6.3: Comparison of different routes of administration. The plots demonstrate 
occidiofungin extracted from the plasma of mice treated with 2.5 mg/kg of occidiofungin 
via A) Intravenous route, B) Intraperitoneal route, C) Sub-cutaneous route and D) Oral 
route. Error bars indicate standard error of the mean (S.E.M) 
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Figure 6.4: Comparison of peak plasma concentrations between administration of free 
and liposomal occidiofungin via intravenous administration. A) DOPC vesicles, B) 
DOPC:DPPG (9:1) vesicles. Error bars indicate S.E.M. 
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Figure 6.5: Comparison of kill kinetics. The effects of A) free and B) liposomal 
occidiofungin against Candida glabrata ATCC 2001 are represented. Figure legends are 
denoted adjacent to each graph.  
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Figure 6.6: Histopathology analysis of kidney tissue. Images showing tubular necrosis 
in kidney tissue following treatment with 2.5 mg/kg of occidiofungin for 24 hours by i.v 
(right). Tissue from the control group that did not receive occidiofungin (left) 
demonstrates the normal state. Images are at 40x magnification.  
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Figure 6.7: Effects of occidiofungin treatment on body weight of mice. The trendlines 
denote body weight changes in mice treated with 2 mg/kg liposomal occidiofungin for 
28 days compared with a control group that received empty vesicles for the same 
duration. Error bars indicate standard deviation. 
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Figure 6.8: Histopathology analysis of organs from mice treated with 2mg/kg liposomal 
occidiofungin every 48 hours for 28 days. A) Lung (20x), B) Trachea (20x), C) Thyroid 
(20x), D) Thymus (20x), E) Esophagus (20x), F) Kidney (20x), G) Heart (20x), H) 
Spleen (20x), I) Liver (20x), J) Stomach (20x), K) Pancreas (20x), L) Small intestine 
(20x), M) Colon (20x), N) Brain (10x), O) Adrenal gland (20x). All tissues were found 
to be normal. 
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Figure 6.9: Analysis of efficacy of occidiofungin in vivo. Efficacy analysis of liposomal 
occidiofungin in a murine model of systemic candidiasis. No statistically significant 
reduction in fungal load was observed following occidiofungin treatment. Error bars 
denote deviation from the mean. 
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7. CONCLUSION 
 
Major breakthroughs in the development of antifungals to treat systemic fungal 
infections have been few and far between since the discovery of amphotericin. The 
mechanisms of action of those classes of antifungals cluster around cell wall and cell 
membrane biosynthesis, leading to the development of resistance. Widespread resistance 
to the antifungals in use has created an urgent necessity for the identification and 
development of antifungals with novel targets. Such antifungals have a better chance of 
working against fungal infections that are resistant to the currently available antifungals. 
Our research suggests that occidiofungin holds promise to be developed as a clinically 
useful alternative to treat systemic fungal infections. 
This dissertation is a compilation of studies that have expanded our 
understanding of occidiofungin. We report findings that suggest occidiofungin has 
multiple advantages over other antifungals. One such advantage is derived from the fact 
that the bacterium produces a pool of variants of the base structure of occidiofungin. 
Sections two and three discuss the structural and functional characterization of two such 
variants. We were able to characterize a variant of occidiofungin that retained activity 
without the xylose sugar that is found attached to the base structure. The advantage lies 
in the fact that future development of this variant could further minimize toxicity in an 
animal system since xylose is a sugar that is alien to higher vertebrates. In addition, we 
discovered that an additional thioesterase that was evolutionarily incorporated into the 
biosynthetic pathway of occidiofungin added unique diastereomers of the compound to 
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the wild type pool. This could potentially be advantageous against other microbes that 
the bacterium naturally encounters in its surroundings. These studies aided in improving 
our understanding of the biosynthetic machinery of occidiofungin and the benefits of 
these structural variants.  
One of the most important advantages of occidiofungin lies in the fact that the 
mechanism of action and the molecular target are unique. Sections four and five discuss 
the induction of apoptosis, possibly as a result of the perturbation of actin dynamics in 
yeast. Although other actin binding compounds such as jasplakinolide have antifungal 
properties
221
, occidiofungin is taken up much more efficiently by fungal cells at a much 
lower concentration. Its activity against caspofungin and fluconazole resistant strains of 
fungi is possibly due to its unique target. We observed that occidiofungin binds to actin, 
as a result of affinity purification assays. Further, filaments of F-actin were seen to 
clump together following occidiofungin treatment. This could lead to induction of 
apoptosis resulting in cell death. Discovery of the molecular target of occidiofungin is 
important for pre-clinical development of the drug. 
This dissertation also reports formulation of occidiofungin in lipid vesicles to 
improve plasma concentration and mitigate toxicity effects. Toxicity analysis of 
occidiofungin reported in section six of this dissertation suggests that liposomal 
occidiofungin is well- tolerated in murine models. Histopathology studies on multiple 
organs showed that exposure of occidiofungin over a long period of time to mice did not 
cause toxic effects. Although occidiofungin could be recovered from the plasma, it was 
found to be unavailable to reduce fungal load in select organs in mice. This effect was 
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observed in the in vitro bioactivity assays done in serum. This suggests strong, 
irreversible binding of occidiofungin with serum proteins. Our findings from our 
experiments identify areas where further development of occidiofungin can be done to 
improve availability and effect activity in the presence of animal serum.  
One of the ways that the problem of binding to serum can be overcome is by 
chemically modifying the structure of occidiofungin to achieve improved bioavailability 
while retaining fungicidal activity in an animal model. We have already reported a 
xylose-free variant of occidiofungin that retains activity. Further experiments in 
modifying this variant for use in animal systems could lead to potential alternatives. In 
addition, other formulations of occidiofungin could be attempted in order to minimize 
interaction with proteins. Another area which requires focus is the subsequent process 
that is triggered following the binding of occidiofungin to actin leading up to apoptosis. 
Research in this area could also open up new avenues that could be potential target for 
antifungals. We believe this research could broaden the field of antifungals leading to 
the development of a successful, novel compound that could be used to treat invasive 
fungal infections. 
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